

Applied BioCode Corporation

2025

Annual Report

The contents of this annual report and the Company's information can be found on the following websites

Market Observation Post System: <https://mops.twse.com.tw>

Website: <http://www.apbiocode.com.tw>

Printed on 2026/5/22

- I. The Company's spokesperson, deputy spokesperson, litigation and non-litigation agents in Taiwan.
- (I) Spokesperson:
- | | | | |
|-------|------------------|--------|-------------------|
| Name: | Winston Z. Ho | Title: | President |
| TEL: | +886-2-8791-6833 | Email: | who@apbiocode.com |
- (II) Deputy Spokesperson:
- | | | | |
|-------|------------------|--------|--|
| Name: | Yu-Lin Chen | Title: | Vice President of
Taiwan's sub-
subsidiary |
| TEL: | +886-2-8791-6833 | Email: | ychen@apbiocode.com |
- (III) Domestic litigation and non-litigation agents:
- | | | | |
|-------|------------------|--------|-------------------|
| Name: | Winston Z. Ho | Title: | President |
| TEL: | +886-2-8791-6833 | Email: | who@apbiocode.com |
- II. Address and Telephone Number of Head Office, Branch and Plant
- (I) The Company
- Name: Applied BioCode Corporation
Address: Grand Pavilion, Hibiscus Way, 802 West Bay Road, P.O. Box 31119, KY1-1205, Cayman Islands
Website: www.ApBioCode.com TEL: +886-2-8791-6833
- (II) Subsidiaries and sub-subsidiaries
1. Name of US subsidiary: Applied BioCode, Inc.
Address: 12130 Mora Drive, Unit 2, Santa Fe Springs, CA 90670, USA
Website: www.ApBioCode.com TEL: +1-562-777-9800
 2. Taiwan's sub-subsidiary: Applied BioCode Corporation
Address: 6F, No. 1, Lane 28, Xingzhong Road, Neihu District, Taipei
Website: www.ApBioCode.com/tw TEL: +886-2-8791-6833
- III. Name, Address, Website, and Contact Number of the Stock Agency:
- Name: Stock Agency Department of SinoPac Securities
Address: 3F, No. 17, Bo'ai Road, Zhongzheng District, Taipei
Website: www.sinotrade.com.tw
TEL: +886-2-2381-6288
Website: www.sinotrade.com.tw
- IV. Names of CPAs and the Name, Address, Website, and Contact Number of the Accounting Firm for the Latest Financial Statements:
- Names of CPAs: Wendy Liang and Alan Chien
Name of the Accounting Firm: PwC Taiwan
Address: 27F, No. 333, Section 1, Keelung Road, Xinyi District, Taipei
TEL: +886-2-2729-6666
Website: http://www.pwc.tw/
- V. Name of Exchange for Trading in Overseas Listed Securities and Information Inquiry for the Securities: Not applicable
- VI. Website: http://www.apbiocode.com.tw

VII. List of the Board of Directors

Position	Name	Nationality or Place of Registration	Major Work Experience (Education)
Chairman	George J. Lee	Taiwan / USA	Ph.D. in Chemistry, New York State University Master, Department of Agricultural Chemistry, National Taiwan University R&D Manager, Syntex USA Inc Chairman, Epitomics
Director	Winston Z. Ho	Taiwan / USA	Ph.D. of Physical chemistry and Master of Biochemistry, Arizona State University, U.S. Post-doctoral researcher, Columbia University, New York, U.S. - high-speed optics Researcher, optical center of University of Arizona, U.S. - non-linear optics Bachelor of Chemistry, National Chung Hsing University Founder / CEO, Maxwell Sensors Incorporation Director of smart optical system and sensor Director, Biomedical Sciences, Physical Optics Corp. US-NIH Grant review committee
Director	Benjamin Jen	Taiwan	Master in Science and Technology Management, Massachusetts Institute of Technology Director, Strategy and Investment / Director, Marketing, Quanta Computer
Corporate Director	Maxwell Sensors, Inc.	United States	-
Director (Representative of Corporate Director)	Huan-Rung Li (Note 1)	Taiwan	MSc Accounting and Finance, The London School of Economics and Political Science Director of Risk Control, GRC SinoGreen Fund Investment Manager, SinoPac Financial Holdings Co., Ltd.
Director (Representative of Corporate Director)	Chia-Hao Li (Note 1)	Taiwan / USA	Ph.D. in Microbiology, UCLA Chief Scientist, Transplant Diagnostics, Thermo Fisher Scientific
Independent director	Wen-Jing Tsai	Taiwan	Master in Accounting, National Chengchi University Bachelor in Accounting, National Taiwan University Manager, Deloitte Taiwan CEO, the Tax Committee, Taipei CPA Association Deputy Chairman, the National Federation of CPA Associations of the R.O.C.
Independent director	Ta-Ch'eng Hsu (Note 2)	Taiwan	Master of Accountancy, University of Missouri-Columbia Bachelor of Science in Industrial Engineering, National Tsing Hua University President, China Development Biomedical Venture Capital Managing Director, China Development II Biomedical Venture Capital L.P. Senior Associate Vice President, Investment Department, China Development Industrial Bank Vice President, CTBC Venture Capital
Independent director	Yi-Ming Wu (Note 2)	Taiwan	J.D., Cornell Law School B.S. in Business Administration, University of California, Berkeley

Position	Name	Nationality or Place of Registration	Major Work Experience (Education)
			Founder/Chairman, eMERG Group Executive Partner, Ignite Partners Company Limited Partner, K&L Gates LLP CEO/Co-Founder/Director, 6DXCHANGE, Inc. COO/Co-Founder/Directo, Spring Creek Acquisition Corp. CLO/Senior Vice President/Corporate Secretary, Openwave System, Inc. Vice President, Yahoo! Inc.

Note 1: The institutional director Maxwell Sensors, Inc. changed its designated representative in December 2025, replacing the former representative Director Huan-Jung Li with Director Chia-Hao Li as the new designated representative.

Note 2: The Company held a general election of directors and independent directors on June 6, 2025.

Applied BioCode Corporation

Index

One. Letter to Shareholders.....	7
Two. Company Profile	10
I. Date of Incorporation and Corporate Profile	10
II. Group Structure	11
III. Company and Group History.....	11
IV. Risk Disclosure: Please refer to Chapter Six: 6. Risk Management and Assessment in this Annual Report on pages 123-127.....	13
Three. Corporate Governance Report	14
I. Profiles of Board of Directors, Supervisors, President, Vice President, Directors, Department and Branch Heads	14
II. Remuneration of Board of Directors, Supervisors, President and Vice Presidents for the last fiscal year	29
III. Implementation of Corporate Governance	34
IV. Information of CPA Professional Fees.....	63
V. Change of CPAs.....	63
VI. Status of whether the company’s chairman, president, or any managerial officer in charge of finance or accounting matters has for the last fiscal year held a position at the accounting firm of its auditing CPAs or at an affiliate.	63
VII. Evaluation of CPAs’ Independence	63
VIII. Information of shares transfers or pledges from Board of Directors, managerial officers, and shareholders with more than 10% shareholding	63
IX. Information of Relationship between top 10 shareholder.....	64
X. Number of shares and shareholding percentage of an invested entity held by the company, the company’s board members, supervisors, managerial officers and directly or indirectly controlled entities.....	65
Four. Fundraising.....	66
I. Capital and Shares	66
II. Corporate Bonds (overseas included).....	69
III. Preferred Shares.....	69
IV. Global Depository Receipts.....	69
V. Employees Incentive Stock Options.....	69
VI. Employees Restricted New Shares	83
VII. New shares issued for merger or acquisition.....	83
VIII. Usage of Injected Capital.....	83
Five. Operation Overview	85
I. Business Scope	85
II. Industry, Supply and Sales Overview	105
III. Number of Employees of past two years	113
IV. Environmental Expenditure	114
V. Employer-Employee Relation.....	115
VI. Information and Technology Security Management:	116
VII. Important Agreements	117
Six. Analysis of Financial Position, Performance, and Risk	119
I. Financial Position	119
II. Financial Performance	120
III. Cash Flow	121
IV. Impact to Finance and Business from Major Capital Expenditure on financial business	122
V. Investment Policies of last fiscal year, causes of profit or loss, improvement plan and	

upcoming year’s investment plans.....	122
VI. Risk Management and Assessment.....	123
VII. Other important disclosures	127
Seven. Special disclosures.....	128
I. Information of Affiliates	128
II. Issuance of Securities through Private Placement in the most recent fiscal year and up to publication date of the annual report	129
III. Other Required Amended Explanation	130
IV. If any of the situations listed in Article 36, paragraph 2 subparagraph 2 of the Securities and Exchange Act, which might materially affect shareholders’ equity or the price of the company’s securities, has occurred during the most recent fiscal year or up to publication of the annual report	137

One. Letter to Shareholders

Dear Shareholders:

First of all, I would like to thank all shareholders for their continued strong support of the Company, enabling us to maintain smooth operations and achieve positive developments for the near future.

(I) 2025 operating results

For fiscal year 2025, the Group's operating revenue reached NT\$475,200 thousand, a record high, representing an increase of NT\$132,134 thousand (38.5%) from NT\$343,066 thousand reported in the 2024 financial statements. This growth was primarily attributable to increased shipments of diversified diagnostic reagents and optical instruments, which rose by NT\$90,613 thousand (61.3%) and NT\$20,577 thousand (469.3%), respectively.

The Group's operating loss for fiscal year 2025, excluding non-operating income and expenses, amounted to NT\$223,333 thousand, a reduction in loss of NT\$54,579 thousand (19.6%) compared with the operating loss of NT\$277,912 thousand reported in the 2024 financial statements, driven primarily by the increase in revenue.

With respect to profit or loss for the period, the net loss for fiscal year 2025 was NT\$201,200 thousand, a reduction in loss of NT\$59,607 thousand (22.9%) from the net loss of NT\$260,807 thousand reported in the 2024 financial statements, attributable to the same factors described above.

IVD products achieved significant commercial milestones in 2025, with new customer additions reaching an all-time high. Having previously centered its flagship offerings on the 17-plex Gastrointestinal Pathogen Panel (GPP), the Company has now secured a major customer for its 20-plex Respiratory Pathogen Panel as well, enabling both flagship products to expand their customer base concurrently. Additionally, the Company secured its first-ever opportunity to introduce its products into a national laboratory group in the United States.

(II) Financial analysis for 2025

As of the end of 2025, the Group's debt to asset ratio was 36.5% (NT\$369,489 thousand/NT\$1,012,704 thousand), long-term capital to property, plant and equipment (NT\$886,157 thousand) ratio was 1030%, shareholders' equity was NT\$643,215 thousand, loss per share was NT\$(1.96). The total cash in the Group's books (including time deposit) was NT\$569,588 thousand.

(III) 2026 outlook:

1. The commercialization of the Company's flagship IVD products has continued to yield significant results, with upper respiratory diagnostics registering the most substantial growth. Customers S and L on the U.S. East Coast both placed their first official purchase orders in 2025, driving upper respiratory testing volume to surpass that of the Company's other flagship product, the gastroenteritis reagent. The Group will work with distributors across the United States to develop a broader base of users for multiplex molecular diagnostic reagents, which is expected to have a positive impact on revenue.

2. In Q4 2025, the Company submitted a 510(k) premarket notification to the U.S. FDA for the BioCode MDx3000 fully automated molecular diagnostic instrument, paired with the KingFisher nucleic acid extraction instrument, for use with the 20-plex Respiratory Pathogen Panel (RPP). The application is currently progressing smoothly through FDA review.

3. The Company's 20-plex multiplex fungal detection panel — the most comprehensive offering of its kind on the market — was evaluated and tested by key opinion leaders in mycology laboratories, who provided optimization recommendations targeting 3 fungal analytes. The Company is actively

implementing the suggested improvements to enhance market acceptance and facilitate commercialization.

4. Artificial intelligence and laboratory automation are unstoppable trends. We will also develop an upgraded version of the MDx3000 — building upon its existing foundation by integrating a nucleic acid extraction instrument to achieve one-stop multiplex molecular diagnostics, thereby reducing manual operation time and the incidence of operational errors for laboratory clients and end users. This advancement is expected to have a significant and positive impact on securing large-scale clients. We will develop a prototype system within this year. -

5. From 2026 to 2028, the Company is committed to developing a detection kit for urinary tract infections (UTI) combined with antimicrobial resistance (AMR) testing. The Company targets initiating UTI clinical trials in 2027, with the earliest submission of a U.S. FDA marketing authorization application anticipated in Q4 2027.

6. Our licensed client IDEXX has expanded the instruments and reagents incorporating the Company's BMB technology to all central veterinary laboratories across the United States. In addition to the already commercialized offerings — including serum testing, parasite fecal examination, and lymphoma detection for companion animals — the Company will further promote companion animal health screening programs in 2026, which is expected to have a significant and positive impact on the procurement of the Company's digital bio-barcodes.

(IV) Future development strategy:

In addition to developing existing proprietary brands of multiplex molecular testing assays and licensing customer development in non-infectious disease areas, the Group's core technology Barcoded Magnetic Beads (BMB) platform provides benefits such as high throughput, multiple target detection, and low cost. With resource allocation permission from the group, the group will begin research and development on innovative technical products such as multiple liquid biopsy testing assays, multiple dementia testing assays, and multiple allergen testing assays. The Group's goal is to become a global leader in multiplex molecular testing assays and multiple antibody-antigen testing assays.

(V) Impact from external competitive environment, regulatory environment and overall business environment

1. Impact from the external competitive environment

The seven major IVD manufacturers in the world are Roche, Abbott, Siemens, Hologic, Danaher/Cepheid, Qiagen and BioMerieux. These manufacturers have high market shares in medical diagnostic assays but lack innovative technology, especially in multiplex testing. Multiplex testing is the mainstream trend of the current market. Global manufacturers that lack this type of technology risk losing in the future's highly competitive diagnostic market. As such, these manufacturers are catching up by acquiring companies with multiple diagnostic technologies. For example, BioMerieux acquired Biofire in 2014 and the procurement of Cepheid by Danaher in 2016 (up to 4 tests). Roche acquired GenMark and DiaSorin acquired Luminex in 2021. This illustrates the emphasis of global major pharmaceutical companies on multiplex testing. Presently, except for Luminex and BioMerieux, none of the seven major manufacturers have technology platforms and products for multiplex detection (more than 4 labels). The Company is currently a technology leader in terms of high throughput, number of detection targets and high automation. Based on the above advantages, we will prioritize the sales to large hospitals and laboratories, while also closely keeping an eye on the countermeasures of competitors and latecomers that are being divided in the market in order to quickly adjust our marketing strategies, ensuring that the development target of our businesses can be achieved.

2. Impact from the regulatory environment

Given that the Group's in-vitro diagnostic products and most of the final products developed by our licensed customers require a review by the competent authorities (FDA in each country), the decision to enter the market is determined by the FDA. For this reason, products with FDA clearance will significantly reduce external competition. As a result, the Group will continue to develop a variety of in-vitro diagnostics assays and with the clinical and trial experience of the first and second products, the time to enter the market will be gradually shortened.

3. Impact from the overall business environment

Given that the Group's principal place of operation is the U.S., changes in politics, economics and taxation in the U.S. affect the Group's overall operating performance. The COVID-19 outbreak has effected the overall economy, and the trade barriers created by geopolitics are all unfavorable factors for business in the short term. However, the medical industry is a steadily growing industry in the U.S. or even around the world, and the importance of testing assays for epidemic prevention further expands the market share. Through the advantages of our products, the expansion of our experienced sales and technical service teams, strategic alliances with licensed partners as well as diversified commercialization outlets, we will overcome challenges faced in the industry, creating maximum value for our shareholders.

Two. Company Profile

I. Date of Incorporation and Corporate Profile

Applied BioCode Corporation (the Group or ABC-KY) is a holding company established in the Cayman Islands on April 15, 2016. The denomination of shares issued by the Company is NT\$10 per share. Applied BioCode, Inc. (ABC-US) and APPLIED BIOCODE TAIWAN LTD. (ABC-TW) are subsidiaries of the Group, which are collectively referred to as the “Group.” ABC-KY’s headquarters and the R&D Center are currently located in California, U.S.

The Group’s core business encompasses the research and development of multiplex detection platform technologies, as well as the development, manufacturing, and commercialization of diagnostic instruments and reagents. ABC-KY’s Barcoded Magnetic Beads (BMB) platform is able to accurately identify hundreds of thousands of analytes while obtaining dozens or even hundreds of thousands of results in one single specimen. The applications of BMB are diverse. They cover infectious disease diagnosis, genetic disease diagnosis, allergen diagnosis, autoimmunity, oncology, precision medicine, animal testing, food testing, genetic medicine, life science research, gene expression profiling, drug, and biomarker screening.

Human Medical IVD represents the Group’s primary target market. The Group has independently developed the GPP (17-Plex Gastrointestinal Pathogen Panel), the RPP (Respiratory Pathogen Panel), and the Automated Molecular Diagnostics System (MDx 3000), all of which have obtained FDA marketing authorization in the United States as in vitro diagnostic products, differentiating themselves in the market through multiplex diagnostics as opposed to single-pathogen testing for common infectious diseases. Since the Group’s first IVD product received FDA marketing authorization in the fourth quarter of 2018, IVD products have become the Group’s primary revenue driver and have continued to grow steadily.

During the COVID-19 pandemic, the Group successively obtained Emergency Use Authorization (EUA) from the U.S. FDA beginning in June 2020 for COVID-19-related tests, including SARS-CoV-2, Pooling Test, and Cov-Flu-Plus, which at their peak became the Company’s principal products by sales volume. Following the subsidence of the COVID-19 pandemic, however, these products have been consolidated into the RPP respiratory pathogen product line. Following the subsidence of the COVID-19 pandemic, however, these products have been consolidated into the RPP respiratory pathogen product line.


The Group’s automated diagnostics system, MDx 3000, is an integrated, all-in-one molecular testing instrument incorporating digital barcode technology, compatible with the Company’s proprietary branded molecular diagnostic reagents. In addition to pairing with FDA-authorized reagent products such as GPP and RPP, the Group has continued to develop a series of highly innovative, first-to-market molecular diagnostic reagents for use with the MDx 3000, with the aim of providing laboratories with an unparalleled breadth of testing options through a single instrument. The innovative product Fungal Panel RUO — a “20-Plex Fungal Detection RUO” — was tested by the renowned Johns Hopkins University Hospital, which subsequently published a detection protocol that generated adoption interest from multiple laboratories. STI+AMR, a sexually transmitted infection combined with antimicrobial resistance gene detection kit, is the first product on the market to simultaneously detect infectious diseases and bacterial antimicrobial resistance. UTI+AMR, a multiplex urinary tract infection detection kit, is an innovative product that employs molecular diagnostics to detect urinary tract infections while simultaneously identifying bacterial antimicrobial resistance. With the completion of development across GPP, RPP, Fungal, STI+AMR, and UTI+AMR, the MDx3000 will have accumulated molecular detection capabilities covering 100 pathogens.

Our digital biological QR code platform can improve the diagnostic accuracy rate, reduce the consumption of medical resources, and help patients receive the right care as early as possible. Its advantages of accuracy, real-time and wide application, have been successfully licensed to many global companies for simultaneous multi-field development. These well-known companies include: IDEXX Technologies GmbH, PerkinElmer (an NYSE-listed company), Diatherix Laboratories - a subsidiary of

Eurofins Scientific Group (a Euronext N.V.-listed company), Molecular Device - a subsidiary of Danaher Group (a NYSE-listed company), Zhuhai Livzon Diagnostics - a subsidiary of Livzon Pharmaceutical Group (A shares that trade on SZSE and H shares that trade on the HKEX), Genetic Analysis AS Norway, Imusyn Germany, ALPCO and Hardy Diagnostic Inc. We have also licensed Guoyao Group Beijing Medical Apparatus and Instruments to sell our Biocode 2500 and BMB. Our achievements have proven that our core technologies have been approved in the industry.

Within the animal and pet health segment developed in collaboration with the IDEXX Group, the substantial demand in the pet market has necessitated large-scale procurement of digital barcodes from the Company for use as consumables in product development and diagnostics. As a result, animal health has become the Company's second-largest revenue-generating market, surpassed only by the human medical IVD market.

II. Group Structure



III. Company and Group History

Time	Important Matters of ABC-KY History
March 2008	ABC-US is founded in Santa Fe Springs, Southern California, USA.
May 2010	Successfully developed and commercialized 128 plex Barcoded Magnetic Beads (BMB).
November 2010	Launched the instrument Biocode 1000 and obtained CE marking.
December 2010	Received US 7,858,307 BMB patent - exclusive, irrevocable and perpetual license from Maxwell Sensors for the production and structure of barcoded beads.
January 2011	Received US 7,871,770 BMB patent - exclusive, irrevocable and perpetual license from Maxwell Sensors for the production and structure of barcoded magnetic beads (BMB).
April 2012	Received US 8,148,139 patent - exclusive, irrevocable and perpetual license from Maxwell Sensors for the production and structure of polymeric barcoded magnetic beads.
July 2012	Received US 8,232,092 BMB scanner patent - exclusive, irrevocable and perpetual license from Maxwell Sensors for the production and structure of BMB of instruments.
April 2013	Passed the quality system inspection by the Department of Health California and received a medical device manufacturing license.
July 2013	Successfully developed and commercialized 4,096 plex BMB (based on 12 barcodes)
August 2013	Passed FDA QSIT inspection as a Class II medical device manufacturer of

Time	Important Matters of ABC-KY History
	IVD products
November 2013	Signed a non-exclusive license agreement with Genetic Analysis Norway for nucleic acid testing for intestinal ecological disorders and irritable bowel syndrome
March 2014	Attained China 102246037 BMB Patent - Polymer Materials for BMB
May 2014	Development and commercialization of human medical IVD-related products
December 2014	Signed a non-exclusive license agreement with PerkinElmer Group (NYSE-listed company) for the Asian infectious disease diagnostics market
December 2015	Founded ABC-TW
January 2016	Signed a non-exclusive license agreement with Diatherix Laboratories for a third-party diagnostic laboratory
April 2016	Founded ABC-KY to apply for stock listing in Taiwan
June 2016	Attained US 9,255,922 BMB patent - polymeric barcoded magnetic beads
June 2016	ABC-KY became the parent company with 100% ownership of ABC-US through share swapping
September 2016	ABC-KY held a shareholders meeting and elected 9 board members, including 3 independent directors. The Audit Committee and Remuneration Committee were established.
October 2016	BioCode 2500 Analyzer successful developed and commercialized.
February 2017	Registered with the Emerging Stock Board
July 2017	Signed a non-exclusive license agreement for diagnostic panels with Zhuhai Livzon Diagnostics, Livzon Pharmaceutical Group
October 2017	ABC-US signed a supply agreement with IDEXX Technologies GmbH.
December 2017	ABC-KY completed a cash capital increase of NT\$140 million.
January 2018	Submission of 17-Plex Gastrointestinal Pathogen Panel (GPP) to the USFDA for market approval.
April 2018	ABC-TW relocated to a new office and set up a BMB factory.
April 2018	Maxwell Sensors transferred four patents to ABC-KY: 7,871,770, 7,858,307, 8,232,092 and 8,148,139.
October 2018	Obtained USFDA 510(k) clearance for 17-Plex Gastrointestinal Pathogen Panel (GPP).
October 2018	Received FDA 510(k) clearance for the MDx3000 (an automated molecular diagnostic system)
October 2018	ABC-KY completed a cash capital increase of NT\$406,600,000.
March 2019	ABC-KY attained a letter of opinion of “Product or Technology Development is Successful and Marketable” from the Industrial Development Bureau, Ministry of Economic Affairs.
June 2019	Licensed Guoyao Group Beijing Medical Apparatus and Instruments for the sale of Biocode 2500 and BMB.
June 2019	Passed FDA 510(k) clearance for the GPP MDx 3000 with MagNa Pure 96 pre-processing system.
June 2019	Attained patent EP2342561B1 from EUIPO.
September 2019	Submitted a marketing application to the USFDA for the Respiratory Infection Panel (RPP) with MDx 3000 (an automated molecular diagnostic system).
September 2019	ABC-KY completed a cash capital increase of NT\$342 million.
December 2019	ABC-KY completed a cash capital increase of NT\$48.64 million.
December 2019	Obtained an USFDA clearance for the Respiratory Infection Panel (RPP) with MDx 3000 (an automated molecular diagnostic system).
December 2019	Signed a non-exclusive license with Paitaike Co. Ltd. for the development of cytohormone assays in China.
March 2020	The listing of ABC-KY was approved by the board of directors of TWSE.

Time	Important Matters of ABC-KY History
June 2020	ABC-KY was successfully listed.
June 2020	Received the EUA for the Group's self-developed molecular assays for COVID-19 from the USFDA.
December 2020	Received the EUA from the USFDA for COVID-19 molecular assays by Pooling Testing.
March 2021	Worked with City of Hope to investigate the feasibility of using Liquid Biopsy on a PAP and BMB platform to perform genetic testing for cancer mutation.
June 2021	Signed a U.S. food safety non-exclusive authorization with Hardy Diagnostic Inc.
December 2021	Received an EUA for Covid flu plus from the U.S. FDA.
May 2022	Signed a US\$12 million technical authorization for Singulation Process with IDEXX
March 2023	Signed a U.S. non-exclusive distribution agreement with Medline Industries, LP
June 2023	Completed the development of 20 multiplex fungus testing assays (RUO).
April 2024	Completed the development of 13 sexually transmitted infection combined antimicrobial resistance target detection assays (RUO)
July 2024	ABC-KY completed a cash capital increase of NT\$441 million.
September 2024	Detection products including GPP, RPP, and Cov-Flu-Plus have obtained exclusive U.S. insurance reimbursement codes.
September 2024	Submitted a supplemental premarket approval application to the U.S. FDA for GPP, including the addition of ThermoFisher extraction instruments KingFisher Flex/Apex to the list of compatible DNA extraction instruments for the MDx3000.
January 2025	Obtained U.S. FDA approval for the use of GPP in conjunction with ThermoFisher extraction instruments KingFisher Flex/Apex with the MDx3000.
July 2025	Selected as a recipient of the Taiwan Excellence Biotechnology Industry Award.
December 2025	Submitted a supplemental premarket approval application to the U.S. FDA for RPP, including the addition of ThermoFisher extraction instruments KingFisher Flex/Apex to the list of compatible DNA extraction instruments for the MDx3000.

IV. Risk Disclosure: Please refer to Chapter Six: 6. Risk Management and Assessment in this Annual Report on pages 123-127.

Three. Corporate Governance Report

I. Profiles of Board of Directors, Supervisors, President, Vice President, Directors, Department and Branch Heads

(I) Directors and Supervisors

1. Information on Directors

April 08, 2025

Position (Note 1)	Nationality or Place of Registration	Name	Gender / Age	Date elected	Term of Office (year)	Date First Elected	Shareholding when Elected		Current shareholding		Current Shareholding of Spouse & Minor Children		Shares Held by Proxy		Major Work Experience (Education)	Current Concurrent Positions in the Group and Other Companies	Other Managers, Directors or Supervisors Who are Spouses or within Second-Degree of Kinship to Each Other			Remarks
							Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio			Position	Name	Relation	
							Chairman	Taiwan / USA	George J. Lee	Male/ 71 - 80	2025.6.6	3	2016.6.30	-			-	-	-	
Director	Taiwan / USA	Winston Z. Ho	Male/ 71 - 80	2025.6.6	3	2016.4.15	108,750	0.11	108,750	0.11	4,959,574	4.82	4,913,418	4.78	Ph.D. of Physical Chemistry and Master of Biochemistry, Arizona State University, U.S. Post-doctoral researcher, Columbia University, New York, U.S. - high- speed optics	President, ABC-KY Director, President and Founder / Chief Technology Officer, ABC-US Director, Maxwell Sensors Director, ABC-TW	-	-	-	None

Position (Note 1)	Nationality or Place of Registration	Name	Gender / Age	Date elected	Term of Office (year)	Date First Elected	Shareholding when Elected		Current shareholding		Current Shareholding of Spouse & Minor Children		Shares Held by Proxy		Major Work Experience (Education)	Current Concurrent Positions in the Group and Other Companies	Other Managers, Directors or Supervisors Who are Spouses or within Second-Degree of Kinship to Each Other			Remarks
							Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio			Position	Name	Relation	
														Bachelor of Chemistry, National Chung Hsing University Maxwell Sensors Incorporation Founder / CEO Director of smart optical system and sensor Director, Biomedical Sciences, Physical Optics Corp. US-NIH Grant review committee Member Research Scientist - Nonlinear Photonics, University of Arizona College of Optical Sciences						
Director	Taiwan	Benjamin Jen	Male/ 51 - 60	2025.6.6	3	2016.9.29	-	-	-	-	-	-	-	Master in Science and Technology Management, Massachusetts Institute of Technology Vice Chairman,	Executive Partner, GRC Managers Limited Taiwan, Virgin Islands Director, Applied Biocode, Inc. Director, ABC-TW	-	-	-	None	

Position (Note 1)	Nationality or Place of Registration	Name	Gender / Age	Date elected	Term of Office (year)	Date First Elected	Shareholding when Elected		Current shareholding		Current Shareholding of Spouse & Minor Children		Shares Held by Proxy		Major Work Experience (Education)	Current Concurrent Positions in the Group and Other Companies	Other Managers, Directors or Supervisors Who are Spouses or within Second-Degree of Kinship to Each Other			Remarks
							Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio			Position	Name	Relation	
														Danen Technology Corporation Sales President, Yu Jing Energy Technology Co., Ltd Director, Strategy and Investment / Director, Marketing, Quanta Computer						
Corporate Director	United States	Maxwell Sensors, Inc.	-	2025.6.6	3	2022.6.13	8,307,042	8.08	8,307,042	8.08	-	-	-	-	-	-	-	-	-	None
Director (Representative of Corporate Director)	Taiwan	Huan- Rung Li (Note 2)	Female/ 31-40	2025.6.6	3	2023.6.14	-	-	-	-	50,000	0.05	-	-	MSc Accounting and Finance, The London School of Economics and Political Science Director of Risk Control, Shenzhen Fuhua Equity Investment Fund Management Co., Ltd. Director, Maryvale Limited	-	-	-	None	
Director (Representative of Corporate Director)	Taiwan / USA	Chia-Hao Li (Note 2)	Male/ 71 - 80	2025.12.1	3	2025.12.1	-	-	-	-	-	-	-	-	Ph.D. in Microbiology, UCLA Chief Scientist, Transplant Diagnostics, Thermo Fisher Scientific	Director, ABC-KY	Chairman	George J. Lee	Brother	None

Position (Note 1)	Nationality or Place of Registration	Name	Gender / Age	Date elected	Term of Office (year)	Date First Elected	Shareholding when Elected		Current shareholding		Current Shareholding of Spouse & Minor Children		Shares Held by Proxy		Major Work Experience (Education)	Current Concurrent Positions in the Group and Other Companies	Other Managers, Directors or Supervisors Who are Spouses or within Second-Degree of Kinship to Each Other			Remarks
							Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio			Position	Name	Relation	
Independent director	Taiwan	Wen-Jing Tsai	Male/ 51 - 60	2025.6.6	3	2016.9.29	-	-	-	-	-	-	-	-	Master in Accounting, National Chengchi University Bachelor in Accounting, National Taiwan University Manager, Deloitte Taiwan CEO, the Tax Committee, Taipei CPA Association Deputy Chairman, the National Federation of CPA Associations of the R.O.C.	President, Gaowei Accounting Firm Supervisor, Shinho Energy & Technology CO., LTD. Supervisor, Mirror TV Inc.	-	-	-	None
Independent director	Taiwan	Ta- Ch'eng Hsu	Male/ 61 - 70	2025.6.6	3	2025.6.6	-	-	-	-	-	-	-	-	Master of Accountancy, University of Missouri-Columbia Bachelor of Science in Industrial Engineering, National Tsing Hua University President, China Development Biomedical Venture Capital	Director, Ta-ch'üan Investment Co., Ltd. Independent Director, Handa Pharmaceuticals, Inc.	-	-	-	None

Position (Note 1)	Nationality or Place of Registration	Name	Gender / Age	Date elected	Term of Office (year)	Date First Elected	Shareholding when Elected		Current shareholding		Current Shareholding of Spouse & Minor Children		Shares Held by Proxy		Major Work Experience (Education)	Current Concurrent Positions in the Group and Other Companies	Other Managers, Directors or Supervisors Who are Spouses or within Second-Degree of Kinship to Each Other			Remarks
							Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio			Position	Name	Relation	
														Managing Director, China Development II Biomedical Venture Capital L.P. Senior Associate Vice President, Investment Department, China Development Industrial Bank Vice President, CTBC Venture Capital						
Independent director	Taiwan	Yi-Ming Wu	Male/ 51 - 60	2025.6.6	3	2025.6.6	-	-	-	-	-	-	-	J.D., Cornell Law School B.S. in Business Administration, University of California, Berkeley Founder/Chairman, eMERG Group Executive Partner, Ignite Partners Company Limited Partner, K&L Gates LLP CEO/Co- Founder/Director, 6DXCHANGE, Inc. COO/Co-	Senior Advisor, TNL Mediagene Independent Director, Aibi Technology Co., Ltd. Director, National Bills Investment Corporation Director, National Bills Securities Co., Ltd. Director, Pao-Kuo Construction and Engineering Co., Ltd. Director, Taiwan	-	-	-	None	

Position (Note 1)	Nationality or Place of Registration	Name	Gender / Age	Date elected	Term of Office (year)	Date First Elected	Shareholding when Elected		Current shareholding		Current Shareholding of Spouse & Minor Children		Shares Held by Proxy		Major Work Experience (Education)	Current Concurrent Positions in the Group and Other Companies	Other Managers, Directors or Supervisors Who are Spouses or within Second-Degree of Kinship to Each Other			Remarks
							Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio			Position	Name	Relation	
														Founder/Directo, Spring Creek Acquisition Corp. CLO/Senior Vice President/Corporate Secretary, Openwave System, Inc. Vice President, Yahoo! Inc.	Branch of Wiswell Life Technology Co., Ltd. (incorporated in the Cayman Islands)					

Note 1: A full re-election of directors and independent directors of the Company took place on June 6, 2025.

Note 2: The institutional director Maxwell Sensors, Inc. changed its designated representative in December 2025, replacing the former representative Director Li Huan-Jung with Director Li Chia-Hao as the new designated representative.

2. Supervisors: The Group has an Audit Committee; therefore, there are no supervisors.

3. Major shareholders of corporate shareholders:

Name of corporate shareholder	Major shareholders of corporate shareholders
Maxwell Sensors, Inc.	The ZAAD Living Trust

4. Major shareholders of corporate shareholders are juristic persons' major shareholders:

Name of corporate	Major shareholders of corporate
The ZAAD Living Trust	Winston Z. Ho, April Tang

5. Directors or Supervisors' professional qualifications and their independence:

Name \ Qualification	Professional qualifications and experience (Note 1)	Independence Criteria (conforms to the criteria set out in Note 2)	Number of Other Public Companies in Which the Individual is Concurrently Serving as an Independent Director
George J. Lee	<p>Professional Qualifications: Required working experience at least five years in commerce, law, finance, accounting or other fields required by the business of the Company.</p> <p>Experience: Ph.D. in Chemistry, New York State University R&D Manager, Syntex USA Inc Chairman, Epitomics, Inc.</p> <p>None of the directors was in the circumstances under Article 30 of the Company Act (Note 3)</p>	Not applicable	-
Winston Z. Ho	<p>Professional Qualifications: Required working experience at least five years in commerce, law, finance, accounting or other fields required by the business of the Company.</p> <p>Experience: Ph.D. in Physical chemistry and Masters Degree in Biochemistry, Arizona State University, U.S. Maxwell Sensors Incorporation Founder / CEO Director of smart optical system and sensor Director, Biomedical Sciences, Physical Optics Corp.</p> <p>None of the directors was in the circumstances under Article 30 of the Company Act (Note 3)</p>	Not applicable	-
Benjamin Jen	<p>Professional Qualifications: Required working experience at least five years in commerce, law, finance, accounting or other fields required by the business of the Company.</p> <p>Experience: Masters Degree in Science and Technology Management, Massachusetts Institute of Technology Director, Strategy and Investment / Director, Marketing, Quanta Computer</p> <p>None of the directors was in the circumstances under Article 30 of the Company Act (Note 3)</p>	Not applicable	-
Maxwell Sensors, Inc.	Not applicable	Not applicable	-
Huan-Rung Li (Note 4)	<p>Professional Qualifications: Required working experience at least five years in commerce, law, finance, accounting or other fields required by the business of the Company.</p> <p>Experience: MSc Accounting and Finance, The London School of Economics and Political Science</p>	Not applicable	-

Name \ Qualification	Professional qualifications and experience (Note 1)	Independence Criteria (conforms to the criteria set out in Note 2)	Number of Other Public Companies in Which the Individual is Concurrently Serving as an Independent Director
	Director of Risk Control, GRC SinoGreen Fund Investment Manager, SinoPac Financial Holdings Co., Ltd. None of the directors was in the circumstances under Article 30 of the Company Act (Note 3)		
Chia-Hao Li (Note 4)	Professional Qualifications: Required working experience at least five years in commerce, law, finance, accounting or other fields required by the business of the Company. Experience: Ph.D. in Microbiology, UCLA Chief Scientist, Transplant Diagnostics, Thermo Fisher Scientific None of the directors was in the circumstances under Article 30 of the Company Act (Note 3)	Not applicable	-
Wen-Jing Tsai	Professional Qualifications: Professional or technical specialists who have passed a national examination or hold a license in accounting or another profession required for the Company's business operations with at least five years' experience. Experience: Master in Accounting, National Chengchi University Bachelor in Accounting, National Taiwan University Manager, Deloitte Taiwan CEO, the Tax Committee, Taipei CPA Association Deputy Chairman, the National Federation of CPA Associations of the R.O.C. None of the directors was in the circumstances under Article 30 of the Company Act (Note 3)	(1) No; (2) None; (3) No; (4) None; (5) Yes	-
Ta-Ch'eng Hsu (Note 5)	Professional Qualifications: Required working experience at least five years in commerce, law, finance, accounting or other fields required by the business of the Company. Experience: Master of Accounting, University of Missouri-Columbia Bachelor of Science in Industrial Engineering, National Tsing Hua University President, China Development Biomedical Venture Capital Managing Director, China Development II Biomedical Venture Capital L.P. Senior Associate Vice President, Investment Department, China Development Industrial Bank Vice President, CTBC Venture Capital	(1) No; (2) None; (3) No; (4) None; (5) Yes	1

Name \ Qualification	Professional qualifications and experience (Note 1)	Independence Criteria (conforms to the criteria set out in Note 2)	Number of Other Public Companies in Which the Individual is Concurrently Serving as an Independent Director
	None of the directors was in the circumstances under Article 30 of the Company Act (Note 3)		
Yi-Ming Wu (Note 5)	Professional Qualifications: Required working experience at least five years in commerce, law, finance, accounting or other fields required by the business of the Company. Experience: J.D., Cornell Law School B.S. in Business Administration, University of California, Berkeley Founder/Chairman, eMERG Group Executive Partner, Ignite Partners Company Limited Partner, K&L Gates LLP CEO/Co-Founder/Director, 6DXCHANGE, Inc. COO/Co-Founder/Directo, Spring Creek Acquisition Corp. CLO/Senior Vice President/Corporate Secretary, Openwave System, Inc. Vice President, Yahoo! Inc. None of the directors was in the circumstances under Article 30 of the Company Act (Note 3)	(1) No; (2) None; (3) No; (4) None; (5) Yes	1

Note 1: Professional qualifications and experiences: Description of director and supervisor qualifications and experiences. If Audit Committee members have professional expertise in accounting or finance, their background and work experience in these fields shall be described in detail.

Note 2: Independent directors shall provide a detailed description of their conformity to independence criteria including but not limited to the following: (1) Does the candidate, his/her spouse, or one of his/her relatives within the second degree of kinship serve as director, supervisor, or employee at the Company or one if its affiliates? (2) How many company shares does the candidate, his/her spouse, or one of his/her relatives within the second degree of kinship (or the candidate under others' names) hold and what is the shareholding ratio? (3) Does the candidate serve as director, supervisor, or employee of a company that has a specific relationship with this Company (as stipulated in Article 3, Paragraph 1, Subparagraph 5-8 of the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies)? (4) Cumulative compensation received for the provision of commercial, law, financial, and accounting services to this Company or its affiliates within the past two years; (5) Do one of the circumstances specified in Article 30 of the Company Act apply?

Note 3: A person who is under any of the following circumstances shall not act as a managerial personnel of a company. If he has been appointed as such, he shall certainly be discharged: (1) Having committed an offence as specified in the Statute for Prevention of Organizational Crimes and subsequently convicted of a crime, and has not started serving the sentence, has not completed serving the sentence, or five years have not elapsed since completion of serving the sentence, expiration of the probation, or pardon; (2) Having committed the offence in terms of fraud, breach of trust or misappropriation and subsequently convicted with imprisonment for a term of more than one year, and has not started serving the sentence, has not completed serving the sentence, or two years have not elapsed since completion of serving the sentence, expiration of the probation, or pardon; (3) Having committed the offense as specified in the Anti-corruption Act and subsequently convicted of a crime, and has not started serving the sentence, has not completed serving the sentence, or two years have not elapsed since completion of serving the sentence, expiration of the probation, or pardon; (4) Having been adjudicated bankrupt or adjudicated of the commencement of liquidation process by a court, and having not been reinstated to his rights and privileges; (5) Having been dishonored for unlawful use of credit instruments, and

the term of such sanction has not expired yet; or (6) Having no or only limited disposing capacity. (7) Having been adjudicated of the commencement of assistantship and such assistantship having not been revoked yet.

Note 4: The institutional director Maxwell Sensors, Inc. changed its designated representative in December 2025, replacing the former representative Director Li Huan-Jung with Director Li Chia-Hao as the new designated representative.

Note 5: The Company held a general election of directors and independent directors on June 6, 2025.

6. Board diversity and independence:

(1) Board diversity:

The composition of the Company’s Board of Directors shall consider the diversification of the Board of Directors from various aspects based on Article 20 of the Corporate Governance Best Practice Principles, and the Board of Directors shall have the knowledge, skills, and experience necessary to perform their duties. The board of directors shall possess the ability to make operational judgments, ability to perform accounting and financial analysis, ability to conduct management administration, ability to conduct crisis management, knowledge of the industry, an international market perspective, ability to lead and ability to make policy decisions. The board is composed of seven directors (incl. three independent directors). All board members have extensive experience and professional expertise in a wide range of fields including commerce, law, finance, accounting, production technologies, and management. One board member (14%) is an employee of the Company; one independent director has served for 10 years; two independent directors have served for 1 year; one independent director has served for more than three consecutive terms. Three directors are aged above 70; one director is aged between 61 and 70; three directors are aged between 51 and 60. All 7 directors are male and hold Republic of China nationality, 3 of whom also hold United States citizenship.

The Company is committed to achieving diversity in board composition; however, given the nature of the industry, identifying suitable candidates within a short timeframe has proven challenging, resulting in female directors currently accounting for less than one-third of board seats. Nonetheless, in future board member selection processes, the Company will adhere to a merit-based approach while continuing to give due consideration to qualified female candidates.

The concrete objectives and implementation of the Board of Directors diversification policy are as follows

Concrete objectives	Implementation status
At least 1/3 of the board members are biotech industry and operation professionals	Achieved
At least 1/3 of the independent directors possess legal, financial or information technology skills	Achieved
One-third of total board seats held by either gender	Not achieved

Diversification of the Board of Directors:

Position	Name	Experience in biotech industry			Professional skill		
		Research and development	Industry knowledge	Business management	Legal	Finance and accounting	Marketing
Chairman	George J. Lee	✓	✓	✓	-	-	✓
Director	Winston Z. Ho	✓	✓	✓	-	-	✓
Director	Benjamin Jen	-	✓	✓	-	-	✓
Corporate Director	Maxwell Sensors, Inc.	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
Director (Proxy of Corporate Director)	Huan-Rung Li (Note 1)	-	✓	✓	-	✓	✓
Director (Proxy of Corporate Director)	Chia-Hao Li (Note 1)	✓	✓	✓	-	-	✓
Independent director	Wen-Jing Tsai	-	-	-	✓	✓	✓
Independent director	Ta-Ch'eng Hsu (Note 2)	-	✓	✓	-	✓	✓
Independent director	Yi-Ming Wu (Note 2)	-	✓	✓	✓	-	✓

Note 1: The institutional director Maxwell Sensors, Inc. changed its designated representative in December 2025, replacing the former representative Director Li Huan-Jung with Director Li Chia-Hao as the new designated representative.

Note 2: A full re-election of directors and independent directors of the Company took place on June 6, 2025.

(2) Board member independence:

The board is composed of seven directors (incl. three independent directors accounting for 43%). Based on the kinship diagram provided by the independent directors, it can be determined that none of the circumstances specified in Article 26-3, Paragraphs 3 and 4 of the Securities and Exchange Act exist.

(II) Profile of Presidents, Vice Presidents, Directors, and Heads of Departments and Branches:

April 13, 2026; Unit: shares

Position	Nationality	Name	Gender	Date of Assumption of Office	Shareholding		Shareholding of Spouse & Minor Children		Shares Held by Proxy (Note)		Major Work Experience (Education)	Current Concurrent Positions in Other Companies	Spouse or Relatives of Second Degree or Closer Acting as Managerial Officers (Note 2)			Remarks
					Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio			Position	Name	Relation	
President and Founder/Chief Technology Officer	Taiwan / USA	Winston Z. Ho (Note 1)	Male	2008.03	108,750	0.11	4,959,574	4.82	4,913,418	4.78	Ph.D. of Physical Chemistry and Master of Biochemistry, Arizona State University, U.S. Post-doctoral researcher, Columbia University, New York, U.S. - high-speed optics Bachelor of Chemistry, National Chung Hsing University Maxwell Sensors Founder / CEO Director of smart optical system and sensor Director, Biomedical Sciences, Physical Optics Corp. US-NIH Grant review committee Member Researcher, optical center of University of Arizona, U.S. - non-linear optics	Director & Presidents, ABC-US Director, ABC-TW Director, Maxwell Sensors Managerial Officer, Oceania, LLC	-	-	-	None
Chief of Scientist	United States	Elisabeth Laderman	Female	2023.11	-	-	-	-	-	-	Ph.D. in Biochemistry, UCLA HYCOR Biomedical, LLC. Chief Scientific Officer	-	-	-	-	None

Position	Nationality	Name	Gender	Date of Assumption of Office	Shareholding		Shareholding of Spouse & Minor Children		Shares Held by Proxy (Note)		Major Work Experience (Education)	Current Concurrent Positions in Other Companies	Spouse or Relatives of Second Degree or Closer Acting as Managerial Officers (Note 2)			Remarks
					Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio			Position	Name	Relation	
											Vice President of Product Development, Biomerica, Inc.					
Operating Vice President, U.S. subsidiary	United States	Gerald Kowalski (Note 3)	Male	2014.07	8,000	0.01	-	-	-	-	Bachelor in Technology in Electronic Instrumentation Engineering, Michigan Technological University Software team leader, BECKMAN COULTER INC. Senior Software Engineer, BAXTER International Inc.	-	-	-	-	None
Senior Director, Product Manufacturing Division	Canada	Gao Chen	Male	2014.10	149,000	0.14	-	-	-	-	Ph.D. in Molecular Biology and Immunology, Gembloux Agro-Bio Tech, Belgium Researcher, UCLA Senior Researcher, R&D Department, Maxwell Sensors Incorporation	-	-	-	-	None
Vice President of Taiwan's sub-subsiary	Taiwan	Yu-Lin Chen	Male	2016.05	46,500	0.05	-	-	-	-	Bachelor in Electrical Engineering, George Washington University Deputy General Manager, Opto-Sensor Ltd. Business Engineer, Opto-Sensor Ltd.	-	-	-	-	None
CFO	Taiwan	Liang-Kai Huang	Male	2018.02	-	-	-	-	-	-	Bachelor in Accounting, Soochow University CFO, BTL Corporate	-	-	-	-	None

Position	Nationality	Name	Gender	Date of Assumption of Office	Shareholding		Shareholding of Spouse & Minor Children		Shares Held by Proxy (Note)		Major Work Experience (Education)	Current Concurrent Positions in Other Companies	Spouse or Relatives of Second Degree or Closer Acting as Managerial Officers (Note 2)			Remarks
					Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio			Position	Name	Relation	
											CFO, Landseed International Medical Group					
Internal Auditor	Taiwan	Zong-Han You	Male	2019.09	40,000	0.04	13,000	0.01	-	-	Bachelor in of Accounting, National Taiwan University Assistant Manager, Merck KGaA Assistant Manager, Deloitte Taiwan	-	-	-	-	None
Director, Administrative Office	United States	Ingrid Joseph	Female	2020.08	10,000	0.01	-	-	-	-	Bachelor, Management at Cerritos College Procurement Supervisor of Maxwell Sensors Incorporation	-	-	-	-	None
Vice President, Market Division	United States	Parisa Hanachi	Female	2021.11	-	-	-	-	-	-	PhD in Molecular Microbiology, University of California, Davis CMO, HiPic Inc. Senior Director, Marketing Division, Alere Inc.	-	-	-	-	None
Vice President, Sales Division	United States	Jim Leigh	Male	2023.03	-	-	-	-	-	-	B.S. in Finance, Department of Business Administration, University of Iowa Vice President, Renovia Inc. Strategic Accounts Senior Director, Genoptix National Accounts	-	-	-	-	None
Director, Human Resources Division	United States	Julian Sanchez (Note 4)	Male	2023.03	-	-	-	-	-	-	M.A., Human Resources in Public Administration, California State	-	-	-	-	None

Position	Nationality	Name	Gender	Date of Assumption of Office	Shareholding		Shareholding of Spouse & Minor Children		Shares Held by Proxy (Note)		Major Work Experience (Education)	Current Concurrent Positions in Other Companies	Spouse or Relatives of Second Degree or Closer Acting as Managerial Officers (Note 2)			Remarks
					Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio			Position	Name	Relation	
											University, Long Beach Interim HR Director, Skillset Group HR Director, G4S					
Accounting Supervisor	Taiwan	Chao-Ku Chen	Male	2024.05	-	-	-	-	-	-	Bachelor in Accounting, Soochow University Accounting Vice Manager, ABC-TW Assistant Manager, PwC Taiwan	-	-	-	-	None
Financial Controller	United States	Yang Zhang	Female	2024.05	-	-	-	-	-	-	Bachelor of Accounting, California State University, Fullerton Accounting Manager, Phoenix Motor Car Senior Accountant and Analyst, ABC-US	-	-	-	-	None

Note 1: Director and President Winston Z. Ho and his spouse April Tang jointly set up the ZAAD Living Trust. They are both the trustees of this trust. The ZAAD Living Trust has total ownership of Maxwell Sensors and Oceanina, LLC. Maxwell Sensors holds 8,307,042 shares of ABC-KY, or 8.08%, and Oceania, LLC holds 1,519,793 shares of ABC-KY, or 1.48%.

Note 2: The President or the person with an equivalent position (the highest level manager) and the chairman of the board of directors are the same person, spouses or relatives within the first degree of kinship.

Note 3 : Managerial officer Gerald Kowalski retired on January 10, 2025.

Note 4: Managerial officer Julian Sanchez resigned on May 23, 2025.

II. Remuneration of Board of Directors, Supervisors, President and Vice Presidents for the last fiscal year

(I) Remuneration of general directors and independent directors for the most recent fiscal year (2025)

December 31, 2025; unit: NT\$ thousand

Position	Name	Remuneration to Directors								Total of A, B, C and D as a percentage of net income after tax (%)		Relevant remuneration received by Directors who are also employed by the Company								Ratio of total remuneration A+B+C+D+E+F+G to net income after tax		Remuneration paid to Directors from an invested company other than the Company's subsidiary or from the parent company
		Remuneration (A)		Severance Payment and Pension (B)		Remuneration to directors (C)		Fees for Performance of Work (D)		The Company	Companies Included in the Financial Statements	The Company	Companies Included in the Financial Statements	Remuneration to Employees (G)				The Company	Companies Included in the Financial Statements			
		The Company	Companies Included in the Financial Statements	The Company	Companies Included in the Financial Statements	The Company	Companies Included in the Financial Statements	The Company	Companies Included in the Financial Statements					Cash Amount	Stock Amount	Cash Amount	Stock Amount					
Director	George J. Lee	-	-	-	-	-	-	41	41	41 (0.02)%	41 (0.02)%	-	-	-	-	-	-	-	-	41 (0.02)%	41 (0.02)%	-
Director	Winston Z. Ho	-	-	-	-	-	-	41	41	41 (0.02)%	41 (0.02)%	-	5,449	-	601	-	-	-	-	41 (0.02)%	6,091 (3.03)%	-
Director	Benjamin Jen	-	-	-	-	-	-	41	41	41 (0.02)%	41 (0.02)%	-	-	-	-	-	-	-	41 (0.02)%	41 (0.02)%	-	
Representative of Corporate Director	Huan-Rung Li	-	-	-	-	-	-	41	41	41 (0.02)%	41 (0.02)%	-	-	-	-	-	-	-	41 (0.02)%	41 (0.02)%	-	
Representative of Corporate Director	Chia-Hao Li	-	-	-	-	-	-	10	10	10 (0.01)%	10 (0.01)%	-	-	-	-	-	-	-	10 (0.01)%	10 (0.01)%	-	
Independent director	Wen-Jing Tsai	424	424	-	-	-	-	-	-	424 (0.21)%	424 (0.21)%	-	-	-	-	-	-	-	424 (0.21)%	424 (0.21)%	-	
Independent director	Ben Liu	212	212	-	-	-	-	-	-	212 (0.11)%	212 (0.11)%	-	-	-	-	-	-	-	212 (0.11)%	212 (0.11)%	-	
Independent director	Jack Hsiao	212	212	-	-	-	-	-	-	212 (0.11)%	212 (0.11)%	-	-	-	-	-	-	-	212 (0.11)%	212 (0.11)%	-	
Independent director	Ta-Ch'eng Hsu	318	318	-	-	-	-	-	-	318 (0.16)%	318 (0.16)%	-	-	-	-	-	-	-	318 (0.16)%	318 (0.16)%	-	
Independent director	Yi-Ming Wu	318	318	-	-	-	-	-	-	318 (0.16)%	318 (0.16)%	-	-	-	-	-	-	-	318 (0.16)%	318 (0.16)%	-	

(1) Please explain the policy, system, standards and structure by which independent director remuneration is paid, and the association between the amount paid and independent directors' responsibilities, risks and time committed: The Company's remuneration to directors is determined concerning the practice of public companies in Taiwan and the participation of the independent directors in the Audit Committee, Remuneration Committee and the Board meeting. Upon discussion and approval by the Board of Directors, payment of USD 3,400 shall be made on a quarterly basis prior to execution.

(2) The Company pays transportation allowance to directors (excluding independent directors) approved by a resolution of the board of directors for the term. The transportation allowance for attending each quarterly board meeting is USD330.

(3) Remuneration received by directors for providing service to any company included in the financial statements (e.g. consultancy service without the title of an employee) for the most recent fiscal year, except those disclosed in the above table: None.

Remuneration to individual directors in respective brackets along the remuneration scale	Name of director			
	Total remuneration (A+B+C+D)		Total remuneration (A+B+C+D+E+F+G)	
	The Group	Companies Included in the Financial Statements	The Group	Companies Included in the Financial Statements
NT\$5,000,000 (inclusive) - NT\$10,000,000 (exclusive)	—	—	—	Winston Z. Ho
NT\$10,000,000 (inclusive) - NT\$15,000,000 (exclusive)	—	—	—	—
NT\$15,000,000 (inclusive) - NT\$30,000,000 (exclusive)	—	—	—	—
NT\$30,000,000 (inclusive) - NT\$50,000,000 (exclusive)	—	—	—	—
NT\$50,000,000 (inclusive) - NT\$100,000,000 (exclusive)	—	—	—	—
Above NT\$100,000,000	—	—	—	—
Total	10 persons	10 persons	10 persons	10 persons

(II) Remuneration to supervisors: The Group has an Audit Committee; therefore, there are no supervisors.

(III) Remuneration to the president and vice president for the most recent fiscal year (2025)

December 31, 2025; unit: NT\$ thousand

Position	Name	Salary (A)		Severance Payment and Pension (B)		Bonuses and special allowances, etc. (C)		Remuneration to employees (D)				Total of A, B, C and D as a percentage of net income after tax (%)		Remuneration paid to Directors from an invested company other than the Company's subsidiary or from the parent company
		The Company	Companies Included in the Financial Statements	The Company	Companies Included in the Financial Statements	The Company	Companies Included in the Financial Statements	The Company		Companies Included in the Financial Statements		The Company	Companies Included in the Financial Statements	
								Cash Amount	Stock Amount	Cash Amount	Stock Amount			
President	Winston Z. Ho	-	5,101	-	601	-	347	-	-	-	-	-	6,049 (3.01)%	-
Vice President	Jim Leigh	-	6,852	-	1,235	-	2,778	-	-	-	-	-	10,865 (5.40)%	-
Vice President	Elisabeth Laderman	-	7,889	-	706	-	0	-	-	-	-	-	8,595 (4.27)%	-
Vice President	Parisa Hanachi	-	6,986	-	1,050	-	0	-	-	-	-	-	8,036 (3.99)%	-
Vice President	Gerald Kowalski (Note)	-	979	-	148	-	0	-	-	-	-	-	1,127 (0.56)%	-
Vice President	Liang-Kai Huang	-	3,726	-	108	-	704	-	-	-	-	-	4,537 (2.26)%	-
Vice President	Yu-Lin Chen	-	1,865	-	108	-	373	-	-	-	-	-	2,346 (1.17)%	-

Note: Managerial officer Gerald Kowalski retired on January 10, 2025.

Breakdown of Remuneration

Remuneration to presidents and vice presidents in respective brackets along the remuneration scale	President and vice president name	
	The Group	Companies Included in the Financial Statements
Below NT\$1,000,000	-	—
NT\$1,000,000 (inclusive) - NT\$2,000,000 (exclusive)	-	Gerald Kowalski (Note)
NT\$2,000,000 (inclusive) - NT\$3,500,000 (exclusive)	-	Yu-Lin Chen
NT\$3,500,000 (inclusive) - NT\$5,000,000 (exclusive)	-	Liang-Kai Huang
NT\$5,000,000 (inclusive) - NT\$10,000,000 (exclusive)	-	Chung-Jen Ho, Parisa Hanachi, Elisabeth Laderman
NT\$10,000,000 (inclusive) - NT\$15,000,000 (exclusive)	-	Jim Leigh
NT\$15,000,000 (inclusive) - NT\$30,000,000 (exclusive)	-	—
NT\$30,000,000 (inclusive) - NT\$50,000,000 (exclusive)	-	—
NT\$50,000,000 (inclusive) - NT\$100,000,000 (exclusive)	-	—
Above NT\$100,000,000	-	—
Total	-	7 persons

Note: Managerial officer Gerald Kowalski retired on January 10, 2025.

(IV) Top 5 managers with the highest remuneration: Details in the table above.

(V) Names of managerial officers who received employee remuneration for the most recent fiscal year (2025): None.

(VI) Compare and analyze the total remuneration as a percentage of net income after tax stated in the parent company only financial reports or individual financial reports, paid by this group and by all consolidated entities (including this company) for the most recent 2 fiscal years to each of this group’s directors, supervisors, presidents, and vice presidents, and describe the policies, standards, and packages for payment of remuneration, the procedures for determining remuneration, and its linkage to business performance and future risk exposure.

1. The total remuneration as a percentage of net income after tax paid by this group and by all consolidated entities (including this group) for the most recent 2 fiscal years to each of this group’s directors, presidents, and vice presidents

Unit: NT\$ thousand

Item \ Year	2024		2025	
	The Company	As a percentage of net income after tax	The Company	As a percentage of net income after tax
Directors, presidents and vice presidents	52,153	(20.00)%	43,215	(21.48)%

Remuneration policy, standards and composition, procedures and the correlation with operational performance and future risks:

(1) Principle of payment of remuneration to directors

The remuneration to directors includes travel expenses, business execution expenses and earnings distribution. The remuneration to the directors of the consolidated company is determined according to the Company’s Articles of Association. The Board of Directors is authorized to determine the remuneration based on the directors’ participation in the consolidated company’s operations, the value of their contributions and the industry standard.

(2) President and Vice President

The remuneration to the president and vice president includes salary and employee bonus. The salary level is determined based on the Company’s contribution and the reference to the industry standard.

(3) Operating performance and the relevance of future risks

The Group has established the Remuneration Committee that is made up of all independent directors. These independent directors review and evaluate on a regular basis the performance of directors and managerial officers as well as the remuneration policy, system, standard and structure.

III. Implementation of Corporate Governance

(I) Functionality of the Board of Directors

The Board of Directors of the Group convened 5 times in 2025 and twice in the reporting year until the annual report’s publication date. The board convened a total of 7 times (A) in the most recent fiscal year until the annual report’s publication date. Director attendance records were as follows:

Position	Name	Actual Attendance (B)	Proxy Attendance	Actual Attendance Ratio (B/A) (%)	Remarks
Chairman	George J. Lee	7	0	100%	
Director	Winston Z. Ho	7	0	100%	

Director	Huan-Rung Li	4	1	80%	Resigned on December 1, 2025
Director	Chia-Hao Li	0	2	0%	Newly appointed on December 01, 2025
Director	Benjamin Jen	7	0	100%	
Independent director	Wen-Jing Tsai	7	0	100%	
Independent director	Ben Liu	2	0	100%	Resigned on June 6, 2025
Independent director	Jack Hsiao	2	0	100%	Resigned on June 6, 2025
Independent director	Ta-Ch'eng Hsu	5	0	100%	Newly appointed on June 12, 2025
Independent director	Yi-Ming Wu	5	0	100%	Newly appointed on June 12, 2025

Supplementary Information:

I. For Board of Directors meetings that meet any of the following descriptions, state the date, session, the content of motions, independent directors' opinions and how the company has responded to such opinions:

(I) Matters listed in Article 14-3 of the Securities and Exchange Act:

Meeting Date and Session	Content of motions	Independent directors' opinions and how the Company has responded to such opinions:
March 13, 2025 4th Board 15th Session	<ol style="list-style-type: none"> Motion of 2024 business report and 2024 consolidated financial statements Acknowledge 2024 Deficit Compensation Statement Internal Control System Statement Motion of election of all directors and independent directors Amendment to the Company's "Memorandum and Articles of Association" Motion for 2024 distribution of employee stock warrants (1st distribution) 	Passed by all independent directors.
May 08, 2025 4th Board 16th Session	<ol style="list-style-type: none"> Motion of the Q1 2025 consolidated financial statements Motion for 2024 distribution of employee stock warrants (2nd distribution) 	Passed by all independent directors.
June 12, 2025 5th Board 1st Session	<ol style="list-style-type: none"> Motion for the election of Chairman Motion for the appointment of Compensation Committee members of the Company Motion for the designation of convener of the Audit Committee 	Passed by all independent directors.
August 21, 2025 5th Board	<ol style="list-style-type: none"> Motion of the Q2 2025 consolidated financial statements Motion of the U.S. subsidiary's capital increase 	Passed by all independent directors.

2nd Session	3. Motion for the preparation of the Company's 2024 Sustainability Report 4. Appointment of HR Director 5. Appointment of Quality Assurance Director 6. Motion for 2024 distribution of employee stock warrants (3rd distribution)	
November 06, 2025 5th Board 3rd Session	1. Motion for the Q3 2025 consolidated financial statements 2. Motion of 2026 budget 3. 2026 audit plan 4. Amendment to the "Procedures for Acquisition or Disposal of Assets" 5. Motion for the determination of remuneration packages for employees in 2026 6. 2026 sales incentive plan for Sales Division 7. Motion for 2024 distribution of employee stock warrants (4th distribution)	Passed by all independent directors.
March 13, 2026 5th Board 4th Session	1. Motion of 2025 business report and 2025 consolidated financial statements 2. Acknowledge 2025 Deficit Compensation Statement 3. Internal Control System Statement 4. Promotion of Equipment Director 5. Promotion of Technical Service Director 6. Motion for 2024 distribution of employee stock warrants (5th distribution)	Passed by all independent directors.
May 08, 2026 5th Board 5th Session	1. Motion of the Q1 2025 consolidated financial statements 2. Motion for 2024 distribution of employee stock warrants (6th distribution) 3. Amendment to the "Rules of Procedures for the Shareholders' Meeting"	Passed by all independent directors.

(II) Any other documented objections or qualified opinions raised by independent directors against board resolutions in relation to matters other than those described above: None.

II. In the case of recusal of a director in a motion related to his/her own interests, please specify the director's names, the content of motions, the reasons for the recusal and the voting results: None.

III. TWSE/TPEX Listed Companies should disclose information on the evaluation content of the board's self (or peer) evaluation:

Evaluation Cycle	Once a year
Evaluation Period	January 1, 2025 to December 31, 2025
Evaluation Scope	Board of directors, individual directors and functional committees
Evaluation method	Internal self-evaluation by the board of directors and self-evaluation by the board members
Evaluation content	1. Performance evaluation of the board of directors: Participation in the operation of the company, improvement of the quality of the board of directors' decision making, composition and structure of the board of directors, election and continuing education of the directors, and internal control.

	<p>2. Performance evaluation of the board members: Alignment of the goals and missions of the Company, awareness of the duties of a director, participation in the operation of the Company, management of internal relationships and communication, the director’s professionalism and continuing education, and internal control.</p> <p>3. Performance evaluation of the functional committees: Participation in the operation of the Company, awareness of the duties of the functional committee, quality of decisions made by the functional committee, makeup of the functional committee and election of its members, and internal control.</p>	
<p>Evaluation outcome</p>	<p>The results of the evaluation are reported to the Board of Directors in Q1 2026 according to the Regulations for Self-evaluation or Peer Evaluation of the Board of Directors adopted by the Board of Directors to be used as the basis for review and improvement.</p> <p>1. Performance evaluation of the board of directors: Excellent. 2. Performance evaluation of the board members: Excellent. 3. Performance evaluation of the Audit Committee: Excellent. 4. Performance evaluation of the Remuneration Committee: Excellent.</p>	
<p>IV. Measures the objectives to strengthen the board’s functionality (e.g. establish Audit Committee, enhance information transparency) and execution status in the current and the most recent fiscal year: The Group has formulated the “Rules of Procedure for Board Meetings” as guidelines for the operation of Board meetings. The Group has 3 independent directors and has established the Audit Committee and Remuneration Committee. In the future, the Group will disclose related information on its website and on the MOPS to improve the transparency of information required by the law.</p>		

(II) The operation of the Audit Committee

The Audit Committee assists the Board in fulfilling its oversight of the quality and integrity of the accounting, auditing, reporting, and financial control practices, as well as risk management of the Company.

The Audit Committee is responsible to review the following major matters:

Financial statements; audit and accounting policies and procedures; internal control system and related policies and procedures; significant asset transactions or derivative transactions; significant lending, endorsement, or guarantees; fundraising or issuance of securities; derivative financial products and cash investments; regulatory compliance; whether managerial officers and directors have related party transactions and possible conflicts of interest; complaint reports; fraud prevention plans and fraud investigation reports; corporate information security; enterprise risk management; qualifications, independence, and performance evaluation of the certifying CPA; appointment, dismissal, or remuneration of the certifying CPA; appointment and removal of financial, accounting, or internal audit heads; fulfillment of the Audit Committee’s responsibilities, etc.

Work focus: The focus of the Audit Committee’s work this year included review of financial reports, assessment of the effectiveness of the internal control system, matters related to corporate governance, and review of amendments to the internal control system.

Current term of the Audit Committee: June 06, 2025 to June 05, 2028.

As of the print date of this annual report, the Audit Committee had held two meetings. In 2025, the Audit Committee had held a total of 4 meetings. Therefore, the Group had held a total of 6 Audit Committee meetings in the last two fiscal years and during the year up to the publication date of this annual report. Below are the attendance records of independent directors:

Position	Name	Actual Attendance (B)	Proxy Attendance	Actual Attendance Ratio (B/A) (%)	Remarks
Independent director	Wen-Jing Tsai	6	0	100%	
Independent director	Ben Liu	2	0	100%	Resigned on June 6, 2025
Independent director	Jack Hsiao	2	0	100%	Resigned on June 6, 2025
Independent director	Ta-Ch'eng Hsu	4	0	100%	Newly appointed on June 12, 2025
Independent director	Yi-Ming Wu	4	0	100%	Newly appointed on June 12, 2025

Supplementary Information:

I. Where Audit Committee meetings meet any of the following criteria, the date and session of the convened Audit Committee meeting, the content of motions, dissenting or qualified opinions or major recommendations by independent directors, Audit Committee resolutions, and the handling of such opinions shall be clearly specified:

(I) Matters listed in Article 14-5 of the Securities and Exchange Act:

Meeting Date and Session	Content of motions	How the Company has responded to the Audit Committee's opinions
March 13, 2025 13th meeting of the 3rd board	<ol style="list-style-type: none"> Motion of 2024 business report and 2024 consolidated financial statements Acknowledge 2024 Deficit Compensation Statement Internal Control System Statement Motion for 2024 distribution of employee stock warrants (1st distribution) 	Passed by all members of the Audit Committee
May 08, 2025 14th meeting of the 3rd board	<ol style="list-style-type: none"> Motion of the Q1 2025 consolidated financial statements Motion for 2024 distribution of employee stock warrants (2nd distribution) 	Passed by all members of the Audit Committee
August 21, 2025 1st meeting of the 4th board	<ol style="list-style-type: none"> Motion of the Q2 2025 consolidated financial statements Motion of the U.S. subsidiary's capital increase Motion for 2024 distribution of employee stock warrants (3rd distribution) 	Passed by all members of the Audit Committee

November 06, 2025 2nd meeting of the 4th board	<ol style="list-style-type: none"> 1. Motion for the Q3 2025 consolidated financial statements 2. Motion of 2026 budget 3. 2026 audit plan 4. Amendment to the “Procedures for Acquisition or Disposal of Assets” 5. Motion for 2024 distribution of employee stock warrants (4th distribution) 	Passed by all members of the Audit Committee
March 11, 2026 3rd meeting of the 4th board	<ol style="list-style-type: none"> 1. Motion of 2025 business report and 2025 consolidated financial statements 2. Acknowledge 2025 Deficit Compensation Statement 3. Internal Control System Statement 4. Motion for 2024 distribution of employee stock warrants (5th distribution) 	Passed by all members of the Audit Committee
May 08, 2026 4th meeting of the 4th board	<ol style="list-style-type: none"> 1. Motion of the Q1 2025 consolidated financial statements 2. Motion for 2024 distribution of employee stock warrants (6th distribution) 3. Amendment to the “Rules of Procedures for the Shareholders’ Meeting” 	Passed by all members of the Audit Committee
<p>(II) Other than those described above, any resolutions not approved by the Audit Committee passed by more than two-thirds of directors: None.</p> <p>II. In case of an independent director’s recusal in a motion related to his/her own interests, please specify the director’s names, the content of motions, the reasons for the recusal, and the voting results: None.</p> <p>III. Communication between Independent Directors, Head of Internal Audit, and CPAs:</p> <p>(I) The Company’s head of internal audit sends audit reports to the independent directors via email on a monthly basis and holds discussions with the independent directors on matters related to internal controls, auditing, and other relevant topics on an irregular basis. The execution and effectiveness of internal audit operations have been communicated appropriately.</p> <p>(II) The Company’s signing CPAs hold discussions and communications with the independent directors on an irregular basis following each quarterly Audit Committee meeting, covering financial statement audit findings, key matters, and regulatory updates.</p>		

(III) Corporate governance execution status and deviations from “Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies”

Evaluation Item	Implementation Status			Difference from the Corporate Governance Best-Practice Principles for TWSE/TEPx Listed Companies and the reasons
	Yes	No	Summary	
I. Whether the Company establishes and discloses its corporate governance rules in accordance with the Corporate Governance Best-Practice Principles for TSE/TPEX Listed Companies?	✓		The Group has established its Corporate Governance Best-Practice Principles to implement vital corporate governance principles to protect shareholders' equity and interests, strengthen the functions of the Board of Directors and enhance the transparency of information. The Group has also formulated related corporate governance rules, such as the Rules of Procedure for Board Meetings, the Audit Committee Charter, the Remuneration Committee Charter, the Procedures for Handling Material Inside Information and Prevention of Insider Trading, the internal audit system, and the Ethical Corporate Management Best Practice Principles. The Group discloses material information as required by applicable laws and regulations and discloses financial and nonfinancial information regularly. 3 independent directors have also been set up; therefore, the Group's practical operations are handled in accordance with corporate governance rules.	No material nonconformity
II. Equity structure and shareholders' equity				
(I) Has the Company established internal procedures to handle shareholders' proposals, doubts, disputes, and litigation matters; also, have the procedures been implemented accordingly?	✓		(I) The Group has appointed a professional stock transfer agency in Taiwan to handle stock affairs. It has set up a spokesperson and deputy spokesperson that are available to deal with shareholders' suggestions, doubts and disputes.	No material nonconformity
(II) Does the Company have the list of the Company's major shareholders and the list of the ultimate controllers of the major shareholders?	✓		(II) Through the insider reporting system, the Group is aware of the changes in the list of major shareholders and ultimate controllers of major shareholders.	No material nonconformity
(III) Has the Company established and implemented the risk control and firewall mechanisms with affiliated enterprises?	✓		(III) The Group has formulated the "Management Measures Governing Transactions between Enterprises, Certain Companies and Related Parties." Related matters are handled accordingly to enforce risk control.	No material nonconformity
(IV) Has the Company set up internal norms to prohibit insiders from utilizing undisclosed information to	✓		(IV) The Group has formulated the Procedures for Handling Material Inside Information and Prevention	No material nonconformity

Evaluation Item	Implementation Status			Difference from the Corporate Governance Best-Practice Principles for TWSE/TEPx Listed Companies and the reasons
	Yes	No	Summary	
trade securities?			of Insider Trading to prevent insiders from trading marketable securities using information that is not yet open to the public. The Group also strengthens the promotion of legal compliance of insiders to be aware of and follow applicable regulations.	
<p>III. The composition, duties of the Board of Directors</p> <p>(I) Has the board of directors formulated a diversity policy and concrete management objectives and have this policy and objectives been implemented?</p> <p>(II) Apart from establishing the Remuneration Committee and audit committee by the law, has the Company established other functional committees voluntarily?</p> <p>(III) Has the Company established rules and methodology for evaluating the performance of its Board of Directors, implemented the performance evaluations on an annual basis, and submitted the results of performance evaluations to the board of directors and used them as reference in determining salary/compensation for individual directors and their nomination and additional office terms?</p> <p>(IV) Does the Company regularly evaluate its external auditors' independence?</p>	<p>✓</p> <p>✓</p> <p>✓</p> <p>✓</p>		<p>(I) The Group's current Board is made up of 4 directors and 3 independent directors, who share backgrounds of biotechnology, healthcare, business management, and finance and accounting.</p> <p>(II) Currently, we have established the Remuneration Committee, Audit Committee and Sustainable Development Committee. In the future, the Group may set up other functional committees according to business needs.</p> <p>(III) The Group has established the Regulations Governing the Board Performance Evaluation and its evaluation methods and conducts a regular performance evaluation as required. The first quarter of 2026 has been evaluated by all members of the board and the result has been submitted to the Board.</p> <p>(IV) The Board of Directors of the Group periodically evaluates the qualifications and independence of the CPAs. Based on the annual independence statements provided by the signing CPAs and the Audit Quality Indicators (AQIs) of PricewaterhouseCoopers, and with reference to the CPA Act and Statement No. 10 of the Code of Professional Ethics for Certified</p>	<p>No material nonconformity</p> <p>No material nonconformity</p> <p>No material nonconformity</p> <p>No material nonconformity</p>

Evaluation Item	Implementation Status			Difference from the Corporate Governance Best-Practice Principles for TWSE/TEPx Listed Companies and the reasons
	Yes	No	Summary	
disclosed?				
(II) Has the company adopted other information disclosure methods (such as establishing an English website, designating a responsible person for collecting and disclosing information of the Company, substantiating the spokesperson system, and upload the procedure of institutional investor conference on its website, etc.)?	✓		(II) The Group has a website in both Chinese and English and provides information on the Group's business and corporate governance. The information is also disclosed on MOPS to facilitate external inquiries about the Group's financial and business information. Dedicated personnel have been appointed to collect and disclose the company's information. The Group has also established a spokesperson and deputy spokesperson system and will convene institutional investor conferences in the future as required by regulations.	No material nonconformity
(III) Has the company published and reported its annual financial report within two months after the end of a fiscal year, and published and reported its financial reports for the first, second, and third quarters, as well as its operating status for each month before the specified deadline?	✓		(III) The Group published and reported its financial reports before the specified deadline.	No material nonconformity
VIII. Is there any important information (including but not limited to employee rights and benefits care, investor relations, supplier relations, stakeholder rights, the continuing education of the directors and supervisors, risk management policy and risk assessment implementation, the pursuit of customer policy, and the purchase of liability insurance for the company's directors and supervisors) that is helpful in understanding the corporate governance operation of the company?	✓		(I) Employee rights and benefits, employee care: We attach great importance to the rights and benefits of employees and maintains smooth communication channels while providing adequate education and training and reasonable remuneration and benefits. (II) Investor relations: We publish all information on MOPS and the Group's website. Spokesperson and deputy spokesperson have also been set up to maintains investor relations. (III) Supply relations: We have clear agreements with suppliers and customers to regulate each other's rights and obligations. (IV) Stakeholder rights: Stakeholders may communicate with and make suggestions to us through our website, spokesperson and deputy	No material nonconformity No material nonconformity No material nonconformity No material nonconformity

Evaluation Item	Implementation Status		Summary	Difference from the Corporate Governance Best-Practice Principles for TWSE/TEPx Listed Companies and the reasons
	Yes	No		
			spokesperson to protect their legitimate rights and interests. (V) The directors and supervisors' continuing education: Continuing education is provided to directors as required by regulations. (VI) Risk management policy and risk assessment implementation: We have established an internal control system and management measures and carry out operating procedures required by regulations. (VII) The pursuit of customer policy: We implement quick response and quality customer service mechanism so as to become our customers' permanent business partner. (VIII) The purchase of liability insurance for the Company's directors and supervisors: The Group currently purchases liability insurance for directors.	No material nonconformity No material nonconformity No material nonconformity

IX. Please explain the improvements made, based on the latest Corporate Governance Evaluation results published by TWSE Corporate Governance Center, and propose enhancement measures for any issues that are yet to be rectified: (Not required for companies not included in the evaluation list):

Status of improvements		
Serial number	Item	Improvement method
1	Does the Company disclose the professional qualifications and experience of the members of the Audit Committee, as well as the annual work focus and operation status?	It has been disclosed in the most recent annual report.
2	Does the Company's Board of Directors periodically (at least once a year) evaluate the independence and competence of the signing CPAs with reference to Audit Quality Indicators (AQIs), and disclose the evaluation procedures in detail in the annual report?	It has been disclosed in the most recent annual report.
3	Has the Company disclosed the annual greenhouse gas emission, water consumption and total weight of waste in the past two years?	It has been disclosed in the most recent annual report.

Evaluation Item	Implementation Status		Difference from the Corporate Governance Best-Practice Principles for TWSE/TEPx Listed Companies and the reasons
	Yes	No	
Prioritized enhancements			
1	Has the Company disclosed the annual greenhouse gas emission, water consumption and total weight of waste in the past two years?	Relevant data will be collected and appropriately disclosed in the annual report.	
2	Does the Company follow the framework of the Climate-related Financial Disclosures (TCFD) to disclose information about corporate governance, strategies, risk management, indicators and goals for climate-related risks and opportunities?	Please provide details about the climate-related information section in annual reports of TWSE/TPEX listed companies.	

Note on CPA Assessment Items:

Assessment Items for Evaluating CPA Independence:	Yes	No
(1) Financial Interest Matters:		
1.1 Having a “direct financial interest” in an audit client.	—	✓
1.2 Having a “material indirect financial interest” in an audit client.	—	✓
1.3 Having a “material financial interest” in another company over which the audit client has control.	—	✓
(2) Loans and Guarantees:		
2.1 Obtaining loans or guarantees from a financial institution that are not conducted on normal commercial terms.	—	✓
2.2 Obtaining loans or guarantees from an audit client that is not a financial institution.	—	✓
2.3 Mutual loans or guarantees between the CPA and an audit client that is not a financial institution.	—	✓
(3) Close Business Relationships with Audit Clients:		
3.1 Having a close business relationship with an audit client.	—	✓
3.2 Having a close business relationship with the directors, supervisors, or managers of an audit client. (E.g., co-investment ventures, profit-oriented strategic alliances, co-marketing and promotional arrangements for products, etc.)	—	✓
(4) Employment or Service in Capacities at Audit Clients:		
4.1 The certifying CPA currently serving, or having served within the past 2 years, as a director, supervisor, or manager of an audit client, or in a position with significant influence over the audit engagement, or as an employee thereof.	—	✓
4.2 Serving as a director, supervisor, or manager of an audit client, or in a position with significant influence over the audit engagement.	—	✓
4.3 Having served, during the audit period, as a director, supervisor, or manager of an audit client, or in a position with significant influence over the audit engagement.	—	✓
4.4 Having a confirmed future appointment as a director, supervisor, or manager of an audit	—	✓

client, or in a position with significant influence over the audit engagement.		
4.5 Serving as a director or supervisor of another company over which the audit client has control.	—	✓
4.6 Providing services as a director, supervisor, manager, or equivalent position for the audit client.	—	✓
4.7 Being employed on a regular basis by the principal or the auditee, receiving a fixed salary.	—	✓
(5) Non-Audit Matters:		
5.1 Valuation Services:		
5.11 Providing valuation services for the audit client that form part of the financial statements and carry significant impact with a high degree of subjectivity.	—	✓
5.12 Providing valuation services for the audit client that form part of the financial statements but carry no significant impact or do not involve a high degree of subjectivity.	—	✓
5.2 Bookkeeping Services:		
5.21 Providing bookkeeping services that do not comply with the requirements of professional ethics standards.	—	✓
5.3 Internal Audit Services:		
5.31 Assisting with or undertaking internal audit services that are not performed in accordance with generally accepted auditing standards.	—	✓
5.32 Assisting with or undertaking internal audit services related to the operational aspects of the enterprise.	—	✓
5.4 Short-Term Staff Secondment Services:		
5.41 Seconding internal staff to assist the audit client in performing work related to management decision-making, approval or execution of contractual documents, or acting as custodian of financial instruments by signing negotiable instruments on behalf of the client.	—	✓
5.42 Seconding internal staff to assist the audit client in performing work unrelated to management decision-making, approval or execution of contractual documents, or acting as custodian of financial instruments by countersigning negotiable instruments.	—	✓
5.5 Recruitment of Senior Management:		
5.51 Recruiting senior management personnel on behalf of the audit client for positions that have a direct and significant impact on audit engagements.	—	✓
5.6 Corporate Finance Services:		
5.61 Promoting, marketing, or trading shares or other securities issued by the audit client on the audit client's behalf.	—	✓
5.62 Acting as an agent to negotiate or commit to transaction conditions with third parties on behalf of the audit client.	—	✓
5.63 Assisting audit clients in developing corporate strategies.	—	✓
5.64 Acting as an intermediary in sourcing financing required by audit clients.	—	✓
5.65 Providing structural advice on the substance of audit clients' transactions and assisting in analyzing the accounting implications thereof.	—	✓

(IV) If the company has established a remuneration committee, its composition, duties and operations should be disclosed:

1. Information of members of the Remuneration Committee

Qualification		Professional qualifications and experience	Independence Criteria (conforms to the criteria set out in the Note)	Number of Other Public Companies Where the Member is Also a Member of Their Remuneration Committee
Identity	Name			
Independent director (Convener)	Wen-Jing Tsai	<p>Professional Qualifications: Professional or technical specialists who have passed a national examination or hold a license in accounting or another profession required for the Company's business operations with at least five years' experience.</p> <p>Experience: Master in Accounting, National Chengchi University Bachelor in Accounting, National Taiwan University Manager, Deloitte Taiwan CEO, the Tax Committee, Taipei CPA Association Deputy Chairman, the National Federation of CPA Associations of the R.O.C.</p>	(1) No; (2) None; (3) No; (4) None; (5) Yes	-
Independent director	Ta-Ch'eng Hsu	<p>Professional Qualifications: Required working experience at least five years in commerce, law, finance, accounting or other fields required by the business of the Company.</p> <p>Experience: Master of Accounting, University of Missouri-Columbia Bachelor of Science in Industrial Engineering, National Tsing Hua University President, China Development Biomedical Venture Capital Managing Director, China Development II Biomedical Venture</p>	(1) No; (2) None; (3) No; (4) None; (5) Yes	1

		Capital L.P. Senior Associate Vice President, Investment Department, China Development Industrial Bank Vice President, CTBC Venture Capital		
Independent director	Yi- Ming Wu	Professional Qualifications: Required working experience at least five years in commerce, law, finance, accounting or other fields required by the business of the Company. Experience: J.D., Cornell Law School B.S. in Business Administration, University of California, Berkeley Founder/Chairman, eMERG Group Executive Partner, Ignite Partners Company Limited Partner, K&L Gates LLP CEO/Co-Founder/Director, 6DXCHANGE, Inc. COO/Co-Founder/Directo, Spring Creek Acquisition Corp. CLO/Senior Vice President/Corporate Secretary, Openwave System, Inc. Vice President, Yahoo! Inc.	(1) No; (2) None; (3) No; (4) None; (5) Yes	1

Note: Independent directors shall provide a detailed description of their conformity to independence criteria including but not limited to the following: (1) Does the candidate, his/her spouse, or one of his/her relatives within the second degree of kinship serve as director, supervisor, or employee at the Company or one of its affiliates? (2) How many company shares does the candidate, his/her spouse, or one of his/her relatives within the second degree of kinship (or the candidate under others' names) hold and what is the shareholding ratio? (3) Does the candidate serve as director, supervisor, or employee of a company that has a specific relationship with this Company (as stipulated in Article 3, Paragraph 1, Subparagraph 5-8 of the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies)? (4) Cumulative compensation received for the provision of commercial, law, financial, and accounting services to this Company or its affiliates within the past two years; (5) Do one of the circumstances specified in Article 30 of the Company Act apply?

2. Information on the operation of the Remuneration Committee

- (1) The Group's Remuneration Committee is made up of 3 persons.
- (2) Term of the current committee members: June 12, 2025 to June 11, 2028. The Remuneration Committee convened 3 times in 2025 and once in the current year until the printing of the annual report for publication. The committee convened a total of 4 times in the most recent fiscal year until the printing of the annual report for publication. Committee member attendance records were as follows:

Position	Name	Actual Attendance (B)	Proxy Attendance	Actual Attendance Ratio (%) (B/A)	Remarks
Convener	Wen-Jing Tsai	4	-	100%	
Member	Ben Liu	1	-	100%	Resigned on June

					6, 2025
Member	Jack Hsiao	1	-	100%	Resigned on June 6, 2025
Member	Ta-Ch'eng Hsu	3	-	100%	Newly appointed on June 12, 2025
Member	Yi-Ming Wu	3		100%	Newly appointed on June 12, 2025

Supplementary Information:

- I. The Remuneration Committee held three regular meetings on March 13, August 21 and November 6, 2025, to discuss the following matters:
 - Report on employee compensation related matters
 - Discussion on directors' evaluation
 - Appointment of the managerial officers
 - Motion of 2024 distribution of employee stock warrants

All of the above matters were reviewed or approved by the Remuneration Committee.
- II. If the Board of Directors declines to adopt or modify a recommendation of the Remuneration Committee, the date, session, the content of motions, and the resolution of the Board meeting and handling of the resolution of the Remuneration Committee shall be specified (if the compensation package approved by the Board is better than the recommendation made by Remuneration Committee, please specify the discrepancy and its reason): None.
- III. If a particular member holds an adverse opinion or qualified opinion on the resolution of the Remuneration Committee on record or in a written declaration, specify the date, the session, the content of motions, the opinions of all members, and the responses to the opinions of the members: None.

(V) Promotion of sustainable development and deviation from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the reasons thereof

Item	Implementation Status		Summary Description	Deviation from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the reasons thereof
	Yes	No		
I. Has the Company established a governance framework for the promotion of sustainable development and has it designated units that are directly or concurrently responsible for the promotion of sustainable development? Has the board of directors authorized senior management to handle relevant matters and does it fulfill its supervisory duties?	✓		The Sustainable Development Committee, chaired by the President, is in charge of setting annual corporate social responsibility goals in economic, environmental, and social areas and regularly supervising their implementation, leading the Group's sustainable development, reviewing various short, medium, and long-term goal implementation progress, and operation implementation performance.	No material nonconformity
II. Has the company performed risk assessments on environmental, social, and corporate issues in relation to the Company's operations according to material principles and formulated relevant risk management policies or strategies?	✓		The scope of this disclosure and risk assessment boundary encompasses the Group's sustainability performance from January to December 2025. The Sustainable Development Committee conducted materiality analysis in accordance with the materiality principles of the sustainability report, engaging with internal and external stakeholders to assess material ESG issues, formulate risk management policies for effective identification, measurement, monitoring, and control, and adopt concrete action plans to mitigate the impact of relevant risks.	No material nonconformity
III. Environmental issues (I) Does the company have an appropriate environmental management system established in accordance with its industrial character? (II) Has the company committed efforts to upgrade the efficient use of energy and using recycled materials, causing less burden to the environment? (III) Does the company assess potential risks and opportunities associated with	✓		(I) The Group has successfully passed U.S. FDA inspections and established comprehensive management systems for its production processes. All generated waste is handled strictly in accordance with standard operating procedures and managed by professional external contractors for disposal. (II) The Group is committed to enhancing energy efficiency. As our core business involves the R&D and sales of diagnostic reagents, we do not belong to a	No material nonconformity No material nonconformity No material nonconformity

Item	Implementation Status		Summary Description	Deviation from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the reasons thereof
	Yes	No		
<p>climate change and undertake measures in response to climate issues?</p> <p>(IV) Does the company maintain statistics on greenhouse gas emissions, water usage and total waste volume in the last two years and implement policies to reduce energy, carbon, greenhouse gas, water and waste?</p>			<p>high-energy-consuming or high-pollution industry. Nevertheless, we continue to promote sustainable habits among our employees, such as low-carbon office practices and water and electricity conservation.</p> <p>(III) The Group has progressively implemented the TCFD framework, which is structured around four pillars: Governance, Strategy, Risk Management, and Metrics and Targets. Our management team identifies climate-related risks and opportunities to formulate responsive strategies. Furthermore, we have planned regular reporting to the Board of Directors, who will provide oversight to strengthen our overall climate risk management.</p> <p>(IV) We are committed to reducing the impact of the Group’s operation on the environment. We pay attention to the temperature in the office in an attempt to reduce carbon emissions while promoting energy conservation, recycling and reusing.</p>	No material nonconformity
<p>IV. Social issues</p> <p>(I) Does the company have the relevant management policies and procedures stipulated in accordance with the applicable laws and regulations and international conventions on human rights?</p> <p>(II) Has the company established</p>	✓		<p>(I) The Group supports the “United Nations Universal Declaration of Human Rights (UDHR)” and is committed to the understanding of international human rights standards, and follows labor laws and regulations to formulate relevant policies and procedures such as personnel management regulations and work rules to protect the legitimate rights and interests of employees.</p> <p>(II) We have established and implemented reasonable</p>	<p>No material nonconformity</p> <p>No material</p>

Item	Implementation Status		Summary Description	Deviation from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the reasons thereof
	Yes	No		
<p>and implemented reasonable measures for employee benefits (including: remuneration, holidays and other benefits) and appropriately reflect the business performance or achievements in the employee remuneration?</p> <p>(III) Does the company provide employees with a safe and healthy work environment and regularly provide safety and health education to employees?</p> <p>(IV) Has the company established a training program for helping employees with effective career planning?</p> <p>(V) Has the company complied with laws and international standards with respect to customers' health, safety and privacy, marketing and labeling in all products and services offered, and implemented consumer and client protection policies and complaint procedures?</p> <p>(VI) Has the company implemented a supplier management policy that regulates suppliers' conduct with respect to environmental protection, occupational safety and health or work rights/human rights issues, and tracked suppliers' performance on a regular basis?</p>			<p>employee benefit measures (including remuneration, holidays and other benefits), and reflect our business performance or achievements in the employee remuneration.</p> <p>(III) We provide our employees with a safe and healthy workplace. We organize labor safety education and training periodically. No fire incident has occurred within the Group in the past two years.</p> <p>(IV) We organize internal education and training from time to time and encourage our employees to take part in external education and training so that employees are able to improve their working ability.</p> <p>(V) Our marketing and labeling of products and services comply with applicable laws, regulations, and international standards.</p> <p>(VI) Although the Group's contracts currently entered into with its major suppliers do not cover the contents listed on the left, ABC-KY performs audits on suppliers' basic information as required by the internal control system and applicable management measures. Until now, ABC-KY has no suppliers with significant environmental protection concerns, occupational safety and health, or labor and human rights.</p>	<p>nonconformity</p> <p>No material nonconformity</p> <p>No material nonconformity</p> <p>No material nonconformity</p> <p>May be established according to future needs.</p>
V. Does the company prepare a sustainability report or any non-financial information report	✓		The Group has not yet completed the preparation of a sustainability report. The Company plans to obtain	May be established according to future needs.

Item	Implementation Status		Summary Description	Deviation from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the reasons thereof
	Yes	No		
based on international reporting standards or guidelines? Are the abovementioned reports supported by the assurance or opinion of a third-party verification unit?			assurance from a third-party verification unit in accordance with the “Sustainability Development Roadmap for TWSE/TPEX Listed Companies.”	
<p>VI. If the Company has formulated its own sustainable development best practice principles in accordance with the “Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies,” please clearly specify the state of implementation and any deviations: The Group has adopted its own Corporate Social Responsibility Best Practice Principles. There are no significant deviations from the “Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies.”</p>				
<p>VII. Any other important information that may help the understanding of the performance of sustainable development promotion better: Not only do we attach great importance to legal compliance to protect all stakeholders, as a group concerned by society, but it has also become the Group’s culture to strive to fulfill its corporate social responsibility while setting an example.</p>				

(VI) Climate-related information on TWSE/TPEX listed companies.

Evaluation Item	Implementation Status
<p>I. Description of the Board of Directors' and management's oversight and governance of climate-related risks and opportunities.</p>	<p>According to the Group's corporate governance structure, the Sustainable Development Committee is established under the Board of Directors. The President coordinates all units and reports regularly to the Board of Directors on sustainability development progress annually. The Sustainable Environment and Product Service Team is established under the Sustainable Development Committee, specifically responsible for handling environmental-related issues, including greenhouse gas emissions inventory and climate risk identification.</p>
<p>II. Please describe identified climate risks and opportunities, and the impact on an enterprise's business, strategy and finance (short, medium, and long term)</p>	<p>Climate risk and opportunity issues</p> <p>I. Low-carbon technology transition costs: Carbon emission costs from upstream suppliers may cause price increases in raw materials. Response strategy: Seek alternative material suppliers and obtain multiple price quotes to mitigate procurement cost pressures. Furthermore, both offices and factory areas have adopted energy-efficient lighting equipment to reduce lighting energy consumption and have switched to electric forklifts. The potential short-term financial impact is increased costs.</p> <p>II. Customer behavior changes: Rising environmental awareness will affect customer willingness. Response strategy: During product development processes, minimize the use of plastic raw materials and packaging while reducing the use of single-use plastic items and liquid solvents. The potential short-term financial impact is increased costs.</p> <p>III. Implementing more efficient production and distribution processes: Introducing AI technology and digital transformation to achieve more environmentally friendly and sustainable production models. Response strategy: Implement digital material management systems to optimize</p>

Evaluation Item	Implementation Status
	<p>inventory control processes and effectively reduce inventory levels. Additionally, design new packaging to reduce materials used during product shipping. Also, establish automated test tube labeling systems to improve production efficiency. The potential short-term financial impact is increased costs.</p> <p>Due to long-term improvements in production efficiency, overall operational costs can be reduced.</p>
<p>III. Description of the financial impact of extreme climate events and transformation actions</p>	<p>As stated above.</p>
<p>IV. Description of how climate risk identification, assessment, and management processes are integrated into the overall risk management system.</p>	<p>Following the Task Force on Climate-related Financial Disclosures (TCFD) guidelines for climate issue categories, the Group has collected common climate issues from domestic and international benchmark peers and industry trend reports. We initially screened climate issues relevant to Applied BioCode's industry, and integrated these findings with operational experience recommendations from various departments. Ultimately, we identified 11 climate issues for materiality assessment, including 5 transition risks, 2 physical risks, and 4 opportunities.</p> <p>In the future, we will regularly re-identify climate risks and review assessment results based on impact level and probability of occurrence.</p>
<p>V. If scenario analysis is used to assess resilience to climate change risks, please describe the scenarios, parameters, assumptions, analysis factors, and major financial impacts.</p>	<p>We have not used scenario analysis to perform resilience assessment for climate change risks.</p>
<p>VI. If there is a transition plan to address and manage climate-related risks, please describe the content of the plan, as well as the indicators and targets used to identify and manage physical risks and transition risks.</p>	<p>The Company has established a systematic transformation plan through the Sustainable Development Committee, addressing transition risks (such as carbon fees and technology transition costs) and physical risks (such as extreme weather events) with concrete measures including energy conservation and emission reduction, supply chain resilience enhancement,</p>

Evaluation Item	Implementation Status
	<p>and low-carbon product development.</p> <p>The Company uses indicators such as impact probability and severity, greenhouse gas emissions, energy efficiency, supply chain stability, and product sustainability to identify and manage risks.</p> <p>Current goals focus primarily on data inventory and transparency, while specific carbon reduction targets are still under evaluation. However, the Company plans to align with international standards.</p>
<p>VII. If internal carbon pricing is used as a planning tool, the basis for price determination should be explained.</p>	<p>Still under evaluation, not yet implemented.</p>
<p>VIII. If climate-related targets have been set, please describe the activities covered, greenhouse gas emission scopes, planning timeline, annual progress, and other information. If carbon offsets or Renewable Energy Certificates (RECs) are used to achieve related targets, the source and quantity of carbon reduction credits or the number of RECs should be explained.</p>	<p>The Company implemented the Greenhouse Gas Protocol (GHG Protocol) in 2023, establishing 2023 as the base year. The inventory results showed that total carbon emissions were 168.9055 metric tons of CO₂e in 2023, with a slight increase to 181.1689 metric tons of CO₂e in 2024, with a slight increase to 192.0262 metric tons of CO₂e in 2025 primarily due to increased Scope 2 emissions (purchased electricity). The Company plans to follow the “Sustainability Development Roadmap for TWSE/TPEX Listed Companies” by conducting data assurance operations in accordance with the International Standard on Assurance Engagements (ISAE 3410) to ensure transparency and gradually align with international sustainability standards. Climate-related targets are currently in the evaluation phase.</p>
<p>IX. Greenhouse gas inventory, assurance status and specific action plans</p>	<p>According to Ministry of Environment regulations, enterprises with greenhouse gas emissions exceeding 25,000 tons of CO₂e are required to submit quarterly reports and obtain third-party verification for their annual emissions. Although the Group is currently not within the scope of these mandatory controls, we recognize that future regulatory expansions could pose compliance risks and increase operating costs. To proactively manage this, we plan to complete annual inventories and third-party verifications by April each year.</p>

Evaluation Item	Implementation Status
	Furthermore, we will utilize ISO management systems to set annual targets, driving energy-saving initiatives in production processes and utility equipment to enhance energy efficiency and reduce GHG emissions.

(VII) Ethical Corporate Management Best Practice Principles and Deviations from Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and Reasons

Evaluation Item	Implementation Status			Deviations from Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and Reasons
	Yes	No	Summary	
I. Ethical Management Policies and Action Plans				
(I) Has the company established an ethical management policy that its Board of Directors has passed, and clearly specified in its rules and external documents the ethical corporate management policies and the commitment by the Board of Directors and senior management on the rigorous and thorough implementation of such policies and methods?	✓		(I) The Group has formulated the Ethical Corporate Management Best Practice Principles and the Conduct Guidelines, in which the policy, method and commitment of ethical management are clearly listed.	No material nonconformity
(II) Has the company established a risk assessment mechanism against unethical behavior, analyzed and assessed business activities within their business scope regularly that are at a higher risk of being involved in unethical behavior, and established prevention programs at least covering the preventive measures specified in Paragraph 2, Article 7 “Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies”?	✓		(II) The Group has formulated the Ethical Corporate Management Best Practice Principles and the Conduct Guidelines, in which the regulations are clearly listed.	No material nonconformity
(III) Has the company specified operational procedures, behavioral guidelines, disciplines of violations, as well as an appeal system in the program against unethical behavior, and implemented such programs, and reviewed and revised the previous program on a regular basis?	✓		(III) The Group has established the Guidelines for the Adoption of Codes of Ethical Conduct and foster the idea of corporate ethics to the employee. The Group’s management regulations have clear, relevant reward and disciplinary measures.	No material nonconformity
II. Implementation of Ethical				

Evaluation Item	Implementation Status			Deviations from Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and Reasons
	Yes	No	Summary	
<p>Management</p> <p>(I) Does the Company evaluate the integrity of all counterparties it has business relationships with? Are there any integrity clauses in the agreements it signs with business partners?</p>	✓		<p>(I) The Group carries out a review on the basic information of whom the Company does business with, as required by the internal control system and applicable management measures. So far, there is no significant irregularity in the content of purchase and sales or payment and receipt. Therefore, the main counterparties should have no unethical record. Although ABC-KY does not specify integrity terms in the contract entered into with counterparties, both the Company and counterparties carry out operating procedures in accordance with our respective internal norms. ABC-KY also enforces the regulations stipulated in the Ethical Corporate Management Best Practice Principles and the Conduct Guidelines.</p>	<p>No significant differences/the contract explicitly stipulates integrity clauses, which will be managed according to relevant regulations as needed in the future.</p>
<p>(II) Has the Company set up a dedicated, responsible unit to promote corporate ethical management under the Board of Directors, and has such unit reported its execution in terms of ethical management policy and preventive programs against unethical behaviors and the supervision status to the Board of Directors on a regular basis (at least once a year)?</p>	✓		<p>(II) Although the Group has not established a dedicated unit to promote corporate ethical management under the Board of Directors, all of the Group's operating activities adhere to the spirit of ethical Corporate Management Best Practice Principles and the Conduct Guidelines, and implement ethical management policy while proactively preventing any unethical conduct.</p>	<p>May be established according to future needs.</p>
<p>(III) Does the Company have any policy that prevents conflict of interest and channels that facilitate the reporting of</p>	✓		<p>(III) The Group has established the Guidelines for the Adoption of Codes of Ethical Conduct for the</p>	<p>No material nonconformity</p>

Evaluation Item	Implementation Status			Deviations from Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and Reasons
	Yes	No	Summary	
<p>conflicting interests?</p> <p>(IV) Has the Company established an effective accounting system and internal control system in order to implement ethical management, and propose relevant audit plans according to the assessment results of the risks of unethical behaviors, and review the compliance status of the prevention of unethical behaviors, or entrust an accountant to carry out the review?</p> <p>(V) Does the Company organize internal or external training on a regular basis to maintain ethical management?</p>	<p>✓</p> <p>✓</p>		<p>employee to follow, to prevent them from sacrificing the Company's interests for their personal gains.</p> <p>(IV) The Group has established an effective accounting system and internal control system. These systems are regularly reviewed for compliance by internal auditors.</p> <p>(V) The Group has established rules for ethical management and promotes the importance of ethical management to the employee from time to time.</p>	<p>No material nonconformity</p> <p>No material nonconformity</p>
<p>III. Operation of the Company's whistleblowing system</p> <p>(I) Does the company have a specific whistleblowing and reward system established, a convenient report channel established, and a responsible staff designated to handle the individual being reported?</p> <p>(II) Has the company implemented any standard procedures and/or</p>	<p>✓</p> <p>✓</p>		<p>(I) The Company has established its own whistleblowing system and measures in accordance with Article 23 of the Ethical Corporate Management Best Practice Principles approved by the Board of Directors, and has set up and announced the whistleblowing e-mail box on the Company's website, where internal and external parties can whistle-blower and accept criminal, fraud, or illegal matters.</p> <p>(II) The relevant procedures have been defined in the Company's whistle-blowing</p>	<p>No material nonconformity</p> <p>No material nonconformity</p>

Evaluation Item	Implementation Status			Deviations from Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and Reasons
	Yes	No	Summary	
<p>subsequent measures after carrying out an investigation or confidentiality measures for handling reported misconducts?</p> <p>(III) Has the company taken appropriate measures to protect the whistle-blower from suffering any consequences of reporting an incident?</p>	✓		<p>system.</p> <p>(III) The relevant procedures have been clearly defined in the Company's whistle-blowing system. Any breach of confidentiality regulations will be punished internally.</p>	No material nonconformity
<p>IV. Information Disclosure Strengthening</p> <p>Has the company disclosed the content of its ethical corporate management best practice principles and the results of implementation on its official website and MOPS?</p>	✓		<p>The Group's information is released in a timely and transparent manner, and information related to ethical corporate management is fully disclosed in the annual report.</p>	No material nonconformity
<p>V. For companies who have established Ethical Corporate Management Best Practice Principles in accordance with the "Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies," please describe the current practice and any deviations from the code of conduct: So far, there are no significant differences in the operation.</p>				
<p>VI. Other important information that helps to understand the practice of ethical management of the company: (e.g., the review and revision of Ethical Corporate Management Best Practice Principles): The Group arranges corporate governance courses for directors on a regular basis and promotes the ethical management policy through internal meetings from time to time.</p>				

Note: Regardless of clicking "yes" or "no," it should be explained in the summary field.

(VIII) Other important information that is sufficient to enhance the understanding of the operation of corporate governance: None.

(IX) Internal control system implementation status

Please see the Declaration of Internal Control System posted on the Market Observation Post System.

<https://mopsov.twse.com.tw/mops/web/t06sg20>

If an accountant is entrusted to perform a special audit on the internal control system, the audit report shall be disclosed: None.

(X) Important resolutions of board of directors' meeting during the last fiscal year and up to the date of publication of the annual report:

Date of Meeting	Session	Content of motions	Resolution
2025/03/13	15th meeting of the 4th board	<ul style="list-style-type: none"> (1) Motion of 2024 business report and 2024 consolidated financial statements (2) Acknowledge 2024 Deficit Compensation Statement (3) Internal Control System Statement (4) Motion of election of all directors and independent directors (1) Amendment to the Company's "Memorandum and Articles of Association" 	Motion has been passed
2025/05/08	16th meeting of the 4th board	<ul style="list-style-type: none"> (1) Motion of the Q1 2025 consolidated financial statements 	Motion has been passed
2025/06/12	1st meeting of the 5th board	<ul style="list-style-type: none"> (1) Election of chairman (2) Proposed to appoint members of the Company's Remuneration Committee (3) Motion of the convener appointment by the Audit Committee (selected by mutual recommendation among members of the Audit Committee.) 	Motion has been passed
2025/08/21	2nd meeting of the 5th board	<ul style="list-style-type: none"> (1) Motion of the Q2 2025 consolidated financial statements (2) Motion of the U.S. subsidiary's capital increase (3) Motion for the preparation of the Company's 2024 Sustainability Report 	Motion has been passed
2025/11/06	3rd meeting of the 5th board	<ul style="list-style-type: none"> (1) Motion of the Q3 2025 consolidated financial statements (2) Motion of 2026 budget (3) 2026 audit plan (4) Amendment to the Company's "Procedures for Acquisition or Disposal of Assets" 	Motion has been passed
2026/03/11	4th meeting of the 5th board	<ul style="list-style-type: none"> (1) Motion of 2025 business report and 2025 consolidated financial statements (2) Acknowledge 2025 Deficit Compensation Statement (3) Internal Control System Statement 	Motion has been passed
2026/05/08	5th meeting of the 5th board	<ul style="list-style-type: none"> (1) Motion of the Q1 2025 consolidated financial statements (2) Amendment to the "Rules of Procedures for the Shareholders' Meeting" 	Motion has been passed

- (XI) Any other documented objections or qualified opinions raised by directors or supervisors against board resolutions in relation to matters, and their content for the most recent fiscal year and as of the publication date of the annual report: None.

IV. Information of CPA Professional Fees

(I) Information of CPA Professional Fees

Unit: NT\$ thousand

Name of the Accounting Firm	Name of the CPAs	CPA audit period	Audit Fee	Non-Audit Fee	Total	Remarks
PwC Taiwan	Chan-Niu Liang	2025	7,020	0	7,020	
	Alan Chien					

- (II) When the company changes its accounting firm and the audit fees paid for the financial year in which the change took place are lower than those paid for the financial year immediately preceding the change, the amount of the audit fees before and after the change and the reason shall be disclosed: None.

- (III) Over 10% decrease in audit fee compared to the previous year, the decreased amount, percentage and reason of the audit fee shall be disclosed: None

V. Change of CPAs: None.

VI. Status of whether the company's chairman, president, or any managerial officer in charge of finance or accounting matters has for the last fiscal year held a position at the accounting firm of its auditing CPAs or at an affiliate: None.

VII. Evaluation of CPAs' Independence:

The Audit Committee assessed the independence of the CPAs using the following criteria and reported the results of its assessment to the Board of Directors.

- (I) Independence Declaration of the CPAs
- (II) The same CPA has not performed audit services for more than seven consecutive years
- (III) The CPA's independence evaluation report is used to evaluate the financial interests, business relationships, and employment relationships of the CPA annually in order to summarize the results of the evaluation of the CPA's independence.

VIII. Information of shares transfers or pledges from Board of Directors, managerial officers, and shareholders with more than 10% shareholding

- (I) Changes in shareholding and changes in pledge of shares by directors, supervisors, managerial officers and major Shareholders:

Please refer to the subsequent declaration of changes in shareholding by insiders on the Market Observation Post System.

- (II) Information on transfer of shares or pledge of shares to related parties: Not applicable.

IX. Information of Relationship between top 10 shareholder

April 13, 2026; Unit: shares; %

Name	Shareholding		Shareholding of Spouse & Minor Children		Number of shares held under another person's name		Names and relationship of top ten shareholders who are related parties, spouses or within second-degree of kinship to each other		Remarks
	Shares	Shareholding Ratio	Shares	Shareholding Ratio	Shares	Shareholding Ratio	Name	Relation	
Fu-Lung Shiu	8,901,723	8.66	-	-	-	-	-	-	-
Maxwell Sensors Inc.	8,307,042	8.08	-	-	-	-	-	-	-
(Representative: Winston Z. Ho)	108,750	0.11	4,959,574	4.82	4,913,418	4.78	-	-	-
Eureka BioVenture Partners	3,571,060	3.47	-	-	-	-	-	-	-
(Representative: George J. Lee)	-	-	-	-	3,571,060	3.47	-	-	-
Celerus Diagnostics Inc.	2,729,061	2.65	-	-	-	-	-	-	-
GVT Fund, L.P.	2,608,421	2.54	-	-	-	-	-	-	-
(Representative: Hsiu-Chun Wang)	-	-	-	-	-	-	-	-	-
Cathay Venture	2,250,000	2.19	-	-	-	-	-	-	-
(Representative: Jen-Han Chang)	-	-	-	-	-	-	-	-	-
Tsai-Kuei Wang	2,153,837	2.09	-	-	-	-	-	-	-
Jih-Yuan Venture & Investment Inc.	2,088,427	2.03	-	-	-	-	-	-	-
(Representative: Chiou-Huang Jang)	50,000	0.05	-	-	-	-	-	-	-
Wistron Corporation	2,075,000	2.02	-	-	-	-	Wise Cap Limited Company	-	-
(Representative: Shian-Ming Lin)	-	-	-	-	-	-	-	-	-
Wise Cap Limited Company	1,724,514	1.68	-	-	-	-	Wistron Corporation	-	-
(Representative: Fu-Chian Lin)	-	-	-	-	-	-	-	-	-

X. Number of shares and shareholding percentage of an invested entity held by the company, the company's board members, supervisors, managerial officers and directly or indirectly controlled entities

April 13, 2026; Unit: thousand shares; %

Re-invested business	Group Investment		Directors, supervisors, managerial officers and investments in direct or indirectly controlled entities		Comprehensive Investment	
	Shares	Shares Ratio	Shares	Shares Ratio	Shares	Shares Ratio
Applied BioCode, Inc.	50,140	100.00	-	-	50,140	100.00
ABC-TW (Note)	10,300	100.00	-	-	10,300	100.00

Note: Originally named Wei-Cih Biotechnology Corporation; changed its name on August 12, 2016.

Four. Fundraising

I. Capital and Shares

(I) Source of Share Capital

1. Formation of Share Capital

Unit: NT\$; Shares

Year / Month	Issue Price	Authorized Share Capital		Paid-up Share Capital		Remarks		
		Number of shares	Amount	Number of shares	Amount	Source of Share Capital	Paid in properties other than cash	Others
2024.02	USD 0.286	150,000,000	1,500,000,000	81,771,352	817,713,520	Conversion of 3,000 shares of employee stock warrants	None	—
2024.03	USD 0.286	150,000,000	1,500,000,000	81,777,561	817,775,610	Conversion of 6,209 shares of employee stock warrants	None	—
2024.08	NT\$ 21	150,000,000	1,500,000,000	102,777,561	1,027,775,610	Cash capital increase to issue 21,000,000 new shares	None	—
2024.08	USD 0.286	150,000,000	1,500,000,000	102,787,561	1,027,875,610	Conversion of 10,000 shares of employee stock warrants	None	—
2025.06	USD 0.286	150,000,000	1,500,000,000	102,801,061	1,028,010,610	Conversion of 13,500 shares of employee stock warrants	None	—
2025.07	USD 0.286	150,000,000	1,500,000,000	102,811,061	1,028,110,610	Conversion of 10,000 shares of employee stock warrants	None	—
2026.03	USD 0.286	150,000,000	1,500,000,000	102,819,061	1,028,190,610	Conversion of 8,000 shares of employee stock warrants	None	—

2. The Company's private placement of common stock for the past 3 years and as of the publication date of the annual report: The Group was not engaged in the private placement of common stock for the past 3 years and as of the publication date of the annual report.

3. Types of shares issued

April 13, 2026; Unit: shares

Types of shares	Authorized share capital			Remarks
	Outstanding shares (Note)	Unissued shares	Total	
Ordinary share	102,819,061	47,180,939	150,000,000	

Note: The outstanding shares are the shares of the listed company.

4. General information about the reporting system: Not applicable.

(II) List of major shareholders

April 13, 2026; Unit: shares

Name of major shareholder	Share	Number of shares held	Shareholding ratio
Fu-Lung Shiu		8,901,723	8.66%
Maxwell Sensors Inc.		8,307,042	8.08%
Eureka BioVenture Partners		3,571,060	3.47%
Celerus Diagnostics Inc		2,729,061	2.65%
GVT Fund, L.P. (investment account of GRC SinoGreen Fund under the custody of Bank SinoPac)		2,608,421	2.54%
Cathay Venture		2,250,000	2.19%
Tsai-Kuei Wang		2,153,837	2.09%
Jih-Yuan Venture & Investment Inc.		2,088,427	2.03%
Wistron Corporation		2,075,000	2.02%
Wise Cap Limited Company		1,724,514	1.68%

1. The status of directors, supervisors and shareholders holding more than 10 percent of outstanding shares waived their subscription right to the cash capital increase during the most recent 2 fiscal years and in the current fiscal year.

(1) The status that directors, supervisors and shareholders holding more than 10 percent of outstanding shares had waived their subscription right to the cash capital increase:

Position	Name	2024		2025	
		Numbers of shares for subscription	Number of shares subscribed	Numbers of shares for subscription	Number of shares subscribed
Director	Winston Z. Ho	For this capital increase, after considering the overall investment strategy, both directors waived their subscription rights.		There was no cash capital increase conducted this year.	
Major shareholder	Maxwell Sensors				

(2) If the subscription to the cash capital increase being waived was subscribed by a related person who was designated for such subscription, the name of such related person, its relationship with the company, directors, supervisors and shareholders holding more than 10 percent of outstanding shares, and the number of the shares thus subscribed shall also be disclosed: No cash capital increase was carried out during the current year.

(III) Company dividend policy and implementation status

1. Dividend policy in Articles of Association

It is determined based on the Group's dividend policy, and the Board understands that the Group's operations are in a growth stage. The Board of Directors, when determining the amount of dividends or other distributions (if any) to be proposed for shareholders' approval in each fiscal year: (1) may take into consideration the Group's earnings for the respective fiscal year, overall development, financial planning, capital requirements, industry outlook, and future prospects of the Group, in order to ensure the protection of shareholders' rights and interests; and (2) As required by Article 14.4 of the Company's Articles of Association, not only remuneration to employees and directors shall be distributed. The following shall also be set aside from the current net income: (i) losses to be made up; (ii) 10% of the general reserve (the "legal reserve"); and (iii) the special reserve required by the Board of Directors in accordance with the rules for public companies promulgated by the Securities Authority, or the surplus

resolved in Article 15.1 of the Company's Articles of Association.

Without violating the Company Law of the Cayman Islands, after remuneration to employees and directors in accordance with Article 14.4 of the Company's Articles of Association and an amount deemed appropriate by the Board of Directors in accordance with Article 14.5 of the Company's Articles of Association are set aside, the Board of Directors shall set aside not less than 10% of the distributable amount of the earnings from the previous fiscal year (excluding the accumulated earnings from previous years) as dividends for shareholders. These dividends must be resolved by the shareholders meeting prior to distribution. Distribution of dividends to shareholders and remuneration to employees shall be determined by the Board of Directors and distributed in cash, or by the amount of the unissued shares in such amount, or both. However, dividends to shareholders may not be less than 10% of the total dividends and shall be distributed in cash. The Group does not pay interest on undistributed dividends and remuneration.

2. The proposed distribution of dividends for the year

The Group suffered a loss in 2025; therefore, there is no distribution of the previous year's earnings in 2026.

(IV) The impact of bonus shares on company operating performance and earnings per share for the current fiscal year: None.

(V) Remuneration to employees, directors and supervisors

1. The percentage or scope of remuneration to employees, directors and supervisors stipulated in the Articles of Association

As stipulated in the Group's Articles of Association, if the Group makes a "profit" (as defined below) in the year, no more than 12% of the profit shall be set aside as remuneration to employees ("employee remuneration"). Employee remuneration is paid to employees of the Group and of its subsidiaries who are subject to meet certain criteria. The Group may set aside no more than 3% of the said profit as remuneration to directors (directors' remuneration) (excluding independent directors). The motion of the employee remuneration and directors' remuneration shall be approved by a resolution made by the Board of Directors' meeting attended by two-thirds of the total number of directors and approved by a majority of the directors present at the meeting. Then it will be submitted to the shareholders meeting. Where the Group still has accumulated losses, the amount of remuneration shall be retained in advance. Employee remuneration and directors' remuneration shall be set in accordance with the aforementioned ratio. The term "profit" refers to the Group's profit before tax. So as to avoid confusion, the term "profit before tax" refers to the amount before the payment of employee remuneration and directors' remuneration.

2. The accounting of the difference between the estimates of remuneration to employees, directors and supervisors, the basis for the calculation of outstanding shares for dividend payment and the accounting treatment of the discrepancy, if any, between the actual distributed amount and the estimated figure:

The Group suffered a loss in 2025; therefore, there is no allocated remuneration to employees and directors.

3. Remuneration to employees passed by the Board of Directors: None.
4. Remuneration distribution and the result reported by the shareholders meeting: None.
5. If there is any discrepancy between actual distribution (including the number of shares distributed, amount and stock price) and the recognized remuneration for employees, directors and supervisors for the previous year, please specify the discrepancy, cause, and how it is treated: None.

(VI) Repurchase of shares:

Until now, the Group has not repurchased or acquired the Group's shares from the market as approved by the Board of Directors. Therefore, the Group has not been engaged in matters stipulated in Article 28-2 of the Securities and Exchange Act. However, since the Company began its public offering in Taiwan in January 2017, only employees restricted new shares owned by an employee were withdrawn due to their departure as required by the issuance regulations. Currently, there are no ongoing repurchasing procedures.

II. Corporate Bonds (overseas included): None.

III. Preferred Shares: None.

IV. Global Depository Receipts: None.

V. Employees Incentive Stock Options

(I) For employee stock warrants issued by the Company but not yet mature, the date of effective registration from the competent authority; issue date, number of units issued; the ratio of the number of issued shares for subscription to total number of issued shares; subscription period, exercise method; period and ratio in which subscription is restricted; the number of shares that have been obtained through exercise of subscription rights, NT dollar amount of the shares subscribed, number of shares that have not been subscribed, subscription price per share of the unsubscribed shares, and the ratio of the number of unsubscribed shares to the number of issued and outstanding shares up to the publication date of the annual report, and effect on shareholders' equity:

April 13, 2026

Type of employee stock warrants	2008 1st Employee Incentive Plan (amended in 2016)				
Filing Effective Date and Total Units	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
Date of issuance	2016/2/29	2016/6/8	2016/9/18	2016/9/29	2016/11/2
Total number of issued units	211,700 shares (of which 80,295 shares have lapsed)	112,800 shares (of which 32,892 shares have lapsed)	13,100 shares (of which 4,167 shares have lapsed)	20,000 shares	7,000 shares (of which 5,032 shares have lapsed)
Number of units still available for issuance	-	-	-	-	-
Ratio of the number of issued shares for subscription to total number of issued shares	0.13%	0.08%	0.01%	0.02%	0.00%
Subscription period	10 years	10 years	10 years	10 years	10 years
Exercise method	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares
Period and ratio in which subscription is restricted	1 to 4 years; vesting conditions include: (1) Four-year vesting schedule; certificate holders are granted 25% of the stock options after one year of	0~4 years; Vesting conditions include: (1) Immediate vesting. (2) Four-year vesting schedule; certificate holders are granted 25% of	Four-year vesting schedule; certificate holders are granted 25% of the stock options after one year of employment and 1/48 of the total grant of shares	Four-year vesting schedule; certificate holders are granted 25% of the stock options after one year of employment and 1/48 of the total grant of shares	Four-year vesting schedule; certificate holders are granted 25% of the stock options after one year of employment and 1/48 of the total grant of shares

Type of employee stock warrants	2008 1st Employee Incentive Plan (amended in 2016)				
	employment and 1/48 of the total grant of shares will vest each month thereafter. (2) 1-year vesting schedule; 1/12 of the total grant of shares will vest each month using the straight-line method.	the stock options after one year of employment and 1/48 of the total grant of shares will vest each month thereafter.	will vest each month thereafter.	will vest each month thereafter.	will vest each month thereafter.
Number of shares that have been obtained through the exercise of subscription rights	131,405 shares	79,908 shares	8,933 shares	20,000 shares	1,968 shares
Amount of the shares subscribed	USD 37,581.83	USD 22,853.69	USD 5,100.74	USD 5,720	USD 1,123.73
Number of shares that have not been subscribed	-	-	-	-	-
Subscription price per share of the unsubscribed shares (Note)	USD 0.286	USD 0.286	USD 0.571	USD 0.286	USD 0.571
Ratio of the number of unsubscribed shares to the number of issued (%)	-	-	-	-	-
Effect on shareholders' equity	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant
Type of employee stock warrants	2008 1st Employee Incentive Plan (amended in 2016)				
Filing Effective Date and Total Units	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
Date of issuance	2016/2/29	2016/6/8	2016/9/18	2016/9/29	2016/11/2
Total number of issued units	211,700 shares	112,800 shares	13,100 shares	20,000 shares	7,000 shares

Type of employee stock warrants	2008 1st Employee Incentive Plan (amended in 2016)				
	(of which 80,295 shares have lapsed)	(of which 32,892 shares have lapsed)	(of which 4,167 shares have lapsed)		(of which 5,032 shares have lapsed)
Number of units still available for issuance	-	-	-	-	-
Ratio of the number of issued shares for subscription to total number of issued shares	0.13%	0.08%	0.01%	0.02%	0.00%
Subscription period	10 years	10 years	10 years	10 years	10 years
Exercise method	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares
Period and ratio in which subscription is restricted	1 to 4 years; vesting conditions include: (1) Four-year vesting schedule; certificate holders are granted 25% of the stock options after one year of employment and 1/48 of the total grant of shares will vest each month thereafter. (2) 1-year vesting schedule; 1/12 of the total grant of shares will vest each month using the straight-line method.	0-4 years; Vesting conditions include: (1) Immediate vesting. (2) Four-year vesting schedule; certificate holders are granted 25% of the stock options after one year of employment and 1/48 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 25% of the stock options after one year of employment and 1/48 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 25% of the stock options after one year of employment and 1/48 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 25% of the stock options after one year of employment and 1/48 of the total grant of shares will vest each month thereafter.
Number of shares that have been obtained through the exercise of subscription rights	131,405 shares	79,908 shares	8,933 shares	20,000 shares	1,968 shares
Amount of the shares subscribed	USD 37,581.83	USD 22,853.69	USD 5,100.74	USD 5,720	USD 1,123.73

Type of employee stock warrants	2008 1st Employee Incentive Plan (amended in 2016)				
Number of shares that have not been subscribed	-	-	-	-	-
Subscription price per share of the unsubscribed shares (Note)	USD 0.286	USD 0.286	USD 0.571	USD 0.286	USD 0.571
Ratio of the number of unsubscribed shares to the number of issued (%)	-	-	-	-	-
Effect on shareholders' equity	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant

Note: The exercise price is the exercise price adjust by the anti-dilution terms and conditions to accommodate the capital increase proposal of the capital company resolved at the shareholders meeting held on November 7, 2016. The base date for the capital increase of the capital reserve ex-rights is November 15, 2016.

April 13, 2026

Type of employee stock warrants	2017 1st Employee Incentive Plan			
Filing Effective Date and Total Units	2018/5/22 650,000 shares	2018/5/22 650,000 shares	2018/5/22 650,000 shares	2018/5/22 650,000 shares
Date of issuance	2018/7/2	2018/9/28	2018/12/11	2019/4/11
Total number of issued units	215,000 shares (of which 104,500 shares have lapsed)	172,000 shares (of which 142,000 shares have lapsed)	51,000 shares (of which 22,500 shares have lapsed)	26,500 shares (of which 22,000 shares have lapsed)
Number of units still available for issuance	435,000 shares	263,000 shares	212,000 shares	185,500 shares
Ratio of the number of issued shares for subscription to total number of issued shares	0.11%	0.03%	0.03%	0.00%
Subscription period	10 years	10 years	10 years	10 years
Exercise method	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares
Period and ratio in which subscription is restricted	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will

Type of employee stock warrants	2017 1st Employee Incentive Plan			
	vest each month thereafter.	vest each month thereafter.	vest each month thereafter.	vest each month thereafter.
Number of shares that have been obtained through the exercise of subscription rights	48,500 shares	11,000 shares	10,000 shares	-
Amount of the shares subscribed	NT\$1,721,750	NT\$390,500	NT\$334,000	-
Number of shares that have not been subscribed	62,000 shares	19,000 shares	18,500 shares	4,500 shares
Subscription price per share of the unsubscribed shares (Note)	NT\$35.50	NT\$35.50	NT\$33.40	NT\$38.50
Ratio of the number of unsubscribed shares to the number of issued (%)	0.06%	0.02%	0.02%	0.00%
Effect on shareholders' equity	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant

Note: Pursuant to Article 60 of the Regulations Governing the Offering and Issuance of Securities by Foreign Issuers, employee stock warrants issued after 2017 are price-adjusted in the event of a change in conformity to applicable regulations in the shares of the Company's common stock. The price for such stock options is adjusted in accordance with the Company's stock option regulations.

April 13, 2026

Type of employee stock warrants	2020 1st Employee Incentive Plan				
	2020/7/21	2020/7/21	2020/7/21	2020/7/21	2020/7/21
Filing Effective Date and Total Units	800,000 shares	800,000 shares	800,000 shares	800,000 shares	800,000 shares
Date of issuance	2020/7/21	2020/8/11	2021/1/5	2021/3/18	2021/5/14
Total number of issued units	347,360 shares (of which 231,670 shares have lapsed)	72,000 shares (of which 72,000 shares have lapsed)	25,500 shares (of which 6,000 shares have lapsed)	10,500 shares (of which 6,000 shares have lapsed)	331,800 shares (of which 187,910 shares have lapsed)
Number of units still available for issuance	452,640 shares	380,640 shares	355,140 shares	344,640 shares	12,840 shares
Ratio of the number of issued shares for subscription to total number of issued shares	0.11%	-	0.02%	0.00%	0.14%
Subscription period	10 years	10 years	10 years	10 years	10 years
Exercise method	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares
Period and ratio in which subscription is restricted	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of

Type of employee stock warrants	2020 1st Employee Incentive Plan				
	employment and 1/24 of the total grant of shares will vest each month thereafter.	employment and 1/24 of the total grant of shares will vest each month thereafter.	employment and 1/24 of the total grant of shares will vest each month thereafter.	employment and 1/24 of the total grant of shares will vest each month thereafter.	employment and 1/24 of the total grant of shares will vest each month thereafter.
Number of shares that have been obtained through the exercise of subscription rights	-	-	-	-	-
Amount of the shares subscribed	-	-	-	-	-
Number of shares that have not been subscribed	115,690 shares	-	19,500 shares	4,500 shares	143,890 shares
Subscription price per share of the unsubscribed shares	NT\$92.30	NT\$94.80	NT\$53.70	NT\$46.80	NT\$46.90
Ratio of the number of unsubscribed shares to the number of issued (%)	0.11%	—	0.02%	0.00%	0.14%
Effect on shareholders' equity	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant
Type of employee stock warrants	2020 1st Employee Incentive Plan				
Filing Effective Date and Total Units	2020/7/21 800,000 shares	2020/7/21 800,000 shares	2020/7/21 800,000 shares	2020/7/21 800,000 shares	2020/7/21 800,000 shares
Date of issuance	2020/7/21	2020/8/11	2021/1/5	2021/3/18	2021/5/14
Total number of issued units	347,360 shares (of which 231,670 shares have lapsed)	72,000 shares (of which 72,000 shares have lapsed)	25,500 shares (of which 6,000 shares have lapsed)	10,500 shares (of which 6,000 shares have lapsed)	331,800 shares (of which 187,910 shares have lapsed)
Number of units still available for issuance	452,640 shares	380,640 shares	355,140 shares	344,640 shares	12,840 shares
Ratio of the number of issued shares for subscription to total number of issued shares	0.11%	-	0.02%	0.00%	0.14%
Subscription period	10 years	10 years	10 years	10 years	10 years

Type of employee stock warrants	2020 1st Employee Incentive Plan				
Exercise method	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares
Period and ratio in which subscription is restricted	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.
Number of shares that have been obtained through the exercise of subscription rights	-	-	-	-	-
Amount of the shares subscribed	-	-	-	-	-
Number of shares that have not been subscribed	115,690 shares	-	19,500 shares	4,500 shares	143,890 shares
Subscription price per share of the unsubscribed shares	NT\$92.30	NT\$94.80	NT\$53.70	NT\$46.80	NT\$46.90
Ratio of the number of unsubscribed shares to the number of issued (%)	0.11%	—	0.02%	0.00%	0.14%
Effect on shareholders' equity	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant

Note: Pursuant to Article 60 of the Regulations Governing the Offering and Issuance of Securities by Foreign Issuers, employee stock warrants issued after 2017 are price-adjusted in the event of a change in conformity to applicable regulations in the shares of the Company's common stock. The price for such stock options is adjusted in accordance with the Company's stock option regulations.

April 13, 2026

Type of employee stock warrants	2021 Employee Incentive Plan				
Filing Effective Date and Total Units	2021/9/3 800,000 shares	2021/9/3 800,000 shares	2021/9/3 800,000 shares	2021/9/3 800,000 shares	2021/9/3 800,000 shares

Type of employee stock warrants	2021 Employee Incentive Plan				
Date of issuance	2021/9/6	2021/11/8	2022/3/23	2022/5/10	2022/08/26
Total number of issued units	34,500 shares (of which 26,000 shares have lapsed)	83,500 shares (of which 41,000 shares have lapsed)	327,500 shares (of which 318,000 shares have lapsed)	1,000 shares	140,000 shares (of which 136,000 shares have lapsed)
Number of units still available for issuance	765,500 shares	682,000 shares	354,500 shares	353,500 shares	213,500 shares
Ratio of the number of issued shares for subscription to total number of issued shares	0.01%	0.04%	0.01%	0.00%	0.00%
Subscription period	10 years	10 years	10 years	10 years	10 years
Exercise method	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares
Period and ratio in which subscription is restricted	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.
Number of shares that have been obtained through the exercise of subscription rights	-	-	-	-	-
Amount of the shares subscribed	-	-	-	-	-
Number of shares that have not been subscribed	8,500 shares	42,500 shares	9,500 shares	1,000 shares	4,000 shares
Subscription price per share of the unsubscribed shares	NT\$35.50	NT\$29.90	NT\$31.10	NT\$33.20	NT\$29.70
Ratio of the number of unsubscribed shares to the number of issued shares (%)	0.01%	0.04%	0.01%	0.00%	0.00%

Type of employee stock warrants	2021 Employee Incentive Plan				
Effect on shareholders' equity	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant

Note: Pursuant to Article 60 of the Regulations Governing the Offering and Issuance of Securities by Foreign Issuers, employee stock warrants issued after 2017 are price-adjusted in the event of a change in conformity to applicable regulations in the shares of the Company's common stock. The price for such stock options is adjusted in accordance with the Company's stock option regulations.

April 13, 2026

Type of employee stock warrants	2022 Employee Incentive Plan				
Filing Effective Date and Total Units	2022/11/22 1,500,000 shares	2022/11/22 1,500,000 shares	2022/11/22 1,500,000 shares	2022/11/22 1,500,000 shares	2022/11/22 1,500,000 shares
Date of issuance	2023/03/13	2023/05/12	2023/08/24	2023/11/8	2024/03/07
Total number of issued units	124,000 shares (of which 39,000 shares have lapsed)	80,000 shares (of which 75,000 shares have lapsed)	10,000 shares (of which 10,000 shares have lapsed)	25,000 shares	75,000 shares (of which 7,500 shares have lapsed)
Number of units still available for issuance	1,376,000 shares	1,296,000 shares	1,286,000 shares	1,261,000 shares	1,186,000 shares
Ratio of the number of issued shares for subscription to total number of issued shares	0.08%	0.00%	-	0.02%	0.07%
Subscription period	10 years	10 years	10 years	10 years	10 years
Exercise method	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares
Period and ratio in which subscription is restricted	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.
Number of shares that have been obtained through	-	-	-	-	-

Type of employee stock warrants	2022 Employee Incentive Plan				
the exercise of subscription rights					
Amount of the shares subscribed	-	-	-	-	-
Number of shares that have not been subscribed	85,000 shares	5,000 shares	-	25,000 shares	67,500 shares
Subscription price per share of the unsubscribed shares	NT\$26.80	NT\$25.30	NT\$23.20	NT\$20.50	NT\$21.20
Ratio of the number of unsubscribed shares to the number of issued (%)	0.08%	0.00%	-	0.02%	0.07%
Effect on shareholders' equity	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant

Note: Pursuant to Article 60 of the Regulations Governing the Offering and Issuance of Securities by Foreign Issuers, employee stock warrants issued after 2017 are price-adjusted in the event of a change in conformity to applicable regulations in the shares of the Company's common stock. The price for such stock options is adjusted in accordance with the Company's stock option regulations.

April 13, 2026

Type of employee stock warrants	2022 Employee Incentive Plan			2024 Employee Incentive Plan
Filing Effective Date and Total Units	2022/11/22 1,500,000 shares	2022/11/22 1,500,000 shares	2022/11/22 1,500,000 shares	December 17, 2024 600,000 shares
Date of issuance	2024/05/10	2024/08/22	2024/11/11	2025/03/13
Total number of issued units	13,000 shares (of which 5,000 shares have lapsed)	108,000 shares	5,000 shares (of which 5,000 shares have lapsed)	260,000 shares (of which 34,000 shares have lapsed)
Number of units still available for issuance	1,173,000 shares	1,065,000 shares	1,060,000 shares	340,000 shares
Ratio of the number of issued shares for subscription to total number of issued shares	0.01%	0.11%	-	0.22%
Subscription period	10 years	10 years	10 years	10 years

Exercise method	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares
Period and ratio in which subscription is restricted	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.
Number of shares that have been obtained through the exercise of subscription rights	-	-	-	-
Amount of the shares subscribed	-	-	-	-
Number of shares that have not been subscribed	8,000 shares	108,000 shares	-	226,000 shares
Subscription price per share of the unsubscribed shares	NT\$18.80	NT\$22.35	NT\$23.20	NT\$22.35
Ratio of the number of unsubscribed shares to the number of issued (%)	0.01%	0.11%	-	0.22%
Effect on shareholders' equity	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant

Note: Pursuant to Article 60 of the Regulations Governing the Offering and Issuance of Securities by Foreign Issuers, employee stock warrants issued after 2017 are price-adjusted in the event of a change in conformity to applicable regulations in the shares of the Company's common stock. The price for such stock options is adjusted in accordance with the Company's stock option regulations.

April 13, 2026

Type of employee stock warrants	2024 Employee Incentive Plan			
Filing Effective Date and Total Units	December 17, 2024 600,000 shares	December 17, 2024 600,000 shares	December 17, 2024 600,000 shares	December 17, 2024 600,000 shares
Date of issuance	2025/05/08	2025/08/21	2025/11/06	2026/03/11
Total number of issued units	18,000 shares (of which 5,000 shares have lapsed)	54,000 shares	9,000 shares	16,000 shares

Number of units still available for issuance	322,000 shares	268,000 shares	259,000 shares	243,000 shares
Ratio of the number of issued shares for subscription to total number of issued shares	0.02%	0.05%	0.01%	0.02%
Subscription period	10 years	10 years	10 years	10 years
Exercise method	Issuance of new shares	Issuance of new shares	Issuance of new shares	Issuance of new shares
Period and ratio in which subscription is restricted	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.	Four-year vesting schedule; certificate holders are granted 50% of the stock options after two years of employment and 1/24 of the total grant of shares will vest each month thereafter.
Number of shares that have been obtained through the exercise of subscription rights	-	-	-	-
Amount of the shares subscribed	-	-	-	-
Number of shares that have not been subscribed	13,000 shares	54,000 shares	9,000 shares	16,000 shares
Subscription price per share of the unsubscribed shares	NT\$19.20	NT\$19.35	NT\$22.70	NT\$25.30
Ratio of the number of unsubscribed shares to the number of issued (%)	0.01%	0.05%	0.01%	0.02%
Effect on shareholders' equity	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant	The effect on the dilution of original common shareholders is not significant

(II) Names of managerial officers having acquired employee stock warrants and names of employees ranking top ten in convertible shares:

April 13, 2026

Item	Position (Note 1)	Name	Number of acquired shares that have been subscribed	Percentage of subscription quantity acquired to total issued shares (%)	Subscribed			Not subscribed				
					Number of shares subscribed	Subscription price (USD) (Note 2)	Subscription amount (USD) (Note 2)	Ratio of the number of shares that have been subscribed to the number of issued (%)	Volume of shares subscribed	Subscription price (USD) (Note 2)	Subscription amount (USD) (Note 2)	Ratio of the number of shares that have been subscribed to the number of issued (%)
Managerial officer	President	Winston Z. Ho	790,640	0.77	335,500	0.036~ 0.286 ; NTD 35.50~ 37.80	1,390,610.89	0.33	337,140	NTD 20.50~ 92.30	12,916,511	0.33
	Vice President	Liang-Kai Huang										
	Vice President	Yu-Lin Chen										
	Vice President	Gerald Kowalski (Note 3)										
	Vice President	Parisa Hanachi										
	Vice President	Jim Leigh										
	Vice President	Elisabeth Laderman										
	Associate manager	Gao Chen										
	Associate manager	Ingrid Joseph										
	Associate manager	Julian Sanchez (Note 4)										
	Associate manager	Yang Zhang										
	Accounting Supervisor	Chao-Ku Chen										
Internal Auditer	Zong-Han You											

Item	Position (Note 1)	Name	Number of acquired shares that have been subscribed	Percentage of subscription quantity acquired to total issued shares (%)	Subscribed			Not subscribed				
					Number of shares subscribed	Subscription price (USD) (Note 2)	Subscription amount (USD) (Note 2)	Ratio of the number of shares that have been subscribed to the number of issued (%)	Volume of shares subscribed	Subscription price (USD) (Note 2)	Subscription amount (USD) (Note 2)	Ratio of the number of shares that have been subscribed to the number of issued (%)
Employee	Scientist	Chung- Jen Hou	339,950	0.33	93,000	0.036~ 0.286 ; NTD 22.35~ 92.30	863,108.01	0.09	175,150	NTD 22.35~ 92.30	8,778,920	0.17
	Information Specialist	Cliff Chang										
	Engineer	Jie Chen (Note 5)										
	Scientist	Anh Pham (Note 6)										
	Scientist	Roger Wang										
	Senior Manager	Jesse Fisher										
	Director	Pei-Chen Wu										
	Scientist	Kristen Haag										
	Inventory management	Oliver Soller										
	Assistant Manager	Chia-Hsin Lü										

Note 1: Including managerial officers and employees (please indicate if they have resigned or are deceased) - their respective names and titles shall be disclosed, but their acquisition and subscriptions shall be disclosed in an aggregate manner.

Note 2: The subscription price is the subscription price adjust by the anti-dilution terms and conditions to accommodate the capital increase proposal of the capital group resolved at the shareholders meeting held on November 7, 2016. The base date for the capital increase of the capital reserve ex-rights is November 15, 2016.

Note 3 : Managerial officer Gerald Kowalski retired on January 10, 2025.

Note 4: Managerial officer Julian Sanchez resigned on May 23, 2025.

Note 5: Employee Jie Chen has resigned on April 04, 2025.

Note 6: Employee Anh Pham has resigned on March 07, 2025.

(III) Information shall be furnished on the status of any private placement of employees incentive stock options in the most recent 3 fiscal years and as of the publication date of the annual report, disclosing the date on which the private placement was approved at a shareholders meeting and the amount thus approved; the basis for and reasonableness of the pricing; the manner in which the specified persons were selected (where the offerees have already been arranged, the names of the offerees and relationship between the offerees and the company shall also be described); the reasons why the private placement was necessary; the targets of the private placement, their qualifications, subscription amounts, relationship with the company, participation in the operations of the company,

actual subscription price, the difference between the actual subscription price and the reference price; the effect of the private placement on shareholders' equity; and for the period from receipt of payment in full to the completion of the related capital allocation plan, the status of use of the capital raised through the private placement of employees incentive stock options, the implementation progress of the plan, and the realization of the benefits of the plan: None.

VI. Employees Restricted New Shares

Dates of effective registration from the competent authority for all employees restricted new shares under which the vesting conditions have not been fully met; issue date; number of shares issued; number of shares still available for issuance; issue price; vesting conditions; restricted rights; custody status; measures to be taken when vesting conditions are not met; number of shares that have been redeemed or bought back; number of shares in which the restrictions on rights have been released; number of shares in which the restrictions on rights have not been released; and the ratio of the number of shares in which the restrictions on rights have not been released to the number of total issued shares and the effect on shareholders' equity: None.

VII. New shares issued for merger or acquisition: None.

VIII. Usage of Injected Capital

The Group has not been involved in mergers, acquisitions, or issuance of new shares for acquisition of other companies' shares within the past three years, nor has it issued corporate bonds; therefore, these provisions are not applicable. Regarding the Group's 2024 cash capital increase, the relevant plan contents and implementation analysis are explained as follows:

(I) Contents of Plans

In 2024, the Company issued 21,000 thousand shares for a cash capital increase. The shares were issued at NT\$21 per share for a total of NT\$441,000 thousand. After completion, it was planned to fully fund the Company's working capital.

(II) Implementation

Public offering of 21,000 thousand shares issued through cash capital increase in 2024

(1) Progress of raised funds utilization

Unit: NT\$ thousand

Plans	Implementation		As of the first quarter of 2025	Is the progress ahead or behind, the reason and the improvement plan
Enriching working capital	Amount	Estimated amount	441,000	As of the first quarter of 2025, the progress in strengthening operating capital has fallen behind schedule, mainly because research and development projects are still in discussion with the US FDA regarding clinical trial methods and standards, causing delays in clinical timelines and relatively reduced operational expenditures. All raised funds were fully utilized by the end of the first quarter of 2025.
		Actual amount	441,000	
	Execution progress (%)	Estimated amount	100.00%	
		Actual amount	100.00%	

(2) Execution benefits of raised funds

Unit: %

Item	Year	Q2 2024 (prior to the fundraising)	Q3 2024 (after the fundraising)
Solvency	Current ratio	789.71	1,130.10
	Quick ratio	596.63	937.36
Financial structure	Debt ratio	37.69	26.35
	Long-term fund to property, plant and equipment	870.28	1,304.88

Source: The Group's consolidated financial reports audited by CPAs for Q2 and Q3 2024.

The Group raised a total of NT\$441,000 thousand through this cash capital increase. Although the utilization of funds has fallen behind the planned implementation schedule, this fundraising plan has successfully supported research and development progress and company operations through the injection of stable medium to long-term funds, enhanced R&D momentum, strengthened the financial structure, increased funding stability, and improved the flexibility of fund allocation to ensure normal company operations and reduce operational risks. Therefore, the benefits of this cash capital increase have already become evident.

Five. Operation Overview

I. Business Scope

1. Scope of business affairs


(1) Main contents of business affairs

Looking at the diagnostic reagent products in the market, most technology platforms are designed for single-target testing, unable to provide multiple and precise diagnostic results in one test. The Group's core concept is to develop a multi-testing technology platform that can provide accurate results for multiple testing targets simultaneously, significantly improving testing efficiency and offering diagnostic solutions that are precise, rapid, convenient, and cost-effective.

Therefore, the Group has successfully applied the digital barcode technology, commonly used in supermarkets, logistics and shopping industry, into the realm of "Digital Biotechnology." By shrinking the length and width of the barcode by about a million fold with advanced technology, we can precisely identify thousands of analytes in a single specimen.

The Group innovatively utilizes silicon wafer semiconductor manufacturing processes to mass-produce "Barcoded Magnetic Beads" (BMB), which are stored as solid micro-barcode in liquid form. Whether for reactions with biological probes or specimen testing, these barcodes can be directly mixed with samples in liquid, offering excellent stability and operational convenience.

The Group's Barcoded Magnetic Beads (BMB) technology platform is able to encode 4,096 (2^{12}) numbers and chemically bond molecular probes or antibodies/antigens from various diseases onto the BMB, allowing rapid and precise analysis of single or multiple analytes. For example, we can detect thousands of bacteria, viruses, parasites, DNA and RNA from a single specimen or any of the proteins, hormones and allergens present in the specimen. If target biological molecules to be analyzed are present in the specimen, the barcodes will produce fluorescent signals. A brief description of the technical features is as follows:




- 將數位條碼 (常見於超市、貨運的條碼) 縮小 **1000倍** 製作在磁珠上



以磁珠上的條碼識別特異性探針

穩定的BMB光學掃描: 以螢光訊號標示定量/定性



The Group is the developer and technology proprietor of the Barcoded Magnetic Beads (BMB) assay platform, we can collaborate with international vendors through licensing. This technology platform has obtained multiple patents in the U.S. and the world, including various BMB core patents (7871770, 7858307, 8232092, 8148139 and 9255922 were approved by the United States Patent and Trademark Office; the European Union Intellectual Property Office approved the EP2342561B1; CN 102246037 B was approved by Chinese Patent). In addition, in 2023, the group applied for four Barcoded Magnetic Beads extension patents with the United States Patent and Trademark Office to strengthen the protection of our core technology.

Our corporation's critical technologies' intellectual property rights are the following four: Barcoded Magnetic Bead (BMB), Light transmitted assay bead, Biocompatible and photocurable polymer, Image Decoding and System. When combined, these patents protect our corporation's technologies and ensure their applications in various biomedical fields. Our innovative technology have been successfully licensed to many global companies for multi-field development. These well-known companies include: IDEXX Technologies GmbH, PerkinElmer (an NYSE-listed company), Diatherix Laboratories - a subsidiary of Eurofins Scientific Group (a Euronext N.V.-listed company), Molecular Device - a subsidiary of Danaher Group (a NYSE-listed company), Zhuhai Livzon Diagnostics - a subsidiary of Livzon Pharmaceutical Group (A shares that trade on SZSE and H shares that trade on the HKEX), Guangzhou Improve Medical Instruments (a ChiNext-listed company), Shanghai Kexin Biotech (a new OTC market-listed company), Genetic Analysis AS Norway, Imusyn Germany, ALPCO, Taipaike Beijing and Hardy Diagnostic Inc. We have also licensed Guoyao Group Beijing Medical Apparatus and Instruments to sell our Biocode 2500 and BMB. These international giants are expected to continue to contribute to the Group's revenue, including sales of BMB, Optical Scanners, and licensing fees for future product sales.

In addition to licensing partners to develop diversified application areas, the Group's main focus is to develop the infectious disease molecular testing market that has grown rapidly in recent years and has a high demand for testing. Through a marketing model similar to leasing printers and selling ink gate consumables, the MDx3000 automated diagnosis system was deployed in major laboratories and hospitals to sell testing assays. Gastrointestinal tract testing, respiratory tract testing, fungus testing, STD testing, and urine testing are all multiplexed reagents that are highly demanded in the clinic. These tests are outfitted with the MDx 3000 automated diagnosis system, which includes the Polymerase

chain reaction (PCR), hybridization, automated operation, and molecular image interpretation systems. The BioCode MDx 3000, developed by the Group, is one of the few products in the global clinical diagnosis market that can provide fully automated, high-throughput, and diverse testing products to large hospitals and laboratories.

In the future, the Group will also give full play to the features of the platform technology that can be expanded and applied to the development of liquid biopsies, allergy, food safety, agricultural and industrial applications, and life sciences research, etc. To become more diversified, to develop business domain and customer base in different end markets.

(2) Operating proportion of primary products

Unit: NT\$ thousand

Year	2023		2024		2025	
	Net revenue	Operating proportion (%)	Net revenue	Operating proportion (%)	Net revenue	Operating proportion (%)
Barcoded Magnetic Beads (BMB)	205,593	52.03	145,180	42.32	143,786	30.26
Optical Scanner	7,093	1.79	4,385	1.28	24,962	5.25
Reagent/In-vitro diagnostic assay (Panel)	144,384	36.54	147,796	43.08	238,409	50.17
Others	38,099	9.64	45,705	13.32	68,044	14.32
Total	395,169	100.00	343,066	100.00	475,200	100.00

(3) The Company's current products (services)

The Group's core business affairs are Barcoded Magnetic Beads (BMB) analysis technology platform and related products, which primarily include BMB, instruments, development, and sale of in-vitro diagnostic assays. Our BMB technology offers high precision and diverse test services for a single analysis, and significantly saves costs of in-vitro diagnostic assays. Instrument MDx 3000, our corporation's latest development, is characterized by fully-automatic, high throughput and diversified analysis applications, easy to operate and small footprint. Coupled with our BMB and test assays, these systems form a technology platform that will satisfy the current market needs. Following is a summary description of products developed by the Group:

Product	Introduction	Application
Barcoded Magnetic Beads (BMB)	The BMB technology contains 4,096 encoded barcodes. Each BMB allows binding to DNA, antibodies or antigens, and specific binding identification with target molecules.	A wide-ranging analysis platform provides detection of bacteria, viruses, parasites, hormones, allergens, DNA, RNA or proteins from a single test specimen. It can be applied to diverse disciplines such as academic research, agricultural testing, animal health testing and environmental testing.
Instrument- Optical Scanner	The Instrument is used in decoding each Barcoded	Provides a test analysis platform for proteins and

Product	Introduction	Application
	<p>Magnetic Beads and fluorescent signal. Our corporation's Instrument systems - BioCode 1000, BioCode 2500 and BioCode MDx 3000, are characterized by high sensitivity and user-friendly analysis software operation. BioCode MDx 3000, our latest instrument, is a fully-automated multivariate test system.</p>	<p>nucleic acids.</p>
<p>GPP 17-Plex Gastrointestinal Pathogen Panel</p>	<p>Can simultaneously test 17 types of bacteria, viruses and parasites that commonly cause diarrhea, providing diagnostic reference and medication guidelines.</p>	<p>Gastrointestinal infections resulting in severe diarrhea are a significant problem. The US Centers for Disease Control and Prevention (CDC) estimates that two billion cases of diarrhea occur each year, resulting in approximately 1.8 million deaths. Diarrhea is the second leading cause of death and the most common cause of malnutrition in children under the age of five. Simultaneous and rapid detection of possible infectious agents is of great help in improving the treatment outcomes of patients. The market size is projected to reach USD 1 billion.</p>
<p>RPP 20-Plex Respiratory Pathogen Panel</p>	<p>Allows rapid identification and phenotyping of common bacteria and viruses and can determine respiratory infection as early as possible, which lowers treatment costs.</p>	<p>For respiratory symptoms including influenza, confirmed diagnoses in the United States exceed 18 million cases annually, representing the infectious disease category with the greatest diagnostic demand. To ensure patients can promptly identify viral or bacterial infections and receive correspondingly effective treatment, this represents the optimal diagnostic product for such needs. The market size is</p>

Product	Introduction	Application
		projected to reach USD 2.8 billion.
COVID-19 and Influenza Combo Test Assay (Cov-2 Flu Plus)	For one-time testing of COVID-19, type A influenza and its subtypes (H1, H1N1 2009pdm, H3), type B influenza and respiratory syncytial virus (RSV), and to distinguish between COVID-19 and recurrent influenza.	For the Emergency Use Authorization (EUA).
20-Plex Fungal Panel Reagent (Fungal Panel RUO)	The Fungal Panel includes test assays for lung infection, meningitis, bloodstream infection, allergy and skin infection. Fungal meningitis is most commonly caused by Cryptococcus. In the U.S., Cryptococcus infection is the 4th ranking pathogens aside from bloodstream infection. Its mortality rate is estimated between 35 and 55% and is a common type of pathogen for nosocomial infections. The Candida auris, known for its multiple drug resistance characteristic, has a mortality rate of about 30 to 60% for those infected, and is listed as one of the emergency threats by the U.S. CDC.	Commercialization in the form of RUO will begin in June 2023. Once the testing protocol is written and published by the clinical laboratory, other laboratories can import and purchase RUO reagents for testing. The fungal detection market size is projected to reach USD 0.5 billion.
Sexually Transmitted Infection Combined Antimicrobial Resistance Target Detection Kit (RUO Version) (STI+AMR RUO)	According to the WHO data, at least 0.37 billion people are infected with sexually transmitted disease (STD) every year. The risk of STD and resistance mutation among pathogens also increases in specific populations with multiple partners and group sex. Drug resistance of pathogens is considered by public health experts to be one of the major threats to the modern human society. Due to the widespread usage of anti-biotics and mutation of pathogens after multiple infections, there are more pathogens nowadays that	Commercialization in the form of RUO will begin in April 2024. Once the testing protocol is written and published by the clinical laboratory, other laboratories can import and purchase RUO reagents for testing. The Company also plans to establish a B2C commercial model (direct sales to user) for these STD tests that require large amount of samples and high degree of privacy. Adopting the model developed during the Covid pandemic, many laboratories

Product	Introduction	Application
	have begun developing resistance to medication. The Company has introduced an unprecedented first-line test tool for infectious disease with the option of including drug resistance genes. This will allow more timely treatment while eliminating the overuse of antibiotics.	utilized a domestic sampling and shipping the samples to the laboratory approach for STD tests as well. The Company will provide the domestic sampling method and consumables with anticipation to rapidly enter this market with unmet demands. The molecular diagnostics market for sexually transmitted infections is projected to reach USD 1.8 billion.
Consumables	Assay buffers, DNA extraction reagents and detection buffers.	Provide higher quality analysis results for diagnostic tests.
Technical Service	A fixed percentage of the system pricing is collected each year for system maintenance and the analytical instrument's service charges.	Technical support and customized product services.

Our corporation's BMB multiplex analysis technology platform has been awarded multiple patents. In addition to clinical diagnostics, it can be applied to diverse disciplines such as academic research, agricultural testing, animal health testing and environmental testing. Due to its high application values, our corporation have issued licenses to the following:

Subject	Discipline	Main field of license	Types of license
PerkinElmer Health Science Inc. (USA)	Infectious diseases - genotype analysis of Hepatitis B and C viruses	Asia	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.
DIATHERIX Laboratories, LLC/Eurofins group (U.S.)	3rd party molecular test laboratory	Global	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.
Molecular Devices Inc./Danaher group (U.S.)	Proteomics research	Global	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.
Genetic Analysis AS (Norway)	Irritable bowel diseases (IBD), Gutmicrobiota	Global	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment,

Subject	Discipline	Main field of license	Types of license
			consumables fees, instrument fees and royalties from sales.
Imusyn GmbH & Co. KG (Germany)	Organ transplant, human leukocyte antigen pairing (HLA Proteins)	Europe	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.
Improve Medical Instrumentation Co., Guangzhou Improve/Hecin Scientific. (China)	Respiratory track research, cancer research	China	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.
Shanghai Kexin Biotech Co., Ltd. (China)	Autoimmuno diseases, infectious disease test	China	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.
Zhuhai Livzon Diagnostics Inc. (China)	Autoimmuno diseases, tumor test	China	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.
IDEXX Technologies GmbH (Switzerland)	Non-human animal testing	Global	1. Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.
ALPCO	Gut microbiota and inflammation analysis	United States	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.
Paitaike	Development of autoimmuno and cytokine biomarkers	China	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.
Hardy Diagnostic	Food Safety Testing Methods for Molecules and Immuno Detection	United States	1. Non-Exclusive License 2. Client is responsible for the initial royalty payment, consumables fees, instrument fees and royalties from sales.

(4) Planning of new product development (service)

Product	Introduction
Urinal Track Infection	Common pathogens that cause urinary tract infections include Escherichia coli, Citrobacter freundii, Acinetobacter

Product	Introduction
	<p>baumannii, Proteus mirabilis, Enterococcus, Klebsiella, Enterobacter, Morganella, Mycoplasma and Chlamydia. Considering the efficiency and insurance reimbursement in the clinical practice in the U.S., a negative result of pathogens by a single rapid screening test is usually confirmed by a molecular test approach. Our product utilizes molecular testing to screen these pathogens and provides a comprehensive and accurate diagnosis of urinal tract infection. Our goal is to offer a less expensive retail price and a shorter test diagnosis/treatment process.</p>
<p>Antimicrobial Resistance Markers Panel RUO</p>	<p>Drug resistance of pathogens is considered by public health experts to be one of the major threats to the modern human society. Due to the widespread usage of anti-biotics and mutation of pathogens after multiple infections, there are more pathogens nowadays that have begun developing resistance to medication. Nowadays, the antimicrobial resistance is determined primarily by susceptibility test. This test still has a lot of shortcomings including highly manpower consuming, one single marker at a time and a wait time up to 24 hours. The product is designed to provide a molecular test option that is innovatively designed for multiple markers and generates results within hours for large laboratories and public health departments.</p>
<p>Vaginitis test</p>	<p>Female vaginitis comes in many forms, including Candidiasis (yeast infection), bacterial vaginitis, viral vaginitis, trichomoniasis and non infectious vaginitis. Considering the efficiency and insurance reimbursement in the clinical practice in the U.S., a negative result of pathogens by a single rapid screening test is usually confirmed by a molecular test approach. Our product utilizes molecular testing to screen these pathogens and provides a comprehensive and accurate diagnosis of vaginitis. Our goal is to offer a less expensive retail price and a shorter test diagnosis/treatment process.</p>
<p>Opportunistic Infection</p>	<p>Immunosuppressed populations, such as the elderly, cancer patients, immunocompromised patients and HIV patients are more likely to be infected. For tests of common infection targets (fungus, bacteria, virus), our Company provides existing test kits that cover most of these targets. After re-grouping, we intend to introduce test kits suitable for opportunistic infections via RUO for test facilities specializing in this field.</p>
<p>Molecular testing with semi-automated nucleic acid extraction (Semi-Automation)</p>	<p>Considering laboratories' increasing demand for automation and intelligence, the Company has also begun developing semi-automated systems that combine molecular testing with nucleic acid extraction. Previously, the Company's various infectious disease testing products were based on a nucleic acid extraction preprocessing instrument and an MDx3000 molecular detection system, with manual operations connecting the</p>

Product	Introduction
	workflows between these two instruments. For the next generation of products, the DNA samples obtained after nucleic acid extraction will be automatically transferred to the MDx3000 through mechanical automation, achieving “semi-automation.” This will reduce manual operations and provide customers with an enhanced user experience.
120-Plex Allergy Diagnostic Panel and Automated Immunoassay System	<p>The global market of rapid immunoassay is expected to grow from 18.725 billion U.S. dollars in 2017 to 31.885 billion in 2026, a compound annual growth rate of 8.49%. The rapid assay is suitable for preliminary or emergency medical diagnosis and use by medical institutions with limited resources. Due to its convenience and rapid testing capability, it will assist in providing timely treatment. There is currently a great demand globally on preventive management, and as the awareness for early disease detection continues to increase globally, it is expected that this segment of the market will grow significantly in the future.</p> <p>Diseases related to allergies include asthma, rhinitis, angioedema, urticaria, conjunctivitis and eczema. Populations suffering from these diseases are rapidly increasing due to industrial pollution and population growth. For the asthmatic population alone, the World Health Organization forecasts that the global asthmatic population will growth to 400 million people by the year 2025. Allergies result in an increase of direct medical costs and decrease of social behavioral efficiency; the decrease in work efficiency will result in health burdens for all. Treating these kinds of diseases requires effective testing tools of allergens.</p>
Liquid Biopsy	<p>The global market of Liquid Biopsy is also expecting growth from USD1.2 billion dollars in 2020 to USD6.8 billion dollars in 2028, a compound annual growth rate of 20%. Before 2020, the tumor liquid biopsy tests on the market were mostly developed in laboratories (LDT). However, since 2020, companies like Guardant and Foundation Medicine (acquired by Roche) have begun to develop companion diagnostics for cancer treatment drugs, which have received FDA approval in the United States. It is expected that this will stimulate more companies to increase their development and promotion efforts, accelerating the expansion of this emerging market. In addition, most products in the existing market use the next generation sequencing (NGS) as the testing platform. It takes as long as 2 weeks to sequence, and requires professional biometrics interpretation, and the cost is expensive. Therefore, the development goal of oncology liquid testing products will be to shorten the testing time, reduce the threshold for personnel, and reduce the cost through the Company’s technology platform.</p>

2. Industry Status

(1) Industry Status and Development

Our corporation provides an automated multiplex detection platform, research and development of platform applications, and development and sales of infectious disease test assays. Our technology platform aims to provide accurate real-time diagnosis and precision treatment to greatly improve the efficiency of medical analysis and reduce the costs of treatment and risks of patients. The following is an analysis on the global markets for in-vitro diagnostic products, immuno diagnosis, molecular diagnosis and infectious disease detection:

A. Global In Vitro Diagnostics Market Overview

In-Vitro diagnostics, also known as IVD, are assay kits or medical instruments (like instrument system) that are used in the collection, preparation and analysis of specimens collected from the human body, which are used for disease diagnosis and other purposes (including the determination of health status). In-vitro diagnostics assays refer to any assays, calibration substances or control substances described previously. IVD is classified based on the diagnostic basics and methods used and is mainly classified as hematology diagnosis, biochemical diagnosis, urinary diagnosis, immuno diagnosis, microbial diagnosis and molecular diagnosis.

According to a 2025¹ analysis report by Global Market Insights, the estimated value of the IVD market in 2025 is USD 108.6 billion. The IVD market is expected to maintain a compound annual growth rate of approximately 4.1% from 2025 to 2034, potentially reaching USD 155.4 billion by 2034. The main drivers promoting this market are the prevalence of chronic and infectious diseases, early screening, preventive testing, and personalized medicine.

B. Overview of the Global Immunodiagnosics Market

According to a report² by Markets and Markets, the global immunodiagnosics market is projected to grow from USD 35.5 billion in 2025 to USD 47.8 billion in 2030, representing a compound annual growth rate of 6.1%. The revenue of the immunoassay market is mainly based on immuno technology, products and service applications. Based on the aforementioned product types and service applications, kits and reagents of immuno assays occupied a significant market portion. As the population continues to age and chronic diseases become more prevalent, it is expected that demand for immuno assay kits and analytical technology will continue to push the market to grow. Household assay and kits for a wide range of tests will be the future development trends of the market.

Diagnosis of allergens is the key step for effective treatment. The diagnosis of allergens can identify specific factors inducing individual immuno responses, and is a process required for drug development, manufacturing and treatment. The main factors that attract the attention of the application is the high disease incidence rate of allergic diseases and the enormous accompanying financial burden, exacerbation of environmental pollution, increase in healthcare expenses and utilization of medical insurance. The market of allergen diagnostics can be divided according to products and services into test assays, instruments, and services. In the future, it is expected that

¹ *Global Market Insights* <https://www.gminsights.com/industry-analysis/in-vitro-diagnostics-market>

² *Markets and Markets* <https://www.marketsandmarkets.com/Market-Reports/immunoassay-market-436.html>

the market for allergen test assays will grow at a tremendous speed, and the widespread usage and consumption of allergen test assays will continue to promote the growth of this field in the near future.

Diseases related to allergy include asthma, rhinitis, angioedema, urticaria, conjunctivitis and eczema. Populations suffering from these diseases are rapidly increasing due to industrial pollution and population growth. For the asthmatic population alone, the World Health Organization forecasts that the global asthmatic population will grow to 400 million people by the year 2025. Allergies result in an increase of direct medical costs and decrease of social behavioral efficiency; the decrease in work efficiency will result in health burdens for all. Treating these kinds of diseases requires effective testing tools of allergens. Market surveys have shown that the development niche of allergen diagnostic products lie in the increase in turn around time and laboratory automation.

In the overall analysis, the North American market remains the leading segment, followed closely by the European, Asian and other markets. Major international manufacturers of immuno assays are based in North America and Europe, such as Switzerland's Roche Diagnostics, Germany's Siemens Healthcare, Abbott Laboratories, Beckman Coulter and Ortho Clinical Diagnostics from the United States and France's bioMérieux. However, the population growth and rising awareness of health in Asia are expected to create more demands for the diagnostic market, representing a potentially significant business opportunity.

C. Overview of Global Molecular Diagnosis Market

According to a research report³ issued by Grand View Research, the global molecular diagnostics market reached USD 27.9 billion in 2025, and is forecast to grow to USD 40.4 billion by 2034, suggesting a CAGR of 4.2%, with the North American market accounting for the largest share. Molecular diagnostics integrates the specialized knowledge and techniques of laboratory medicine and molecular genetics, and through breakthrough innovations in the field of molecular biology, has undergone tremendous revolutionary advances over the past several decades. Depending on the fields of applications, MDX can be categorized as infectious disease diagnosis, tumor gene mutation analysis, blood screening, microbial identification and other applications (e.g. diagnosis for cardiovascular diseases, neurological diseases, DNA fingerprinting profile, tissue classification and foodborne pathogen analysis). The convenience of molecular diagnostic allows it to occupy a significant portion of the diagnostic market for infectious diseases.

D. Overview of Infectious disease diagnostic market

According to the Mordor Intelligence research report⁴, the global infectious disease diagnostics market size is expected to reach US\$46.8 billion in 2025, and is estimated to grow to US\$57 billion by 2031, suggesting a CAGR of 3.35%. Molecular diagnostic technologies characterized by high sensitivity and high specificity, such as nucleic acid amplification techniques, are poised to register the fastest growth. Segmented by application, the infectious disease diagnostics market can be categorized into gastrointestinal (GPP), influenza and upper respiratory (RPP),

³ Grand View Research <https://www.grandviewresearch.com/press-release/global-molecular-diagnostics-market>

⁴ Mordor Intelligence <https://www.mordorintelligence.com/industry-reports/infectious-disease-diagnostics-market>

pneumonia, sexually transmitted diseases (STD), tuberculosis (TB), Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG), methicillin-resistant Staphylococcus aureus (MRSA), and others (including influenza, Ebola, typhoid fever, malaria, and dengue fever), with such growth attributable to the increasing prevalence of these diseases in recent years.

(2) Correlation between the upstream, midstream and downstream industries



Manufacturers of in-vitro diagnostics assays rely on existing technologies to develop in-vitro diagnostic assays and test instruments. The upstream industries of this field are suppliers of proteins, antibodies, antigens, DNA, reaction assays, instrument components and related consumables; the midstream industries are the designers, sellers and manufacturers of test assay kits, instruments, testing platform and analyzers. The midstream industry can also be retailers who distribute products to the end customers; the downstream customers include university medical centers, community hospitals, government health organizations, regional hospital laboratories and 3rd party reference laboratories.

Our corporation's core business affairs are development, manufacture and sale of BMB, test instruments, fully-automated molecular multiplex diagnostic system, diagnostic platform, and assays. Therefore, our corporation is positioned as the midstream industry within this industry chain, and the downstream industries are our target customers.

(3) Development trends of various products

In general, in-vitro diagnostics are testing specimens collected from the human body, such as urine, blood, tissue, stool and cells, and used as a basis for disease diagnosis and verification of physiological conditions. The following is a brief description of the various development trends of in-vitro diagnostic products:

- A. Advances in clinical chemistry diagnostics, immunodiagnostics, and molecular diagnostics

A biochemical diagnosis like the diagnosis of triglyceride, blood glucose and metallic elements (sodium ions, potassium ions and magnesium ions) are some of the earliest types of in-vitro diagnostics, with more than 70 years of development culminating in a mature market. After 30 years, the diagnostic technology has extended to the immuno diagnostic market with protein detection technology. The compound annual growth rate of the immuno diagnostic market for the past 10 years was 8.49%. From 2000, the flourishing of genomic molecular biology has resulted in the in-vitro diagnostic market's growth based on molecular genetics and molecular biotechnology. It is estimated that the molecular diagnostic market is rapidly growing at a rate of 9.23% compound annual growth rate in the recent decade and is currently the main development axis of in-vitro diagnostics.

B. Full automation

Early test platform requires manual operation and is labor-intensive, requiring technical operators with high technical proficiency and experience to effectively carry out the testing procedures. However, such highly technical proficient talents are costly to train and hard to recruit. The quality of manual operation also varies from person to person and is prone to testing errors. Thus, the tests take time and the labor-cost is intensive, often requiring prolonged testing time to verify the results.

Recently, the rising health consciousness and increasing aging population have resulted in a significant increase in specimen collection by clinical and medical laboratories. Therefore, a testing platform capable of full-automation and high-throughput testing is in urgent demand by the market and has since become a development trend; in addition, a fully automated testing platform can provide immediate, consistent and accurate test results. This excellent feature allows clinicians to arrange personalized treatment quickly and can maintain and improve the quality of medical diagnosis for customers with large-scale testing needs.

C. Multiplex testing

We have integrated molecular diagnostic technology, automated analysis technology and multiple testing platforms into a single system. It is intended to provide technology and products for markets that have not yet been satisfied and address future medical market trends.

Traditionally, a single test means that only one test can be performed from a single specimen. Because specimens are difficult to obtain, the traditional single test is less effective, giving rise to the revolutionary advancement in multiplex and all-in-one testing technology. The benefits of multiplex testing are not only limited to technological breakthroughs. They can be beneficial for instrument users and patients as well:

- (A) Clinician: able to detect the pathogenic causes of the patient early (identify whether it's a single pathogen or shared latent infection) for better and faster patient management.
- (B) Laboratory: improves laboratory efficiency, no longer requires multiple platforms for multiple tests, can effectively save on personnel costs and lower the assay costs from testing.
- (C) Hospital: reduce patient isolation period, increases management efficiency and quality of the patient-doctor relationship, which lead to decreased waiting time for result report and lower operational costs of the hospital.

(D) Patient: allow for optimized therapy regimen, decreases waiting time for follow-up report and the frequency of testing at the hospital.

(4) Competition

A. Analysis of competition of multiplex testing technology

(I) Real-time polymerase chain reaction (Real-time PCR)

Real-time PCR is a testing technology that detects the amplification of nucleic acids in the PCR cycle. The strength of the emitted fluorescent signals reflects the concentrations of the nucleic acids. The Realtime PCR of multiplex detection mainly performs multiplex detection based on different fluorescent signals. Due to the limitation of the current types of fluorescence, the current multiplex detection capability of Realtime PCR can only detect 2 to 3 targets at the same time. A well-known manufacturer of medical diagnostic equipment is the Cepheid of United States (recently acquired by the Danaher Corporation).

(II) Microarray

Biological chips (microarray technology) technology has been developing for nearly 20 years. A carrier vehicle is spotted with over 10 million of microscopic spots, allowing simultaneous detection/testing of multiple types of biomarkers. Microarray technology has been successfully applied in biological science to search for new biomarkers. The main technical difficulty is inaccuracy, and accuracy is a prerequisite for clinical diagnosis. The reason for the inaccuracy is that the dripping technique is used. After dripping dry, it is difficult to have the consistency between each dot, resulting in an excessively large coefficient of variation. Its lack of flexibility, high price and lower stability (the produced batches of signals are inconsistent) hampers its market demand for in-vitro medical diagnosis. Bio-chips are mainly used in the research and application of bio-markers. Affymetrix of the U.S. is one of the well-known companies for this detection technology (recently acquired by the Thermo Fisher Corporation).

(III) Sequencing

Sequencing technology is the process of determining the sequence of nucleic acids. It is now widely implemented in scientific research, such as mapping the whole genome of humans and the detection of gene mutations in cancer patients. It can also be used in the investigation of unknown genes and biomarkers. However, single-sequencing is no longer significant once the genome has been decoded. Although it is a revolutionary technology in the field of genomic study, its time-consuming and costly nature makes it less suitable for the medical diagnostic market's routine demands.

(IV) Bead based assays

Besides our corporation, Luminex of the United States is the other company that develops a barcode-based assay test platform. However, the barcode platform of Luminex mainly uses the ratio of 2~3 kinds of fluorescent dyes as the barcode identification method. Compared to its "analog" type, there can be a maximum of 300-500 kinds of coding methods. The development technology of the Group is based on the "digital" biometric barcode. The coding method uses black and white barcodes for identification directly. Its design principle can clearly and stably identify 4,096 test marks, with a higher number of detectable targets and more accurately. In addition, the Luminex analyzer's microfluidic channels are complicated to maintain, easily blocked and increases the maintenance risks of the test organization, which in turn induces extra costs on maintenance management.

		Luminex Bead	ABC-BMB
Barcoded Magnetic Beads (BMB)	Encoding method	Analog Mix 2-3 types of fluorescent dye beads and based on the intensity of the emitted fluorescence.	Digital Barcoded Magnetic Beads (BMB), high contrast barcode (0:1) for precise identification
	Variety number	50, 100 (2 fluorescent dyes) <500 (3 fluorescent dyes)	4096
	Production	Emulsion solution, unstable barcode Light-sensitive/requires protective covering, interferes with fluorescent labels	Semiconductor photoetching Permanent barcode with high stability Low-cost batch production and easy to scale production
System/operation	Maintenance	Difficult: Blockage of microfluidic channels, residual beads, require washing and cleaning after loading specimens, labor intensive	Easy: Direct optical imaging of microplate, no microfluidic channels
Automation	Convenient to use	No: Complex procedures/labor intensive/potential contamination	Yes: Easy to create workflow/integrated PCR, hybridization and testing/avoids contamination

Source: compiled by our group

B. Market competition analysis

The seven major IVD manufacturers in the world are Roche, Abbott, Siemens, Hologic, Danaher/Cepheid, Qiagen and BioMerieux. These manufacturers have high market shares in medical diagnostic assays but lack innovative technology, especially in multiplex testing. Multiplex testing is the mainstream trend of the current market. Global manufacturers that lack this type of technology risk losing in the future's highly competitive diagnostic market. As such, these manufacturers are catching up by acquiring companies with multiple diagnostic technologies. For example, BioMerieux acquired Biofire in 2014 and the procurement of Cepheid by Danaher in 2016 (up to 4 tests). Roche acquired GenMark and DiaSorin acquired Luminex in 2021. This illustrates the emphasis of global major pharmaceutical companies on multiplex testing. Presently, except for Luminex and BioMerieux, none of the seven major manufacturers have technology platforms and products for multiplex detection (more than 4 labels). Another phenomenon was observed in the U.S. market, where an overspill of test capacity from the existing test facilities caused by the COVID-19 pandemic resulted in a number of new test laboratories. With the decreasing number of COVID-19 samples, these laboratories need to seek new sources of income and therefore created a new blue sea for test demands. The more test items a company can provide, with a high throughput capacity, the more laboratory clients they will attract.

3. Technology and Research & Development Status

(1) Successfully developed technology and products in the past years

Recognizing that the rigorous validation procedures and evaluation processes for introducing molecular diagnostics products into large-scale laboratories often require 3 to 6 months, the Group places particular emphasis on the compatibility of its core multi-analyte diagnostics products with existing laboratory instruments and consumables, thereby accelerating the pace at which customers can adopt and integrate these products. To this end, the Group obtained U.S. FDA approval in prior fiscal years to add the KingFisher nucleic acid extraction pre-processing instrument to the list of compatible nucleic acid extraction workflows for the Group’s GPP “17-analyte gastrointestinal in vitro diagnostic reagents.” The Group also completed clinical trials of the KingFisher in combination with the Group’s RPP “17-analyte respiratory in vitro diagnostic reagents” and the MDx3000 automated instrument, and has submitted a premarket application to the U.S. FDA for marketing authorization. As RPP serves as the Group’s flagship product for expanding its market share in the in vitro diagnostics sector, the Group will continue to invest in the development of additional specimen collection methods and compatible consumables tailored to diverse customer requirements, with the aim of incorporating them into the RPP compatibility list.

The innovative tumor liquid biopsy detection (Liquid Biopsy) has completed the development of diagnostic reagents for eight types of tumor variant genes with corresponding treatment approaches. Initial clinical specimen testing has proven feasible, and we will continue to collect more blood samples from cancer patients for testing to further optimize these reagents while expanding the range of detectable genetic variations.

(2) Research Personnel and Education Background/Professional Experience

A. The main education background distributions of the research and development personnel in our group are as follow:

Education	Year	End of 2023		End of 2024		End of 2025		End of March 2026	
		Number of personnel	Ratio (%)	Number of personnel	Ratio (%)	Number of personnel	Ratio (%)	Number of personnel	Ratio (%)
Ph.D. Degree		9	34.61	9	34.62	7	28.00	7	28.00
Masters Degree		6	23.08	6	23.08	6	24.00	6	24.00
University and College Degree		10	38.46	10	38.46	11	44.00	11	44.00
Others		1	3.85	1	3.84	1	4.00	1	4.00
Total		26	100.00	26	100.00	25	100.00	25	100.00

B. The education backgrounds and professional experiences of the research and development personnel in our group are as follows:

Name	Position	Highest education/ Years of Professional Experience	Expertise	Main education backgrounds and experience
Winston Z. Ho	President and Founder/Chief Technology Officer	Ph.D./ 33 years	Optoelectronics, biochemistry, physical chemistry	Bachelor of Chemistry, National Chung Hsing University Arizona Sate University Master’s Degree in Biochemistry and Ph. D. Degree in Physical Chemistry

				<p>Columbia University in New York City</p> <p>Postdoctoral research fellow - high speed optics</p> <p>Maxwell Sensors, Inc. Founder / CEO</p> <p>Director of smart optical system and sensor</p> <p>Director, Biomedical Sciences, Physical Optics Corp.</p> <p>US-NIH Grant review committee</p> <p>Research Scientist - Nonlinear Photonics,</p> <p>University of Arizona College of Optical Sciences</p> <p>52 publications and 15 authorized patents</p>
Michael Aye (Note 1)	Chief of Scientist (R&D Supervisor)	Ph.D./ 19 years	Microbiology, molecular diagnostics, infectious disease, diagnostic assays	<p>Ph.D. in Microbiology, University of California, Irvine</p> <p>Vice-President of Molecular Products</p> <p>Director of Molecular Analysis, Focus Diagnostics</p> <p>Extensive experience in the development of molecular diagnostics and analysis; developed and launched over 40 products approved by ASR and 4 products approved by 510(k) of the FDA.</p>
Gerald Kowalski	Operating Vice President	Bachelor's Degree/ 33 years	Software engineering, team building and all stages of software projects	<p>Michigan Technological University</p> <p>Bachelor of Electrical and Computer Engineering</p> <p>BECKMAN COULTER INC</p> <p>Leader of Software Team</p> <p>BAXTER International Inc.</p> <p>Senior Software Engineer</p>
Jung-Ren Hou	Senior Scientist	Ph.D./ 27 years	Polymer chemistry, organic chemistry, surface chemistry	<p>Bachelor and Master's Degree in Chemistry, National Taiwan University</p> <p>Ph.D., New York Institute of Technology</p> <p>Post-doctoral researcher, The City University of New York</p>
Gao Chen	Product Manufacturing Division Senior Director	Ph.D./ 29 years	immuno testing, oncology, biochemistry, bio-engineering, molecular biology	<p>Ph.D., Gembloux Agro-Bio Tech, Belgium</p> <p>Bachelor's degree, Gembloux Agro-Bio, Belgium</p>
Anh Pham	Senior	Ph.D./	Microbiology,	Ph.D., Walden University

	Scientist	21 years	biochemistry, infectious disease	Bachelor's degree, UCLA Research scientist, Quest Diagnostics Molecular Diagnostics, Focus Diagnostics
Anna Al- Khouri (Note 2)	Director, Product Manufacturing Division	Ph.D./ 15 years	Cellular and Molecular Biology, Microbiology	University of Colorado Ph.D Degree in Cellular and Molecular Biology, Microbiology Fluidigm Corporation Vice Director of Clinical Study Development R&D Manager, DiaSorin Molecular
Elisabeth Laderman (Note 3)	Chief of Scientist (R&D Supervisor)	Ph.D./ 24 years	Biochemistry, Biology	Ph.D. in Biochemistry, UCLA HYCOR Biomedical, LLC. Chief Scientific Officer Vice President of Product Development, Biomerica, Inc.
Winston Z. Ho	President and Founder/Chief Technology Officer	Ph.D./ 35 years	Optoelectronics, biochemistry, physical chemistry	Bachelor of Chemistry, National Chung Hsing University Arizona Sate University Master's Degree in Biochemistry and Ph. D. Degree in Physical Chemistry Columbia University in New York City Postdoctoral research fellow - high speed optics Maxwell Sensors, Inc. Founder / CEO Director of smart optical system and sensor Director, Biomedical Sciences, Physical Optics Corp. US-NIH Grant review committee Research Scientist - Nonlinear Photonics, University of Arizona College of Optical Sciences 52 publications and 15 authorized patents
Jung-Ren Hou	Senior Scientist	Ph.D./ 29 years	Polymer chemistry, organic chemistry, surface chemistry	Bachelor and Master's Degree in Chemistry, National Taiwan University Ph.D., New York Institute of Technology Post-doctoral researcher, The City University of New York
Gao Chen	Senior Director,	Ph.D./ 31 years	immuno testing, oncology,	Ph.D., Gembloux Agro-Bio Tech, Belgium

	Product Manufacturing Division		biochemistry, bio-engineering, molecular biology	Bachelor's degree, Gembloux Agro-Bio, Belgium
Elisabeth Laderman	Chief of Scientist (R&D Supervisor)	Ph.D./ 26 years	Biochemistry, Biology	Ph.D. in Biochemistry, UCLA HYCOR Biomedical, LLC. Chief Scientific Officer Vice President of Product Development, Biomerica, Inc.
Carlos E. Aldana (Note)	Equipment Director	MBA/ 8 years	Mechanical Engineering, Project Management	Master of Business Administration, University of La Verne California State Polytechnic University, Pomona Production Manager, Applied BioCode, Inc. Mechanical Engineer, Applied BioCode, Inc.
Jesse L. Fisher (Note)	Director of Technical Services	Bachelor's Degree/19 years	Natural Sciences, Microbiology, Chemistry	California State University, Channel Islands Technical Services Engineer, Diasorin Molecular Clinical Microbiologist (Head), West Pacific Medical Lab

Note: Managers Carlos E. Aldana and Jesse L. Fisher were promoted to Associate Vice President in March 2026.

(3) Research and development expenses incurred in each of the most recent five fiscal years

Unit: NT\$ thousand; %

Item \ Year	2019	2020	2021	2022	2023
R&D expenses	216,973	197,005	205,854	238,370	246,005
Total operating income	104,694	299,015	319,962	390,302	395,169
Percentage of research expenses in operating income	207.24	65.88	64.34	61.07	62.25
Year \ Item	2021	2022	2023	2024	2025
R&D expenses	205,854	238,370	246,005	272,615	298,589
Total operating income	319,962	390,302	395,169	343,066	475,200
Percentage of research expenses in operating income	64.34	61.07	62.25	79.46	62.83

Source: Audited consolidated financial statements of the Group.

(4) Successfully developed technology or products

A. Barcoded Magnetic Beads (BMB)

The Group has successfully developed and commercialized Barcoded Magnetic Beads (BMB). Based on the time of development, the products include 32 Plex (5-digit, (25)), 128 Plex (7-digit, (27)), and 4,096 Plex (12-digit, (212)) of BMBs. While the dimension of the products in this series are largely identical, the encoding mode of the BMB has been changed from 1-dimensional encoding to 2-dimensional encoding. This unique encoding method allows 4,096 barcodes or simultaneous detection of 4,096 targets. The 4,096 barcodes are sufficient for use in clinical diagnostic applications of immuno or molecular detection.


B. Instrument

The Group has successfully developed and commercialized automated analyzers, which include the Biocode 1000 and 2500. The products in this series can automatically read BMBs, analyze fluorescence signals, and use them as the basis of quantification/qualification interpretation. The instruments include light sources, scanners, optical filters and optical detectors. The 2500 (II) is a smaller analyzer that uses LED as a high-power light source, which saves on costs and can be integrated with a mechanical fluid system.

C. Automatic Analyzer

MDx 3000 is a user-friendly automated system that integrates fluid processing and optical detection systems into a single unit. The user places the 96-well PCR plate into the system, which will then automatically carry out all operations and produce a final test results report. MDx 3000 is an automated multiplex diagnostic system. It is easy to operate and integrates molecular test steps including PCR amplification, cross-linking, cleaning, automatic interpretation and testing. It can be used with our molecular diagnostic reagent kits to provide diverse, high throughput molecular diagnostic result.

Development progress of instruments



Source: compiled by our group

D. Vitro diagnostics assays (multiplex panels)

The Group has received a 510(k) approval from the USFDA on September 29, 2018 for the “17-Plex Gastrointestinal Pathogen Panel” and the automated diagnostic system MDx3000, and a 510(k) clearance for “20-Plex Upper Respiratory Tract Pathogen Panel” on December 24, 2019. We have also received an EUA from the USFDA for coronavirus test panels on June 16, 2020; an EUA from the USFDA for a pooling test for coronavirus on December 8, 2020; and an EUA from the USFDA for Cov-2 Flu Plus on December 16, 2021; Fungal RUO has been developed, and the LDT protocol has been written by John Hopkins University, Bayler Hospital and other well-known medical centers and introduced into the fungal diagnostic laboratory. The STI+AMR RUO (Sexually Transmitted Infection + Antimicrobial Resistance Research Use Only) detection kit has completed development, with the initial goal of establishing collaboration with the CDC (Centers for Disease Control and Prevention) in the United States. Therefore, the Group has achieved sales and commercialization results of MDx 3000, a fully automated multiplexed testing system for diarrhea, respiratory tract, COVID-19, fungus, sexually transmitted infection and other assays.

4. Short and Long-term business development plans

(1) Short-term business development plans

- A. Expand the infectious disease testing market by targeting the respiratory testing segment, which represents the largest market opportunity. By incorporating multiple nucleic acid extraction devices, specimen collection methods, and consumables into the Company’s compatible list for testing workflows, the Group can enhance customer confidence in its RPP, ensure comprehensive insurance reimbursement coverage, and thereby rapidly accelerate market penetration.
- B. Drive growth in customer adoption and endorsement from key opinion leaders in the medical community for innovative and niche products such as Fungal Panel and STI-AMR, building a diversified product brand identity that in turn elevates customer acquisition and sales for both GPP and RPP.

(2) Long-term business development plans

- A. Targeting third-party laboratories with the highest demand for multiplex infectious disease testing for product development and market penetration. Expected to add 2 to 3 large-scale clients annually, each with procurement requirements exceeding USD 5 million.
- B. Completed development of urinary tract infection (UTI) multiplex molecular testing, establishing a first-mover position in this segment and capturing associated market advantages.
- C. Expanding into additional reagent categories, including oncology, allergens, genetic mutations, cytokines, and food safety testing.

II. Industry, Supply and Sales Overview

1. Market Analysis

(1) Main Locations of Product Sales and Service Provisions

Unit: NT\$ thousand; %

Location \ Year	2023		2024		2025	
	Amount	Ratio (%)	Amount	Ratio (%)	Amount	Ratio (%)
Domestic sales	357,381	90.44	286,001	83.37	433,785	91.28
Exports (Asia)	37,788	9.56	57,065	16.63	41,415	8.72

Total	395,169	100.00	343,066	100.00	475,200	100.00
-------	---------	--------	---------	--------	---------	--------

Note: domestic sales refers to sales in the United States.

The Group’s revenue sources are mainly from BMBs, instruments, in-vitro diagnostics assays, licensing and sales of parts and components. Major markets of sales include the United States, Europe and Asia.

According to our corporation’s business development plans, we will focus on assay sales and we will initially focus on the North American markets. Up to the date of publication of the annual report, the Group has successfully commercialized the “17-Plex Gastrointestinal Pathogen Panel”, “20-Plex Upper Respiratory Tract Pathogen Panel”, coronavirus tests and Fungal RUO in large hospitals and third party laboratories in the United States.

(2) Market shares

The Group’s revenue in 2025 was derived primarily from sales of diagnostic testing products to the in vitro diagnostics (IVD) market and sales of digital barcodes and optical analyzers to the licensed pet health market. Additional contributions to the Group’s revenue were made by individual licensees commercializing the Group’s digital barcode technology. Given that multiplex testing platforms offer a broader range of detection targets and results, delivering greater value to customers, it is anticipated that an increasing proportion of each customer’s product portfolio will migrate to the Company’s technology going forward. Overall, however, the global testing market remains vast, and the relevant products are still in the process of ongoing commercialization, with economies of scale yet to be achieved. Accordingly, as of the date of publication of this annual report, a meaningful analysis of the relevant market share is not practicable.

(3) Future market supply and demand status and opportunities of growth

The multiplex automated molecular diagnostic system provided by our corporation is easy to use, fully-automated, high-throughput, and allows highly varied testings in a small product footprint, which will satisfy the current market needs. In the current molecular diagnostic market, many diversified but low-throughput systems are targeted toward smaller hospitals and clinics; however, as the demand for specimen testing is high in larger hospitals and medical laboratories, products with high-throughput testings are usually favored such as conventional diagnostic instruments from manufacturers like Roche. Although these conventional diagnostic instruments are high-throughput, they could not conduct multiple tests in a single pass and requires more time, money, and manual labors to provide patients with diagnostic reference and medication guidelines. For clinicians, it is expected that the demand for multiple and high-throughput testing will continue to grow.


On the other hand, as FDA regulatory scrutiny and the rigor of insurance reimbursement reviews continue to intensify, the barriers to entry for multiplex infectious disease testing are rising steadily. As a supplier already in possession of formal market authorization and reimbursement codes, the Company is well-positioned to seize the initiative and proactively address the growing laboratory demand for multiplex testing solutions.

The Group retains infectious disease reagents as proprietary in-house developed products. For market conditions of individual products, please refer to pages 87–90 of this annual report for descriptions of each product’s applications.

(4) Competitive niche

A. High throughput, high efficiency, automation

BMB can be used together with the instruments developed by our corporation for analysis. The MDx 3000 is a fully automated multiplex detection system that is easy to operate and integrated many molecular detection steps such as PCR amplification, hybridization, washing and automated reading and interpretation. Up to 4,096 tests can be performed on a single specimen, and up to 188 specimens (8 hours) can be operated and analyzed simultaneously. Compared to the market competitors like Roche and Luminex, while their products also have a high-throughput capability, Roche's offering does not have multiplex detection capability, and neither Roche nor Luminex has full automation built in their systems. Comparing the xMAP instrument of Luminex where each step must be manually completed, our MDx 3000 can reduce the total operation time to 3.5 hours. In addition, full automation can reduce manual operation errors and labor costs, demonstrating the competitive advantages of our corporation's technology platform.



Source: compiled by our group

B. High yield and good stability

BMBs are produced with semiconductor manufacturing technology. As the semiconductor industry has rapidly advanced in the past decades, this production technology's stability is very high and much more stable than other market competitors that offer fluorescent-labeled analog multiplex detection systems. In addition, the fluorescent beads of Luminex are photosensitive and must be stored in darkness. Otherwise, the fluorescent dye will lose its color intensity. The Luminex fluorescent beads are also difficult to produce and can be affected by different barcode reading rates between different batches.

C. Cost price advantages

Since the production of Barcoded Magnetic Beads (BMB) is based on a semiconductor manufacturing process that can scale to mass production, the

production costs of BMB are competitively advantageous compared to the multiplex detection system of Luminex’s fluorescent beads.

D. Proprietary technology and patent protection

Our corporation has previously obtained exclusive, irrevocable and permanent licensing from Maxwell Sensors for our core intellectual property rights, excluding the application in the same fields under our corporation by Maxwell Sensors and third parties. We also have the right to re-authorize applications by third parties. Such core intellectual property rights have been transferred and provided to our corporation. The Group is the developer and technology proprietor of the Barcoded Magnetic Beads (BMB) assay platform, we can collaborate with international vendors through licensing. This technology platform has obtained multiple patents in the U.S. and the world, including various BMB core patents (7,871,770, 7,858,307, 8,232,092, 8,148,139 and 9,255,922 are approved by the United States Patent and Trademark Office; the European Union Intellectual Property Office approves EP2342561B1; CN 102246037 B is approved by Chinese Patent). Our corporation’s critical technologies’ intellectual property rights are the following four: Barcoded Magnetic Beads (BMB), Light transmitted assay bead, Biocompatible and photocurable polymer, Image Decoding and System. When combined, these patents protect our corporation’s technologies and ensure their applications in various biomedical fields. In 2, we will apply for four patents for extended Barcoded Magnetic Beads from the U.S. Patent and Trademark Office, in order to better protect our group’s core technologies.

Patent Number	Patent name	Country of Application	Date of Approval
7,871,770	Barcoded Magnetic Beads Structure and Materials Barcoded Magnetic Bead Manufacturing and Structure	United States	2011/01/18
7,858,307	Barcoded Polymer Beads	United States	2010/12/28
8,232,092	Apparatus and Method for Analyzing Digital Magnetic Beads Barcoded Magnetic Bead Optical Scanner	United States	2012/07/31
8,148,139	Manufacturing and structure of Barcoded Polymer Beads	United States	2012/04/03
CN 102246037 B	Bio-compatible Polymer Materials for Barcode Magnetic Beads	China	2014/05/21
9,255,922	Biocompatible and photocurable Polymers	United States	2016/02/09
EP2342561B1	Biocompatible and photocurable Polymers	Europe	2019/06/26
PCT/US08/08529	Apparatus and Method for Digital Magnetic Beads Analysis	PCT	–
PCT/US09/60043	Biocompatible and Photocurable Polymers	PCT	–
US20240253055A1	Integrated Magnetic Bead Assay Processing Method and Apparatus Barcoded Magnetic Bead Instrument	United States	–

Patent Number	Patent name	Country of Application	Date of Approval
WO2024/163657A1	Integrated Magnetic Bead Assay Processing Method and Apparatus Barcoded Magnetic Bead Instrument	PCT	–
US2024/046198	Process for High Performance Barcoded Magnetic beads High-Performance Barcoded Magnetic Beads	PCT	–
WO2025/024151A1	Method for Dynamic Range Expansion for Multiplex Assays	PCT	–
US20250034629	Method for Dynamic Range Expansion for Multiplex Assays	United States	–

Source: compiled by our group

(5) Advantages and Disadvantages of Development Prospective and Corresponding Measures

A. Advantages

(A) Technology platform that meets the market trend

As the world's population structure continues the aging trend and the concepts of preventive medicine gain maturity, governments of various countries began to value healthcare and the population's welfare. The improvement of personal economic status and changing healthcare concepts have resulted in continuous expansion and growth of the global healthcare markets. In recent years, the biotechnology industry has paid much attention to precision healthcare and personalized medicine. It is expected that in-vitro diagnostics, such as molecular and immuno diagnosis, will become a popular development field. The multiplex diagnostic technology platform of our corporation can satisfy the three market trends simultaneously: 1. Multiple testing, 2. High throughput, and 3. automated operation. In response to the rapid growth of the personalized medicine and precision medical markets, our corporation's testing platform has high compatibility and expandability, making it easy to incorporate new diagnostic targets into our products. Additionally, in response to the multiplex testing market's highly variable demands, our BMB technology platform has good flexibility on diagnostic expansion, allowing rapid inclusion of new biomarkers.

(B) International Brand and Proprietary Technology

The Group is the developer and technology proprietor of the Barcoded Magnetic Beads (BMB) assay platform. This technology platform is protected by various international patents. Through licensing to international vendors, we collect pre-payments and royalties to the licensees and engage in sales of BMBs to licenses, generating technology royalty and revenue for our corporation.

(C) Application in Diverse Disciplines

The scope of application of our corporation's technology platform covers wide market applications like clinical diagnosis, academic research, agriculture testing, animal health testing and environmental testing, in addition to our core diagnostic applications in immuno and nucleic acid analysis. Our BMB technology has been successfully licensed to various international vendors for use as a development platform for various diagnostic products, demonstrating the recognition received for our platform's application value.

B. Disadvantages and corresponding measures

- (A) Existing market competitors: BMB is an innovative technology platform. The existing competitors in the market of multiplex diagnostic can present a threat to the future market share expansion of the BMB technology platform. A major competitor of similar characteristics to our platform is the xMAP system of Luminex, which has been successfully implemented in hospital markets. Compared to our BMB technology platform, Luminex has the advantage of technology and brand familiarity. Other competitors on the market: vendors like Biofire and Genmark provide single-use cassette type operation platforms (one specimen per cassette). Although the volume of specimens is lower, they are nevertheless potential competitors of our corporation.

Corresponding measures

- a. Each step of the Luminex xMAP operation requires manual input, which is time-consuming and challenging to control the quality of results. Our corporation's MDx 3000 is a fully automated operation platform, which reduces labor costs and can decrease total operation time to 3.5 hours. It also has the advantages of easy operation, prevention of DNA contamination, and ease of maintenance and repair. The Group will continue to promote our products through authoritative seminars in the field of clinical diagnosis, publication in international journals, and participation in international conventions so that we can increase our brand visibility and emphasize our unique automation advantages.
 - b. Compared to Biofire and Genmark, whose products do not possess high-throughput capacity, our products are positioned toward high test volume users such as major hospitals, which allows our products to compete for different market objectives. Our corporation's high-throughput feature allows our product to reduce personnel operation time, a shorter testing cycle, and lower costs per diagnosis.
- (B) Costs invested during the research and development phase: The Group was founded fairly recently, and being a biotechnology and medical research and development company, it takes a long time for products to go on sale, as the process requires multiple verifications and clinical trials. If there is no fixed revenue or continuous injection of external funding, it is difficult for us to support the research expenses, and failure of product development will also impact the Group's financial affairs. Therefore, sound financial planning is of paramount importance to the Group's operations.

Corresponding measures

- a. The BMB technology platform can be applied in a wide range of fields. Our BMB technology has been successfully licensed out to various international vendors for research and development in clinical diagnosis and animal health testing. We collect royalty fees from licensees, which, along with BMBs or instruments' sales, have brought in revenue streams for our corporation.
- b. Considering the definitive diagnosis and insurance coverage for infectious disease, the Group persisted in the self-development, production and sales of products for infectious disease and have successfully obtained market approval and achieved commercialization for these products. We will further expand our sales channels and collaboration with international companies with the hope of rapidly expanding our market share.

- c. Utilize capital market fundraising opportunities to increase diversified outlets for financing.

2. Key usage and production processes of main products


(1) Key usage of main products

The BMB technology platform developed by the Group can be applied to nucleic acid and immuno testing principles. Therefore, it can be applied to a wide range of markets, such as clinical diagnosis, technology research, agriculture, animal health, food industry and environment testing. Following is a brief description of the main products developed or currently in development by the Group, and their key usage:

Product name	Key usage
Barcoded Magnetic Beads (BMB)	BMB can encode up to 4,096 unique numbers and bind with DNA, antibodies, or antigens for specific binding and identification of target compounds. It can be used as a carrier for in-vitro diagnostic assays and can be applied to the diverse fields of clinical diagnostic, agriculture and animal health.
Instrument- Optical Scanner	A testing instrument that complements the Barcoded Magnetic Beads (BMB) acts as a diagnostic and analysis platform for proteins and nucleic acids. Our BC2500 is an analytical instrument designed for sale to authorized customers. The Biocode MDx 3000 is targeted to hospitals and third party laboratory clients, and has the advantages of fully automated molecular assays, high-throughput, highly diverse testing, ease of operation and small product footprint. Our Group is currently developing automated testing instrument for immunoassay.
In-vitro diagnostics assay (Reagent)	Diagnostic panel reagents based on BMB technology comprise mainly of molecular and immunoassay products. Panels are divided based on different indications and test targets. Medical personnel can generate important clinical diagnosis basis by following the instructions and operate the tests. Our philosophy is to develop multiple in-vitro diagnostics assays panels for the same testing instrument, which maximizes the testing efficiency for the customer and increases the number of items available.

(2) Manufacturing process of primary products


A. Magnetic Beads (BMB)



B. Optical Scanner



C. Reagent/In-vitro diagnostic assay (Panel)



3. Supply of primary raw materials

Primary products	Primary raw materials	Primary country of origin	Supply situation
Barcoded Magnetic Beads (BMB)	Wafer fabrication	Taiwan	Adequate
Optical Scanner	System manufacturing	Taiwan/China	Adequate
Reagent/In-vitro diagnostic assay (Panel)	Chemical raw materials	United States	Adequate

4. Significant changes in primary products or gross margin in divisions for the most recent 2 fiscal years

- (1) Comparative analysis of changes in the gross margin of primary products for the most recent 2 fiscal years

Unit: NT\$ thousand

Item \ Products	Barcoded Magnetic Beads (BMB)		Optical Scanner		Reagent	
	2024	2025	2024	2025	2024	2025
Net sales	145,180	143,786	4,385	24,962	147,796	238,409
Gross profit	81,468	74,938	1,467	8,118	85,996	139,076
Gross margin (%)	56.1	52.1	33.4	32.52	58.2	58.3
Change in gross margin (%)	(22.47)	(7.13)	(15.57)	(2.63)	(7.4)	0.17

- (2) Description of the change in the gross margin of 20% or more: None.

5. List of main purchasing and selling customers

- (1) The names of the suppliers who have accounted for more than 10% of the total purchase amount in any of the most recent 2 fiscal years, and the amount and proportion of the purchase amount, and explain the reasons for such increase or decrease.

Unit: NT\$ thousand

Item	2024				2025			
	Name	Amount	As a percentage of the total net annual purchase (%)	Relationship with the issuer	Name	Amount	As a percentage of the total net annual purchase (%)	Relationship with the issuer
1	Company S	31,204	34.92	None	Company P	61,108	38.63	None
2	Company P	14,344	16.05	None	Company A	39,619	25.05	None
3	Company W	14,249	15.95	None	Company DNA	22,978	14.53	None
4	Company A	12,832	14.36	None	Others	34,483	21.79	
5	Others	16,733	18.72	—				—
6				—				—
Net purchase		89,362	100.00	—	Net purchase	158,188	100.00	—

Due to the increase in demand for various multiplexed molecular testing assays in 2023, the Group purchased reagent compounds (such as enzyme and buffer) from Company P, and also purchased silicon wafers from Company A to ensure BMB and various multiplexed testing assays. These companies have become the main suppliers of the Group in the past two years. Sales of in vitro diagnostic reagents at DNA company increased substantially, resulting in a corresponding significant rise in procurement from the said company.

- (2) The names of the customers who have accounted for more than 10% of the total sales amount in any of the most recent 2 fiscal years, and the amount and proportion of the sales amount, and explain the reasons for increase or decrease

Unit: NT\$ thousand

Item	2024				2025			
	Name	Amount	As a percentage of the annual total sales (%)	Relationship with the issuer	Name	Amount	As a percentage of the annual total sales (%)	Relationship with the issuer
1	Company I	122,858	35.81	None	Company I	166,969	35.14	None
2	Company Q	79,616	23.21	None	Company Q	71,766	15.10	None
3	Company L	56,803	16.56	None	Company S	50,886	10.71	None
4	Others	83,789	24.42	-	Company L	41,297	8.69	None
-	-	-	-	-	Others	144,282	30.36	-
-	Total sales	343,066	100.00	-	Total sales	475,200	100.00	-

Benefited from the technology licensing customer Company I and L's successful commercialization of multiplexed serum and fecal test reagents for cats and dogs, the number of Barcoded Magnetic Beads (BMB) purchased from me continues to increase. In addition, Company Q continued to purchase from me testing reagents for GI, respiratory, COVID-19, and COVID-19 combined with influenza testing, and these customers have become the main customers in the past two years.

III. Number of Employees of past two years

1. Number of workers in the past two years and as of the publication date of the annual report

Item	Year	End of 2024	End of 2025	End of March 2026
	Number of employees	Management personnel	13	11
Research and technology personnel		50	54	55
Other employees		19	22	22
Total		82	87	88
Average age		42.6	40.00	40.80
Average length of service		4.59	4.54	4.59
Education distribution	Ph.D. Degree	15%	10%	10%
	Masters Degree	13%	14%	15%

ratio	University and College Degree	65%	70%	69%
	Senior high school	7%	6%	6%
	Below high school	-	-	-
Item \ Year		End of 2024	End of 2025	End of March 2026
Number of employees	Management personnel	13	11	11
	Research and technology personnel	50	54	55
	Other employees	19	22	22
	Total	82	87	88
Average age		43.0	40.00	40.80
Average length of service		4.42	4.54	4.59
Education distribution ratio	Ph.D. Degree	15%	10%	10%
	Masters Degree	13%	14%	15%
	University and College Degree	65%	70%	69%
	Senior high school	7%	6%	6%
	Below high school	-	-	-

乙、The employment turnover and movement of managerial officers, and technology and research and development personnel, and other employees

Item \ Year		2024		2025		As of the end of March 2026	
		Number of personnel	Ratio (%)	Number of personnel	Ratio (%)	Number of personnel	Ratio (%)
Separated employees	Managerial officer	4	21.05	2	15.38	0	0
	Research and technology personnel	9	47.37	9	69.24	1	50.00
	Other employees	6	31.58	2	15.38	1	50.00
	Total (A)	19	100.00	13	100.00	2	100.00
Number of active employees at the end of the period (B)		82		87		88	
Turnover rate (%)=A/(A+B)		18.81		13.00		2.22	

Note: Separation rate = separated employees / number of active employees at the end of the period+separated employees).

IV. Environmental Expenditure

1. Companies are required by law to apply for permits for pollution facility installation or emissions, pay pollution prevention and control fees, or establish dedicated environmental personnel. A description of the application, payment, or establishment situation: the Group's subsidiary ABC-US employs qualified institutions to recycle wastewater on a regular basis, in accordance with the Department of Public Health and the Santa Fe Springs Fire Department. The hired institution reports to the competent authority, which issues a limited number of licenses for medical waste production and waste generation each year. In addition, the sub-subsidiary ABC-TW applied for an environmental facility review. Upon review, the Environmental Protection Bureau found that the air pollution is not an industry that should be applied for, and the noise only needs to comply with the noise control. Waste water is taken into the public sewer to prevent water pollution. The industrial waste hands-free waste cleanup plan is not a business responsible for announcing wastes that should be recycled; so far there is no need to apply for a pollution facility installation permit, pollution

discharge permit, pollution prevention and control fees should be paid, or the establishment of a dedicated environmental protection unit.

2. Set forth the group's investment in the major anti-pollution facilities, the use purpose of such facilities, and the possible effects to be produced: The Group has not been required to install environmental pollution prevention equipment as required by law.
3. Describe the process undertaken by the group on environmental pollution improvement for the most recent 2 fiscal years and up to the prospectus publication date. If there had been any pollution dispute, its handling process should also be described: The Group has not been penalized by environmental protection authorities on environmental pollution matters or had any pollution dispute.
4. Any losses suffered by the Group in the last fiscal year and up to the annual report publication date due to environmental pollution incidents (including any compensation paid and any violations of environmental protection laws or regulations found in environmental inspection, specifying the disposition dates, disposition reference numbers, the articles of law violated, the substance of the legal violations, and the content of the dispositions), and disclosing an estimate of possible expenses that could be incurred currently and in the future and measures being or to be taken. If a reasonable estimate cannot be made, an explanation of the facts of why it cannot be made shall be provided: In the past two years and as of the printing date of this annual report, there were no losses as a result of environmental pollution (including and violation of environmental protection laws and regulations as a result of environmental audits).
5. Explain the current condition of pollution and the impact of its improvement to the profits, competitive position and capital expenditures of the group, as well as the projected major environment-related capital expenses to be made for the coming 2 fiscal years: As the Group has not been involved in environmental pollution incidents, there is no impact of significant impact on the Group's profits, competitive position and capital expenditures.

V. Employer-Employee Relation

- (I) The Company's various policies including employee safety and working environment protection, welfare measures, continuing training, training, retirement systems and their implementation, as well as agreements between labor and management and various employee rights protection measures

1. Employee safety and working environment protection

The Group has set up an occupational safety and health management department in accordance with the law, and has defined the procedures for "work environment control and employee health" in the quality management system. The implementation steps include ensuring employee health, environmental cleanliness and pollution control, environmental control, and abnormal condition identification and recording. The specific identification and recording matters and the monitoring frequency include but are not limited to: Office area cleaning (weekly), manufacturing area environmental cleaning and recording (daily), site control (electronic access), personnel safety protection (active detection at any time as required by the company), temperature control records (daily), safety protection equipment inspection (monthly), and employee safety training (once a year). Based on the significance of the situation, the Company will make reports from time to time or at regular management review meetings. The monitoring records for 2024 showed no employee or workplace hazards as confirmed at regular management review meetings.

2. Employee benefits

Not only does ABC-KY's primary place of business, Applied Biocode, Inc., handles the employee's benefits in accordance with applicable regulations of the Social Security Program Rules and Labor Law, Medical Insurance, Dental Insurance and Worker's Compensation Insurance and retirement Plan-401K are also provided, ensuring employees' related benefits. Employees of ABC-TW are also covered by Labor insurance and National Health Insurance as required by the Taiwan government, protecting employees' rights and interests. So far, incidents that affected the rights and interests of employees have not occurred.

3. Employee education and training

(1) Newcomers

On the first day of employment, an introduction to the Company's work rules, environment, supervisors and colleagues is explained to newcomers by HR personnel.

(2) On-the-job training

In an effort to accommodate the organization's goals and manpower development to improve the quality of personnel, after approval, professional capability and work efficiency, employees are offered a variety of professional and technical training courses according to different functions and business needs. e-Learning and book clubs are also promoted in the Company to encourage the employee to share and exchange their knowledge to enhance their academic skills to help achieve their work tasks. Moreover, we provide convenient and diverse learning outlets and opportunities by cultivating talented professional and technical individuals.

4. Retirement system and implementation status

ABC-KY makes contributions to labor pensions according to local laws and regulations so that employees can concentrate on their work without worries. In accordance with Federal Insurance Contribution Act (FICA), Applied Biocode, Inc.'s primary place of business currently contributes 12.4% of the employee's monthly salaries to the Social Security Tax (shared by both the employer and employee at 6.2%) and 2.9% to the Medicare's Hospital Tax (shared by both the employer and employee at 1.45%). After employees retire, they will be entitled to social security benefits, including pension, disability benefits and federal hospital/medical insurance, etc. Applied Biocode, Inc. also offers a pension system (Retirement Plan -401K), allowing employees to contribute 1%-20% of their monthly salary to their retirement account. Employees are free to choose to join the investment plans launched by financial institutions selected by the Company. The amount contributed by the employee can be deducted from the reported income until retirement, when tax will be imposed. On the other hand, ABC-TW contributes labor pension funds to a dedicated account of the Bureau of Labor Insurance required by the Taiwan government. Pension funds are provided to retired employees in accordance with the retirement plan.

5. Agreements between labor and management and various employee rights protection measures

The Group has formulated working rules in accordance with laws and regulations to clearly regulate labor conditions to protect the rights and interests of employees, allowing their rights and interests to be handled fairly and reasonably. Up to now, incidents that would damage the rights and interests of employees have not occurred.

- (II) Any losses suffered by the Company in the last fiscal year and up to the annual report publication date due to labor-capital disputes (including any violations of the Labor Standards Act found in labor inspection, specifying the disposition dates, disposition reference numbers, the articles of law violated, the substance of the legal violations, and the content of the dispositions), and disclosing an estimate of possible expenses that could be incurred currently and in the future and measures being or to be taken. If a reasonable estimate cannot be made, an explanation of the facts of why it cannot be made shall be provided: We have always regarded our employees as the most precious assets, and the relationship between labor and capital has been harmonious, hence, there have not been any major disputes.

VI. Information and Technology Security Management:

- (I) Clear description of the information security risk management framework, information security policies and concrete management approaches, and investment of resources in information and technology security management

1. Information security risk management framework

The Group has set up an Information Management Department, which is responsible for the overall planning of information security matters encompassing the formulation of internal information security policies, planning and execution of information security operations, and raising of information security awareness among staff members.

The Audit Room is the supervisory unit responsible for the supervision of information security implementation status. It conducts annual audits to ensure that information security policies are properly enforced.

2. Information security policies and concrete management approaches

All staff members of the Group have the duty and obligation to comply with information security regulations and maintain information security inside the Company. The Information Management Department conducts regular reviews of information security measures, adds phishing email reporting mechanisms and strengthens firewalls and network controls. In addition, security-related training and education is provided from time to time to ensure that no confidential information is leaked.

2025 Information Security Awareness Training for New Hires: duration 45 minutes, completion rate 100%.

2025 Employee Information Security Training: duration 10 minutes, completion rate 77%.

Following the aforementioned training sessions, the most recently recorded phishing email link click rate stands at 1.18%, outperforming the industry average of 4.1%.

3. Resources input to information and technology security management

Despite the fact that the Group has adopted comprehensive information security protection measures, and has hired external information security consultants to regularly review the information security protection measures. Network attacks of any form still cannot be completely ruled out. With a view to minimizing the damage caused by potential network attacks on the Group's business operations, information security insurance has been effective to protect the Group's operations and safeguard shareholder rights and interests.

(II) The Company is required to disclose losses sustained due to information security deficiencies in the most recent year until the annual report's publication date, in addition to estimated amounts and response measures currently in place or expected to occur in the future. Where reasonable estimates are impossible, reasons shall be specified: The Group has established an information security framework and is committed to strengthening the information security awareness of its employees. No information security-related material losses occurred in the reporting period.

VII. Important Agreements

Agreement Nature	Party concerned	Contract start/end date	Main content	Restricted Terms and Conditions
Development Agreement	Accel Biotech, Inc.	March 15, 2013	Entered into an agreement with Accel Biotech, Inc. for product development and design services.	None
Technology License Agreement	PerkinElmer, Health Sciences, Inc.	December 28, 2014	PerkinElmer was licensed to purchase ABC-KY's BMB technology, assays and instruments for product development. It was also responsible for commercializing the systems and providing them to customers of vitro diagnostic laboratories in specific fields.	None
OEM agreement	Asia Pacific Microsystems, Inc.	July 07, 2016	ABC-KY entered into an OEM agreement with Asia Pacific Microsystems, Inc. for the manufacturing of products.	None

Agreement Nature	Party concerned	Contract start/end date	Main content	Restricted Terms and Conditions
OEM agreement	CrystalVue Medical Corporation	March 15, 2017	ABC-KY entered into an OEM agreement with CrystalVue Medical Corporation.	None
Non-Exclusive Licensing and Supply Agreement	Livzon Reagents Co., Ltd. (Zhuhai), Livzon Pharmaceutical Group	July 04, 2017 - July 03, 2027	Zhuhai Livzon Diagnostics Inc. was licensed to purchase ABC-KY's BMB technology, assays and instruments for product development. It was also responsible for commercializing the systems and providing them to customers of vitro diagnostic laboratories in specific fields.	None
Technology Licensing and Supply Agreement	IDEXX Technologies GmbH	October 10, 2017 - December 31, 2036	BMB and multiplex immunoassay are sold exclusively to IDEXX Technologies GmbH in the non-human health field, and IDEXX Technologies GmbH agrees to a minimum annual purchase volume.	None
OEM agreement	Suzhou Sym-Bio Lifescience Co., Ltd. (Subsidiary of Perkin Elmer)	November 30, 2017	ABC-KY entered into an OEM agreement with Perkin Elmer.	None
Non-Exclusive License Agreement	Accel Biotech, LLC	April 01, 2018	Attained a non-exclusive license from Accel to use its molecular diagnostic analysis equipment.	None
Plant Lease Agreement	PPF INDUSTRIAL 12016 TELEGRAPH RD, LP	November 2025 - October 31, 2028	ABC-US entered into a plant lease agreement.	None
Non-Exclusive Licensing and Supply Agreement	ALPCO	October 21, 2019 - October 21, 2029	ALPCO was licensed to purchase the Group's BMB technology, assays and instruments for product development. It was also responsible for commercializing the systems and providing them to customers of vitro diagnostic laboratories in specific fields.	None
Non-Exclusive Licensing and Supply Agreement	Hardy Diagnostics	August 13, 2021	Authorization of Hardy Diagnostics to utilize the Company's technologies for the development of testing products in the field of food safety	None
Licensing Agreement	Medline Industries, LP	March 27, 2023 - March 26, 2027	Authorization for sales of diagnostic analysis system and reagents signed with Medline Industries, LP.	None

Six. Analysis of Financial Position, Performance, and Risk

I. Financial Position

List the main reasons for any material change in the company's assets, liabilities, or equity during the most recent 2 fiscal years, and describe the effect thereof. Where the effect is of material significance, describe the measures to be taken in response:

Unit: NT\$ thousand

Item	Year	2024	2025	Difference	
				Increase (decrease) amount	Change ratio (%)
Current asset		1,104,285	858,461	(245,824)	(22.26)
Property, Plant and Equipment		85,637	86,028	391	0.46
Right-of-use asset		13,150	58,501	45,351	344.87
Intangible asset		1,799	85	(1,714)	(95.28)
Other assets		10,031	9,629	(402)	(4.01)
Total assets		1,214,902	1,012,704	(202,198)	(16.64)
Current liabilities		129,830	126,546	(3,284)	(2.53)
Non-current liabilities		206,242	242,943	36,701	17.80
Total liabilities		336,072	369,489	33,417	9.94
Equity attributable to parent company owners		878,830	643,215	(235,615)	(26.81)
Share capital		1,027,876	1,028,111	235	0.02
Additional paid-in capital		272,276	37,219	(235,057)	(86.33)
Retained earnings (for making up losses)		(453,973)	(417,807)	36,166	(7.97)
Other items in shareholders' equity		32,649	(4,308)	(36,957)	(113.19)
Total shareholders' equity		878,830	643,215	(235,615)	(26.81)

1. The change ratio reaches over 20% and the amount of change reaching NT\$10 million or more, and the main reason and their effects are as follows:

- (1) Current assets, equity attributable to owners of the parent company, and shareholders' equity: the aforementioned items declined substantially in 2025, attributable to the net loss recorded during the year.
- (2) Right-of-use assets: right-of-use assets increased in 2025 compared to 2024, driven by the execution of new factory lease agreements in both the United States and Taiwan during the year.
- (3) Additional paid-in capital: additional paid-in capital as of year-end 2025 decreased significantly compared to year-end 2024, primarily due to the utilization of additional paid-in capital to offset accumulated deficits carried out during 2025.
- (4) Other shareholders' equity: The significant fluctuations in other shareholders' equity items in 2025 compared to the end of 2024 can mainly be attributed to the weak US dollar resulting in exchange differences in the translation of foreign financial statements.

2. Measures to be taken in response:

In summary, the higher change in the ABC-KY's balance sheet accounts at the end of 2025 compared to 2024 was primarily due to the operating losses; therefore measures to be taken in response are as follows:

- (1) Market development and sales performance

In addition to the Group's existing licensees, Company I and Company L, which have demonstrated strong demand for the Group's digital biobarcode technology in 2026, the Group has also achieved significant progress in developing new IVD customers. These developments are expected to generate steady revenue growth for the Group starting in 2026 and bring about substantial improvement in overall profitability.

Item \ Year	2024	2025	Difference	
			Increase (decrease) amount	Change ratio (%)
(2) Continuous development of new products The Group continues to develop reagent products such as those for urinary tract infections, antimicrobial resistance targets, optimization of certain fungal targets, and automated molecular diagnostic instruments combined with extraction equipment. The diversification of products will help with customer development to increase the Group's future revenue.				

II. Financial Performance

- (I) List the main reasons for any material change in operating revenues, operating income, or income before tax during the most recent 2 fiscal years, provide a sales volume forecast and the basis therefore, and describe the effect upon the company's financial operations as well as measures to be taken in response:

Unit: NT\$ thousand

Item \ Year	2024	2025	Difference	
			Increase (decrease) amount	Change ratio (%)
Net sales	343,066	475,200	132,134	38.52
Operating costs	(139,068)	(214,307)	(75,239)	54.10
Gross profit	203,998	260,893	56,895	27.89
Operating expenses	(481,910)	(484,226)	(2,316)	0.48
Net operating income (loss)	(277,912)	(223,333)	54,579	(19.64)
Non-operating income (expense)	17,131	22,212	5,081	29.66
Profit (losses) before tax	(260,781)	(201,121)	59,660	(22.88)
Income tax (expense)	(26)	(79)	(53)	203.85
Current net income (loss)	(260,807)	(201,200)	59,607	(22.85)
Other comprehensive income (loss) recognized in the current period	39,988	(36,957)	(76,945)	(192.42)
Current total comprehensive loss	(220,819)	(238,157)	(17,338)	7.85

The change ratio reaches over 20% and the amount of change reaching NT\$10 million or more, and the main reason and their effects are as follows:

- (1) Revenue, Cost of Revenue, Gross Profit, Net Loss Before Tax, and Total Comprehensive Loss for the Period: The above figures reflect cumulative revenue growth for the year, driven primarily by market development achievements and increased customer demand, resulting in higher shipment volumes and a reduction in losses.
- (2) Other comprehensive net loss for the period: The significant decline in other comprehensive net profit (loss) in 2025 compared to 2025 was mainly attributable to the increase in cumulative translation adjustments as presented in the Group's financial statements caused by the significant fluctuations in the U.S. dollar exchange rate.

- (II) Provide a sales volume forecast and the basis, and describe the effect upon the company's financial operations as well as measures to be taken in response

As of the annual report's publication date, aside from selling BMBs and Optical Scanners, 17-Plex Gastrointestinal Pathogen Panels, Upper Respiratory Pathogen Panel (RPP), and Sars-CoV-2 (including Pooling Testing) products, we have received EUA from

the FDA in the US for Covid Flu Plus in December 2021 and have concluded a distribution contract with Hardy Diagnostic Inc. for the US market. The Group's expected sales volume is based on the market forecast of major customers, past product sales status, customers' annual procurement plans, licensed customers' agreement, business plans of licensed customers, new customer development and business growth of existing customers. At the same time, to be able to set a shipping goal, the Group also takes into account factors such as the material condition of primary raw materials and the production capacity and delivery time of suppliers. Not only does the Group adopt its original business model of licensing its patented platforms and technologies to a number of strategic customers in various industries and regions, it is at the same time adding new diagnostic panels for the Group to sell so that products and customers are more diverse in the future. Therefore, there should be no material adverse effect on the future financial development of the Group.

(III) Describe the effect upon the company's financial operations as well as measures to be taken in response.

The Group has a robust financial structure and continues to deepen its operational management and adopts reasonable control of costs for future business growth needs.

III. Cash Flow

(I) Describe and analyze any cash flow changes in the most recent 2 fiscal years

Unit: NT\$ thousand

Item	Year	2024	2025	Difference	
		Amount	Amount	Increase (decrease) amount	Change ratio (%)
Net cash (outflow) from operating activities		(207,736)	(226,641)	(18,905)	9.10
Net cash inflow (outflow) from investing activities		(59,091)	127,604	186,695	(315.94)
Net cash inflow (outflow) from financing activities		424,398	(18,811)	(443,209)	(104.43)
Analysis of changes in cash flows:					
1. Business activities: Net cash outflows from business activities in 2025 are comparable to 2024, exhibiting only minor changes caused by daily business activities.					
2. Cash flows from investing activities: Net cash outflows from investing activities in 2025 declined significantly compared to 2024 and turned positive, primarily due to the redemption of a portion of time deposits during 2025, which resulted in net cash inflows from investing activities.					
3. Cash flows from financing activities: Net cash outflows from financing activities decreased substantially in 2025, as the Company completed a cash capital increase totaling NT\$441,000 thousand in 2024, with no such capital increase activity occurring in 2025.					

(II) Measures to be taken in response to illiquidity:

In 2024, the Group increased revenue from a number of multiplex panels. However, given that the sales volume of each product segment has not grown enough to support the Group's operating expenses, we will dedicate ourselves to the sales expansion of each product segment and the development of new products. In the future, we will also build up our working capital by improving our revenue and profitability.

(III) Analysis of cash liquidity in the coming year (2026)

Unit: NT\$ thousand

Beginning cash balance (1)	Estimated full-year net cash flows from operating activities (2)	Estimated full-year net cash flows from investing activities (3)	Estimated full-year net cash flows from financing activities (4)	Expected cash surplus (deficit) (1)+(2)+(3)+(4)	Expected remedies for cash deficits	
					Investment plan	Financing plan
464,786	(73,192)	(8,000)	—	383,594	—	—

Cash flow analysis for the coming year

- A. Operating activities: The Group's 2025 operating activities are expected to include primarily the sales of in-vitro diagnostics assay and RUO products: gastrointestinal panels, respiratory pathway panels, Sars-CoV-2, Covid Flu Plus and fungal panels, sales of BMBs and instruments to licensed customers as well as technology license royalty income. The primary drivers of cash outflows from operating activities will include product development initiatives targeting urinary tract infections and antimicrobial resistance, automation of second-generation testing instruments, and research and development activities related to the second-generation RPP and upper respiratory tract plus COVID panel, including clinical trials and FDA submission.
- B. Cash flows from investing activities: The Group's primary investing activities in 2026 are expected to consist of modest fixed asset purchases, with time deposit balances projected to remain unchanged.
- C. Financing activities: The Group had no fundraising plans for 2025.

IV. Impact to Finance and Business from Major Capital Expenditure on financial business

The Group's cash outflow from the acquisition of property, plant and equipment in 2025 was NT\$8,819 thousand, mainly attributable to the acquisition of leasehold improvements and occasional equipment. Therefore, there should be no material adverse effect on the Group's financial position due to the increase in capital expenditure.

V. Investment Policies of last fiscal year, causes of profit or loss, improvement plan and upcoming year's investment plans

(I) Investment policy for the most recent fiscal year:

The Group's current investment policy is to invest in targets related to the development of the industry; the Company is not engaged in investments in other industries.

(II) The main reasons for the profits or losses on investment and improvement plans:

The Group's investee company ABC-US reported an operating loss in 2025, primarily because it was still focused on developing next-generation products and has not yet become profitable. In addition to the digital biobarcodes, optical analyzers, and various multiplex diagnostic reagents already on the market, the Group recorded growth in both customer count and market share in 2025. Accordingly, the Group anticipates that the future revenue and profitability of its investee companies will improve as it continues to expand its product lines and commercial presence across various markets.

(III) Investment plans for the coming year:

The Group's focus areas encompass the development of diagnostic reagents combining urinary tract and antimicrobial resistance molecular detection, the integration of the KingFisher extraction instrument into the Company's fully automated optical analyzer, the optimization of fungal diagnostic reagents, and the submission of a formal 510(k) premarket notification to the U.S. FDA for the addition of SARS-CoV-2 detection to the

respiratory pathogen panel (RPP).

VI. Risk Management and Assessment

(I) The impact of interest rate, exchange rate changes, and inflation on the Company's profit and loss and corresponding future measures:

1. Interest rate change

The Group's interest income totaled NT\$27,629 thousand and NT\$22,941 thousand in 2024 and 2025, respectively, representing a net loss before tax of 10.59% and 11.41%. The interest expenses for 2024 and 2025 were NT\$1,427 thousand and NT\$1,587 thousand, respectively, representing 0.55% and 0.79% of net loss before tax, respectively, which does not have significant impact on the Group. The Group maintains a sound relationship with banks, and its financial personnel keeps a close eye on changes in market interest rates. In the future, if there are significant changes in interest rates upon borrowing from banks, the Group will take corresponding measures so as to reduce the impact on the Group's profit and loss.

2. Exchange rate change

The functional currencies of the Group's daily operations are U.S. dollars and New Taiwan dollars. Given that the main operating place of business is in the U.S, the U.S. dollars are currently used as the main currency for purchasing and selling, so the impact of foreign exchange gains and losses is limited. The currency position in the accounts related to contract negotiations or transaction payments is considered to reduce the risk arising from exchange rate changes. Additionally, the Group's financial personnel keep track of the movement of major currencies and changes of global noneconomic factors to control and adjust the positions of each currency in a timely manner to minimize the impact of exchange rate changes.

3. Inflation

The Group's payment terms for purchasing and selling have not been too long so far, and given that the Group monitors the price changes for raw materials or parts and components and have always kept a sound relationship with suppliers and customers, the significant impact of short-term price fluctuations on operations is avoided. In the future, the Group will continue to pay close attention to the impact of inflation and maintain a good cooperative relationship with its counterparties to reduce the impact of inflation on the Group.

(II) Main reasons and corresponding future measures of policies for engaging in highly risky and highly leveraged investments, lending funds to others, endorsements and guarantees and derivatives transactions:

As of the annual report's publication date, the Group has not been engaged in highly risky, highly leveraged investments or derivatives transactions. The Group has formulated the "Procedures for Acquisition or Disposal of Assets," the "Operational Procedures for Loaning Funds to Others," and the "Procedures for Endorsements/Guarantees" which have all been approved by shareholders meetings. The Group handles related matters in accordance with these measures.

(III) Future R&D projects and estimated R&D budget:

The Group continues to invest in R&D resources to improve the efficiency of its diverse testing systems, optical analysis equipment, and the development of diagnostic reagents. It has also begun research and development on targeted infectious diseases, urinary

tract infections, vaginal infections, and multi-test reagent products that incorporate drug resistance. R&D expenses are expected to be allocated item by item based on the progress of each product, including R&D technical personnel salaries, experiment materials, equipment, and clinical trial expenses, in order to continuously improve the Group's competitive advantage.

- (IV) Impact on the Company's financial operations of important policies adopted and changes in the legal environment at home and abroad, and measures to be taken in response

The Company is registered in the Cayman Islands, its principal place of business is the U.S. The main economic activity of the Cayman Islands is financial services, while the U.S. is one of the world's major economies with stable economic development and political environment. The Group abides by domestic and international important policies and laws when conducting businesses. In the most recent fiscal year and as of the publication date of the annual report, there were no material events affecting the Group's financial operations due to changes in important policies and laws from the aforementioned regions. Meanwhile, the Group pays close attention to domestic and international policy trends and regulatory changes. Lawyers, accountants and other professional sectors are consulted where there are changes in order to respond to the market while adopting suitable countermeasures in a timely manner.

- (V) Impact on the company's financial operations of developments in science and technology as well as industrial change, and measures to be taken in response:

The Group monitors the impact of technological and industrial changes on the Company closely while paying close attention to the development of multiplex diagnostic testing technology and the biotechnology and medical industry dynamics. By grasping the R&D progress of products and adjusting the allocation of resources, the impact of technological and industrial changes in the future will be minimized.

- (VI) Impact on the company's crisis management of changes in the company's corporate image, and corresponding measures to be taken in response

Since the establishment, the Group adheres to the corporate spirit of integrity and sustainable management. The Group does not cease to strengthen the corporate management and improve operational efficiency, striving to maintain its good corporate image and sound and harmonious industrial relations so as to attract more talented people to make a difference in the Company. To date, no incidents have happened that would affect the Company's corporate image, and there are no plans for corporate image changes.

- (VII) Expected benefits and possible risks associated with any merger and acquisitions, and corresponding measures being or to be taken

As of the publication date of the annual report, the Group has no M&R plans. If there is a plan in the future to carry out such operation, the Group will handle related matters in accordance with the local laws and regulations as well as the applicable measures formulated by the Group to ensure the Group's interests and shareholders' equity.

- (VIII) Expected benefits and possible risks associated with any plant expansion, and corresponding measures being or to be taken

As of the publication date of the annual report, the Group has no plant expansion plans.

- (IX) Risks associated with any consolidation of sales or purchasing operations, and corresponding measures being or to be taken

The Group's purchases from its largest supplier accounted for approximately 34.92% and 38.63% of total procurement in 2024 and 2025, respectively. The higher concentration of purchases from the largest supplier in 2025 was primarily attributable to increased demand for various multiplex diagnostic reagents, which led the Group to procure greater quantities of enzymes and buffers used in PCR processes from Company P. The Group maintains an excellent partnership with its suppliers and carries out price comparisons and raw material quality analyses of each supplier. It is expected that as assays are added to sales and overall revenue increases, and become more scalable, there will be a second or third source of supply for the purchase of each raw material, thereby reducing the proportion of purchases from a single supplier.

In addition, the Group's largest customer accounted for 35.81% and 35.14% of net revenue in 2024 and 2025, respectively, showing a decrease in sales concentration. By 2025, the Group expects to continuously have more customers for multiplexed molecular detection reagents. The increase in IVD product lines for infectious disease diagnosis is helpful for market promotion. At the same time, the Group is working with new Gradually increase the sales scale and reduce the proportion of sales to a single customer.

- (X) Information and technology security risks and response measures

The Company and its subsidiaries constantly monitor technology changes and industry developments affecting their business areas. Dedicated information security personnel are responsible for the installation of information security equipment and administration of training to reinforce information security concepts of our staff members. As of the annual report's publication date, no information security threats have occurred in the Group.

- (XI) Impact upon and risk to the company in the event a major quantity of shares belonging to a director, supervisor, or shareholder holding greater than a 10 percent stake in the company has been transferred or has otherwise changed hands, and corresponding measures being or to be taken: None.

- (XII) Litigious and non-litigious matters. List major litigious, non-litigious or administrative disputes that: (1) involve the company and/or any company director, any company supervisor, the president, any person with actual responsibility for the firm, any major shareholder holding a stake of greater than 10 percent, and/or any company or companies controlled by the company; and (2) have been concluded by means of a final and unappealable judgment, or are still under litigation. Where such a dispute could materially affect shareholders' equity or the prices of the company's securities, disclose the facts of the dispute, amount of money at stake in the dispute, the date of litigation commencement, the main parties to the dispute, and the status of the dispute as of the date of publication of the annual report: None.

(XIII) Impact upon and risk to the company associated with any change in governance personnel or top management, and corresponding measures being or to be taken: As of the publication date of the annual report, there was no change in the the Group’s operating right.

(XIV) Other important risks and corresponding measures

1. Risks of the protection of shareholders’ equity

As the Company Law of the Cayman Islands is very different from the Company Act in Taiwan, the Group has amended the “Articles of Association” in accordance with the “Checklist for Protection of Shareholders’ Interests in the Countries of Registration of Foreign Issuers” promulgated by Taiwan Stock Exchange (TWSE). However, in the matter of company operations, there are many differences between these 2 countries, resulting in investors’ inability to apply the legal protection of Taiwan’s Company Act to the Cayman Islands where they invest in. Investors must thoroughly understand the laws and regulations regarding investing in the Cayman Islands and seek advice from experts to get hold of the differences regarding the protection of shareholders’ equity.

2. Risks in relation to the statements made in the annual report

(1) Facts and statistics

Information and statistics in this annual report were obtained from various statistical publications. However, such information obtained may be inaccurate, incomplete or not up-to-date. The Company makes no declaration as to the truth or accuracy of such statements, and investors should not be overly dependent on such information when making their investment judgments.

(2) Forward-looking statements and risks and uncertainties contained in this annual report

This annual report contains certain forward-looking statements and information about the Company and its subsidiaries, such statements and information are based on the beliefs and assumptions of the Company’s management and information currently held. Words including “anticipate,” “believe,” “can,” “expect,” “future,” “intend,” “may,” “must,” “plan,” “estimate,” “seek,” “should,” “will,” “maybe,” “hope” and words of similar meaning contained in this annual report refer to forward-looking statements when used concerning the Company or the Company’s management. Such statements reflect the company management’s current views regarding future events, operations, liquidity, and sources of funds; certain viewpoints may not be realized or may be subject to change. These statements may be affected by certain risks, uncertainties and assumptions, including other risks stated in this annual report. Investors are cautioned that reliance on any forward-looking statement involves known and unknown risks and uncertainties; these risks and uncertainties faced by the Company may affect the accuracy of forward-looking statements.

The Group does not update the forward-looking statements in this annual report nor does it make amendments to reflect future events or information. Based on these risks and other risks, uncertainties, and assumptions, this annual report’s forward-looking statements and circumstances may not occur in an anticipated manner or may not even occur at all, and investors should not rely on any forward-looking statements.

3. Cash dividend distribution and taxation

The Company Applied BioCode Corporation was organized under the law of the Cayman Islands. Upon the restructuring of its organizational and investment structure, the shares of Applied BioCode, Inc. were acquired through a share swap among all shareholders. As a result, the Company's shareholder structure is the same as the original U.S. enterprise Applied BioCode, Inc. prior to the restructuring. Based on the U.S. federal income tax regulations, the Company is deemed a U.S. corporation and should file federal income tax returns according to the federal income tax policy. In the event of the Company distributing cash dividends to non-U.S. shareholders in the future, the Company should pay tax as a U.S. Company and file U.S. corporate income tax returns. For example: when the Company distributes cash dividends to non-U.S. shareholders, it generally requires to withhold 30% tax on behalf of the non-U.S. shareholders, which is one of the investment risks for investors.

4. Overall economic, political and economic environment, foreign exchange, and legal risks

Because the Company is domiciled in the Cayman Islands and its principal place of business is in the U.S, the overall economic and political environment changes and fluctuations in foreign exchange rates between the Cayman Islands and the U.S. affect the Group's operating condition.

5. The Company is a holding company. It depends on its subsidiaries' performances and their ability to distribute dividends while being restricted to their payment of dividends and the transfer of funds.

The Company is a holding company incorporated in the Cayman Islands; it has no commercial operations and revenue sources, and its source of profit mainly depends on its operating subsidiaries. The Group's subsidiary in the U.S. is the Group's vital source of operating income. Therefore, the Group's cash dividend distribution is affected by the subsidiary's cash dividend distribution or the retention of surplus.

Moreover, the subsidiary's cash dividend distribution is subject to restrictions of the laws of dividends, revenue remittance, cash transfer and foreign exchange controls in the countries in which they are paid. The payment is also affected by the foreign exchange rates, which the Group has no control over.

The Group's subsidiaries are separate and independent corporations. In the event of bankruptcy, insolvency, restructuring, liquidation or asset realization of a subsidiary, assets acquired by the Group or the order of distribution will be inferior to the subsidiary's creditors, including the subsidiary's trading partners.

The distribution of the Group's dividends or other benefits is handled in accordance with applicable regulations. It is advised that investors should understand the taxation policy of the investment in the holding company and seek advice from experts.


6. Please refer to pages 123-127 regarding the favorable and unfavorable factors concerning the Group's future development and their corresponding measures for other important risks and corresponding measures about the Group's operations. However, such corresponding measures may not be fully enforced due to force majeure and other factors. Their related risks may still affect the Group's business, operating results and financial condition.

VII. Other important disclosures: None.

Seven. Special disclosures

I. Information of Affiliates

(I) Organizational table of affiliated enterprises



(II) Basic information of affiliated enterprises

December 31, 2025; NT\$ thousand

Company name	Date of incorporation	Address	Paid-in Capital	Primary business or Production
Applied BioCode Corporation	2016/04/15	Grand Pavilion, Hibiscus Way, 802 West Bay Road, P.O. Box 31119, KY1- 1205, Cayman Islands	1,028,111	Researching and developing multiplex diagnostic platform technologies and development, production and sales of testing instruments, magnetic beads and assays
Applied BioCode, Inc.	2008/03/17	12130 Mora Drive, Unit 2, Santa Fe Springs, CA 90670,	2,254,037	R&D, production, sales and leasing of platform technologies and products including BMB, assay and instruments and products for in-vitro diagnostics assays (multiplex panels).

Company name	Date of incorporation	Address	Paid-in Capital	Primary business or Production
ABC-TW	2015/12/07	6F, No. 1, Lane 28, Xingzhong Road, Neihu District, Taipei City	103,000	R&D, production, and sales of products including BMB, assay and instruments and products for in-vitro diagnostics assays (multiplex panels).

(III) Information on the same shareholders who are presumed to have a relationship of control and subordination: None.

(IV) The industries covered by the business operated by the overall affiliated enterprises: The main businesses of the overall affiliated enterprises of the Group's investment include researching and developing multiplex diagnostic platform technologies and development, production and sales of testing instruments, magnetic beads and panels.

(V) Information on directors, supervisors and presidents of affiliated enterprises

Company name	Position	Name or representative	Number of shares held (capital contribution)	Percentage of shares held (capital contribution)
Applied BioCode, Inc.	President / Director	Winston Z. Ho	-	-
	Director	George J. Lee	-	-
	Director	Benjamin Jen	-	-
ABC-TW	Director	George J. Lee	-	-
	Director	Winston Z. Ho	-	-
	Director	Benjamin Jen	-	-
	Supervisor	Ang-Hsuan Wu	-	-

(VI) Operational overview of affiliated enterprises

December 31, 2025; NT\$ thousand

Company name	Capital	Total asset value	Total liabilities	Net worth	Net sales	Operating (loss) income	Current profit and loss (post tax)	Earnings per share (NT\$) (post tax)
Applied BioCode, Inc.	2,254,037	851,864	409,104	442,760	448,902	(210,971)	(187,824)	(3.75)
ABC-TW	103,000	83,655	10,908	72,747	50,087	14,713	15,388	1.49

(VII) For consolidated financial statements of affiliated enterprises: Please refer to the financial reports available on the Market Observation Post System.

(VIII) Consolidated business reports of affiliated enterprises: The Group is not a subordinate company as stipulated in the chapter regarding affiliated enterprises in the Company Act. It is therefore not applicable.

II. Issuance of Securities through Private Placement in the most recent fiscal year and up to

publication date of the annual report: None.

III. Other Required Amended Explanation

(I) Internal control system implementation status

1. The CPA's recommendations for improving the internal control in the most recent 3 fiscal years

Year	recommendations by the CPAs	Improvement situation
2023	None	None
2024	None	None
2025	None	None

2. Major flaws discovered through internal auditing in the most recent 3 fiscal years: There are no major flaws so far.

3. Internal control statement: Please refer to page 61.

4. Where the company has retained CPAs to exclusively review its internal control systems, the prospectus shall set forth the reason for doing so, the CPAs' review opinions, measures the company has taken for improvement, and the condition of improvement on lacking items: In the opinion of the CPAs of PwC Taiwan, the Group maintained, in all material respects, effective internal controls over external financial reporting and assets safeguard, based on the criteria of effective internal controls set forth in the "Regulations Governing Establishment of Internal Control Systems by Public Companies".

(II) An explanation of any material differences from the rules of Taiwan in relation to the protection of shareholders' equity.

Explanation of any material differences from the rules of Taiwan in relation to the protection of shareholders' equity.

The Group has amended the "Articles of Incorporation" regarding important matters of the protection of shareholders' equity in accordance with the "Checklist of Shareholders' Equity Protection and Interests in the Country of Registration of Foreign Issuers" ("Checklist of Shareholders' Equity Protection") promulgated by Taiwan Stock Exchange (TWSE). However, certain important measures of the protection of shareholders' equity are not applicable under the Cayman Islands laws and are therefore not amended in the Company's Articles of Incorporation. Differences between the Articles of Incorporation and the important matters of shareholders' equity protection are as follows:

Important matters regarding the protection of shareholders' equity	Regulations of the Articles of Association and reasons for differences
1. Physical shareholder meetings shall be held within the territory of the Republic of China. If a shareholders meeting is convened physically outside of Taiwan, it shall be resolved by the Board meeting or shareholders meeting and gain permission from the competent authorities. It shall then be reported to the TWSE for approval within 2	1. In terms of convening shareholders meeting by shareholders physically, given the fact that the Company Law of the Cayman Islands does not have special provisions governing the convening of shareholders meetings physically; therefore, Article 19.6 of the Company's Articles of Association does not stipulate that the shareholders shall report to the competent authorities for approval prior to convening an extraordinarily shareholders meeting by themselves. 2. Furthermore, if shareholders wish to convene a shareholders meeting physically outside of Taiwan, it is stipulated in Article 19.6 of the Company's Articles of Association that it is required that the meeting must obtain permission from the TWSE or the TPEX in advance. Given that a special shareholders meeting

Important matters regarding the protection of shareholders' equity	Regulations of the Articles of Association and reasons for differences
<p>days after the permission is gained by the competent authorities.</p> <p>2. Any or a plural number of shareholder(s) of a company which has (have) continuously held 3% or more of the total number of outstanding shares for a period of one year or a longer time may, by filing a written proposal setting forth therein the subjects for discussion and the reasons, request the board of directors to call a special meeting of shareholders. If the board of directors fails to give a notice for convening a special meeting of shareholders within 15 days after the filing of the request under the preceding Paragraph, the proposing shareholder(s) may, after obtaining approval from the competent authority, convene a special meeting of shareholders on his/their own.</p>	<p>does not require permission from the local authority of the Cayman Islands, the requirements in the "Checklist of Shareholders' Equity Protection" - "report to the TWSE for approval within two days after shareholders obtain approval from the competent authority for the convening of the meeting" do not apply. This part should have no material impact on the rights of Taiwanese shareholders.</p>
<p>1. When convening shareholder meetings, the Company shall list electronic transmission as one of the methods for exercising the voting power.</p> <p>2. When voting rights are exercised by correspondence or electronic means, the method of exercise shall be specified in the shareholders' meeting notice. A shareholder exercising voting rights by correspondence or electronic means will be deemed to have attended the meeting in person. But to have waived his/her rights</p>	<p>In terms of exercising shareholder voting rights by correspondence or electronic means, the Company Law of the Cayman Islands does not mention whether a shareholder exercising his/her voting rights by correspondence or electronic means is deemed to have attended the meeting in person, and lawyers of Cayman Islands have not discovered related cases. To make other arrangements, Article 25.4 of the Company's Articles of Association stipulates that "a shareholder exercising his/her voting at a shareholders meeting by correspondence or electronic means is deemed to have appointed the chair of the meeting as its proxy. His/her voting rights must be exercised as instructed by correspondence or electronic documents. The meeting chair may not exercise his/her voting rights on behalf of the shareholder in matters not mentioned or set out in correspondence or electronic means, and/or amendments to the original motion proposed at the shareholders' meeting. To avoid doubts, such shareholder who exercises his/her voting rights through such means shall be</p>

Important matters regarding the protection of shareholders' equity	Regulations of the Articles of Association and reasons for differences
concerning the extraordinary motions and amendments to original proposals of that meeting;	deemed to have waived his/her rights concerning the extraordinary motions and amendments to original proposals of that meeting.” The voting rights of the chair acting as a proxy at the shareholders’ meeting may not exceed 3% of the total voting rights of the issued shares as stipulated in Article 26.3 of the Company’s Articles of Association.
<p>For the following resolutions involving significant shareholders’ interests, they shall be approved by a majority vote at a meeting of shareholders attended by shareholders representing two-thirds or more of the total number of the issued shares of the company. In the event the total number of shares represented by the shareholders present at a shareholders’ meeting is less than the percentage of the total shareholdings required in the preceding Paragraph, the resolution may be adopted by two-thirds of the voting rights exercised by the shareholders present at the shareholders’ meeting who represent a majority of the outstanding shares of the company.</p> <p>1. Enter into, amend, or terminate any contract for lease of the company’s business in whole, or entrusted business, or regular joint operation with others; transfer the whole or any essential part of its business or assets; or accept the transfer of another whole business or assets, which has great bearing on the business operation of the company.</p> <p>2. Change in the Articles of Association</p> <p>3. Changes in the Articles of Association that damage</p>	<p>1. In terms of the resolution method at a shareholders meeting - in addition to the ordinary resolutions and major resolutions under Taiwan’s laws, “Special Resolution” under the Company Law of the Cayman Islands is stipulated in Article 1.1 of the Company’s Articles of Association. It refers to a resolution passed at the Company’s shareholders meeting who have voting rights either attended in person or by a power of attorney, or by a proxy legally authorized by a corporate shareholder or non-natural person. After calculating the number of voting rights of each shareholder, the resolution shall be approved by at least two-thirds of the voting rights of all attending shareholders.</p> <p>2. In accordance with the Company Law of the Cayman Islands, the following matters shall be resolved by special resolution:</p> <p>(1) Change in the Articles of Association</p> <p>In accordance with the Cayman Islands laws, making changes in the Articles of Association must be performed through a special resolution. Therefore, Article 12.1 of the Company’s Articles of Association regarding the resolution threshold of changing the Articles of Association has not been changed to a major resolution as required by the “Checklist of Shareholders’ Equity Protection” under Taiwan’s laws. Furthermore, according to Article 13 of the Articles of Incorporation, if any amendment or alteration to the Articles of Incorporation would prejudice the preferential rights of any class of shares, such amendment or alteration shall be passed by a Special Resolution and shall also be passed by a Special Resolution at a separate meeting of the holders of the shares of such affected class.</p> <p>(2) Dissolution</p> <p>Under the Cayman Islands laws, if a company resolves to voluntarily liquidate and dissolve because it is unable to pay its debts as they fall due, the dissolution shall be resolved by the shareholders’ meeting. However, suppose a company resolves to voluntarily liquidate and dissolve for reasons other than those mentioned above. In that case, the dissolution shall be made through a special resolution as required by the Company Law of the Cayman Islands. Hence, Article 12.4 of the Company’s</p>

Important matters regarding the protection of shareholders' equity	Regulations of the Articles of Association and reasons for differences
<p>preferred shareholders' rights shall be subject to resolution at the special shareholders' meeting.</p> <p>4. Dividends and bonuses in whole or in part distributed in the form of new shares to be issued</p> <p>5. A resolution for dissolution, consolidation or merger, or split-up of a company</p> <p>6. Share conversion</p>	<p>Articles of Association (a) "the resolution threshold for voluntary liquidation and dissolution of the Company for the reason the Company is unable to pay its debts as they fall due" has not been changed to a major resolution as required by the "Checklist of Shareholders' Equity Protection" under Taiwan's laws.</p> <p>(3) Merger</p> <p>As there are mandatory provisions of the Company Law of the Cayman Islands regarding the voting manner of "Merger as defined by the laws of the Cayman Islands," Article 12.3 of the Company's Articles of Association (b) provides "Merger" (except for any Merger which falls within the definition of "merger and/or consolidation" under the Company Law of the Cayman Islands that requires only a special resolution) that shall be approved by a major resolution.</p> <p>3. The difference between the above matters and the Checklist of Shareholders' Equity Protection is important motions regarding the protection of shareholders' equity should be resolved by a major resolution and special resolution, respectively, in the Company's Articles of Association. As these differences arise due to the laws of the Cayman Islands, the Company's Articles of Associations clearly stipulate major resolutions and special resolutions for the protection of important matters regarding shareholders' equity. Therefore, the effect on the shareholders' equity shall be limited.</p>
<p>1. Supervisors of a company shall be elected by the meeting of shareholders. Among them, at least one supervisor shall have a domicile within the territory of Taiwan.</p> <p>2. The term of office of a supervisor shall not exceed three years, but he/she may be eligible for re-election.</p> <p>3. In case all supervisors of a company are discharged, the board of directors shall, within 60 days, convene a special meeting of shareholders to elect new supervisors.</p> <p>4. Supervisors shall supervise the execution of business operations of the company,</p>	<p>The Company Law of the Cayman Islands does not have the concept of "supervisor." Issuing companies set up Audit Committees and there are no supervisors. Therefore, there are no provisions with regards to supervisors in the Articles of Association.</p>

Important matters regarding the protection of shareholders' equity	Regulations of the Articles of Association and reasons for differences
<p>and may at any time or from time to time investigate the business and financial conditions of the company, inspect, transcribe or make copies of the accounting books and documents, and request the board of directors or Managerial officer to make reports thereon.</p> <p>5. Supervisors shall audit the various statements and records prepared for submission to the shareholders' meeting by the board of directors, and shall make a report of their findings and opinions at the meeting of shareholders.</p> <p>6. Supervisors may appoint a practicing lawyer on behalf of the Company and a certified public account to conduct the review matters.</p> <p>7. Supervisors of a company may attend the meeting of the board of directors to express their opinions. In case the board of directors or any director commits any act, in carrying out the business operations of the company, in a manner in violation of the laws, regulations, the Articles of Association or the resolutions of the shareholders' meeting, the supervisors shall forthwith advise, by a notice, to the board of directors or the director, as the case may be, to cease such act.</p> <p>8. Supervisor may each exercise the supervision power individually.</p> <p>9. A supervisor shall not be</p>	

Important matters regarding the protection of shareholders' equity	Regulations of the Articles of Association and reasons for differences
concurrently a director, a managerial officer or other staff/employee of the company.	
<p>1. Shareholder(s) who has/have been continuously holding 1% or more of the total number of the outstanding shares of the company over six months may request in writing the supervisors of the company to institute, for the company, an action against a director of the company. The Taiwan Taipei District Court shall be the court of the first instance.</p> <p>2. If the supervisor does not institute proceedings within 30 days after the shareholder's request, the shareholder may institute proceedings on behalf of the company, and the Taiwan Taipei District Court shall be the court of the first instance.</p> <p>3. Subject to the condition that the board of directors does not or is unable to convene a meeting of shareholders, the supervisors or independent directors of the Audit Committee may, for the benefit of the company, call a meeting of shareholders when it is deemed necessary.</p>	<p>As there is no equivalent concept of supervisor under the laws of Cayman Islands, and the company has set up an Audit Committee. Therefore, there are no provisions with regards to supervisors in the Articles of Association. However, subject to the provisions stipulated in Article 214 of Taiwan's Company Act regarding minority shareholders requesting to institute proceedings against directors, Article 48.3 of the company's Articles of Association stipulates "within the permission scope of the laws of the Cayman Islands, a shareholder who has continuously held more than one percent of the company's issued shares for 6 months or more may: (a) requesting in writing that the Board of Directors to authorize the independent directors of the Audit Committee to institute proceedings against the director on behalf of the group, and the Taiwan Taipei District Court shall be the court of the first instance; or (b) requesting in writing that independent directors of the Audit Committee to institute proceedings against the director on behalf of the group, and the Taiwan Taipei District Court shall be the court of the first instance. Within 30 days after the request is made in accordance with abovementioned (a) or (b), if (i) the independent directors of the Audit Committee authorized by the Board or the independent directors of the Audit Committee authorized by the Board fail to institute proceedings in accordance (a); or (ii) the requested independent directors of the Audit Committee fails to institute proceedings in accordance with (b), within the permission scope of the laws of the Cayman Islands, the Taiwan Taipei District Court shall be the court of the first instance.</p> <p>However, regarding the above provisions and laws of the Cayman Islands, lawyers of the Cayman Islands have the following polite reminders:</p> <p>There are no specific provisions in the Cayman Islands' Company Law that allow minority shareholders to bring a derivative action against directors in the court.</p> <p>The Articles of Association are not a contract between the shareholders and directors; they agree between the shareholders and the company. Even though the Articles of Association allow minority shareholders to institute proceedings against directors, lawyers in the Cayman Islands suggest that such content will not bind the directors. However, under common law, all shareholders (including minority shareholders) have the right to bring derivative actions (including actions against directors) regardless of their shareholding ratio or their period of ownership. Once</p>


Important matters regarding the protection of shareholders' equity	Regulations of the Articles of Association and reasons for differences
	<p>shareholders have instituted proceedings, the court in the Cayman Islands will determine whether they may proceed with the litigation. In other words, although the Articles of Association stipulate that a minority shareholder (or shareholders with the required shareholding ratio or period of ownership) may institute proceedings against the director on behalf of the Company, the court in the Cayman Islands holds the ultimate right to determine whether or not the litigation shall continue. According to relevant judgments rendered by the Grand Court of the Cayman Islands, when determining whether to approve the continuation of derivative actions, the Cayman Islands courts apply the criterion of whether the court believes and accepts that the plaintiff's claims on behalf of the company are prima facie substantial, that the alleged wrongdoing was committed by those who control the company, and that such controllers can prevent the company from bringing an action against them. The court in the Cayman Islands will determine a case based on facts (although the court may refer to provisions of the company's Articles of Association, it is not a decisive factor). According to the Cayman Islands law, the Board of Directors shall make decisions on behalf of the company as a whole (not as individual directors). The board of directors should authorize one of the directors on behalf of the company to institute proceedings against other directors as prescribed in the company's Articles of Association.</p> <p>The Company Law of the Cayman Islands does not provide the right for shareholders to request the directors to convene a board meeting to resolve specific matters. However, the Cayman Islands' Company Law does not prohibit a company from formulating provisions regarding board meeting procedures in its Articles of Association (including the requirements for the convening of the board meeting).</p>
<p>1. The directors of a company shall have the loyalty and shall exercise the due care of a good administrator in conducting the company's business operation; and if he/she has acted contrary to this provision, shall be liable for the damages to be sustained by the company there-from. If the act is carried out by the director or by others, the meeting of shareholders may, by a resolution, consider the</p>	<p>Although it is stipulated in Article 48.4 of the Company's Articles of Association that "Under the circumstances that do not affect and do not violate the principles of the common law of the Cayman Islands and general directors' duties to the company and shareholders under the law, directors shall faithfully execute the company's business and perform the duty of care of a good manager. If a director causes damage to the Company, he/she shall be liable to the maximum extent permitted by the law. If a director obtains benefits for himself/herself or others due to a violation of carrying out the act mentioned above, the company shall take all appropriate actions and steps to the maximum extent permitted by the law and consider such earnings of the Company. If a director violates the law or order during executing his/her duties that result in the Company becoming liable to any person for any compensation or damages, the director shall be jointly and</p>

Important matters regarding the protection of shareholders' equity	Regulations of the Articles of Association and reasons for differences
<p>earnings in such an act as earnings of the company.</p> <p>2. If the director of a company has, in the course of conducting the business operations, violated any provision of the applicable laws and/or regulations and thus caused damage to any other person, he/she shall be liable, jointly and severally, for the damage to such other person.</p> <p>3. Managerial officers and supervisors shall be liable for the same damages as the company's directors when executing duties within their scope.</p>	<p>severally responsible with the company for any compensation or damage caused to the company. If for any reason the director is not jointly and severally liable with the company, the director shall reimburse the company for any loss suffered by the company due to his/her breach of duty. When a managerial officer carries out company duties, he/she shall bear the same liability for damages as the company's directors.”</p> <p>However, regarding the above provisions and laws of the Cayman Islands, lawyers of the Cayman Islands have the following polite reminders:</p> <p>In general, under the Cayman Islands law, managerial officers or supervisors do not bear the same responsibilities to the company or shareholders as a director of the company. However, if a managerial officer or supervisor is authorized to carry out duties on behalf of a senior executive, he/she will have the same obligations as a director of the company. To avoid confusion, Cayman Islands companies generally define the duties and obligations of a managerial officer and supervisor to the company and its shareholders in their service contracts.</p> <p>The same is true for the Articles of Association acting as an agreement between shareholders and the company. As managerial officers or supervisors are not a party to the Articles of Association, and therefore, all rights of damages and compensation upon a violation of a managerial officer or supervisor shall be regulated in the service contract.</p> <p>Under the law of the Cayman Islands, the Articles of Association are an agreement between shareholders and the company, and directors (as a director of the company) are not a party to the Articles of Association. Lawyers of the Cayman Islands suggest that Articles of Association do not bind the directors. If the company intends to give contractual effect to directors with applicable provisions, lawyers of the Cayman Islands believe that relevant rights should be enclosed in the individual director's contract, such as a service contract.</p>

IV. If any of the situations listed in Article 36, paragraph 2 subparagraph 2 of the Securities and Exchange Act, which might materially affect shareholders' equity or the price of the company's securities, has occurred during the most recent fiscal year or up to publication of the annual report: None.

瑞磁生物科技集團股份有限公司

Applied BioCode Corporation

The logo is a circular emblem with a blue border. Inside the circle, the words "Applied BioCode Corporation" are written in a serif font, following the curve of the inner edge. The text is arranged in three lines: "Applied" at the top, "BioCode" in the middle, and "Corporation" at the bottom.

Chairman: George J. Lee